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Activation of A1 adenosine receptors have previously been researched to protect the 
myocardium from ischaemia reperfusion injury in various animal models throughout the pre-
conditioning phenomenon. The PI3K-AKT and MEK1/2-ERK1/2 cell survival pathways have 
been shown to play a critical role in the regulation in myocardial ischaemia reperfusion injury. 
In this study we investigated whether the A1 adenosine receptor agonist 2’-MeCCPA protects 
the myocardium from ischaemia reperfusion injury when administered at the onset of 
reperfusion or post-reperfusion and whether the protection involved the PI3K-AKT or 
MEK1/2-ERK1/2 cell survival pathways and if this protection was definitely mediated through 
the A1 adenosine receptor. In the Langendorff model of ischaemia reperfusion injury, the 
isolated perfused rat hearts underwent 20 minutes stabilisation, 35 minutes of ischaemia and 
120 minutes of reperfusion. The administration of 2’-MeCCPA (10nM) at the onset of 
reperfusion significantly decreased infarct size to risk ratio in comparison to non-treated 
ischaemic reperfused control hearts. This protection was abolished in the presence of the 
PI3K inhibitor Wortmannin or MEK1/2 inhibitor UO126; as well as in the presence of A1 
adenosine antagonist DPCPX. Western blot analysis determined that the administration of 2’-
MeCCPA (10nM) upregulated AKT phosphorylation. In the adult rat cardiomyocyte model of 
hypoxia/reoxygenation, cells underwent 1 hour of hypoxia and 3 hours of reoxygenation. 
Administration of 2’-MeCCPA (10nM) at the onset of reoxygenation significantly decreased 
cellular apoptosis and necrosis. The administration of 2’-MeCCPA (10nM) in the presence of 
Wortmannin, UO126 and DPCPX significantly reversed the anti-apoptotic and anti-necrotic 
effects.  
The methods used within this study include the Langendorff technique to investigate 
cardioprotection within the ischaemia/reperfusion model of an isolated rat heart. Apoptosis 
and necrosis levels were investigated as well as cleaved caspase-3 activity within the 
hypoxia/reoxygenation model of isolated rat cardiomyocytes. Western blots were also used 
to investigate the AKT phosphorylation levels within this study. 
Our data furthermore implied that 2’-MeCCPA protects myocytes that were subjected to 
hypoxia/reoxygenation injury via decreasing cleaved caspase-3 activity that was also 
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abolished in the presence of PI3K inhibitor Wortmannin as well as in the presence of the 
MEK1/2 inhibitor UO126 and A1 adenosine antagonist DPCPX. 
Interestingly, postponing the administration of 2’-MeCCPA to 15 or 30 minutes after the onset 
of reperfusion significantly protected the isolated perfused rat heart from ischaemia 
reperfusion injury in a Wortmannin, UO126 and DPCPX sensitive manner. This protection was 
associated with an increase in AKT phosphorylation. 
Administration of the A1 adenosine receptor agonist 2’-MeCCPA 15 or 30 minutes after the 
onset of reoxygenation significantly protected isolated adult rat cardiomyocytes that were 
subject 1 hour of hypoxia and 3 hours of reoxygenation from injury in an anti-
apoptotic/necrotic manner. This anti-apoptotic and necrotic effects was abolished upon the 
administration of PI3K inhibitor Wortmannin, MEK1/2 inhibitor UO126 and A1 adenosine 
antagonist DPCPX. Delaying the administrations of 2’-MeCCPA to 15 or 30 minutes after 
reoxygenation was also associated with a decrease in cleaved caspase-3 activity which was 
abolished in the presence of PI3K inhibitor Wortmannin; however MEK1/2 inhibitor UO126 
was only able to abolish protective effects at 15 minutes and no effect at 30 minutes post-
reoxygenation.  
It can be implied for the first time that the administration of 2’-MeCCPA at the onset of 
reperfusion protects the ischaemic reperfused rat myocardium from lethal ischaemia 
reperfusion injury in a PI3K and MEK1/2 sensitive manner. Delaying the administration of 2’-
MeCCPA to 15 minutes or 30 minutes after the onset of reperfusion or reoxygenation, it 
significantly protects the isolated perfused rat heart from ischaemia reperfusion injury and 
also the adult rat cardiomyocyte from hypoxia-reoxygenation injury in an anti-
apoptotic/necrotic manner. Moreover, this protection is associate with recruitment of the 
PI3K-AKT and MEK1/2-ERK1/2 cell survival pathways.  
Furthermore, any protective effects observed with the administrations of 2’-MeCCPA at the 
onset of reperfusion, 15 minutes or 30 minutes post-reperfusion/reoxygenation was 
significantly abrogated in the presence of the A1 adenosine antagonist DPCPX which implies 
that protection was definitely occurring through the A1 adenosine receptor subtype.  
The work carried out in this thesis has implied the cardioprotective effects of the activation 
of A1 adenosine receptors in an ischaemia/reperfusion injury model. This is the first study to 
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imply the delayed activation of A1 adenosine receptors with A1AR agonist 2’-MeCCPA to 
confer cardioprotection in isolated perfused rat hearts. The findings from this study imply 
clinically important developments in the field of managing myocardial infarction. Urgent 
studies are required to investigate the potential role of A1 adenosine receptor agonists in 
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Chapter 1: Introduction 
 
1.1  Cardiovascular Disease 
 
Cardiovascular diseases (CVDs) are yet to remain the single leading causes of global deaths 
worldwide with a constant increase in mortality and morbidity and a projected number of 
deaths expecting to increase to almost 23.6 million by the year 2030 (WHO 2020). Within the 
UK alone, there are around 7.4 million people living with CVDs (British Heart Foundation 
2020). More than a quarter of deaths in the UK are due to CVDs meaning nearly 170 000 
deaths per year; this is an average of 460 deaths per day or one death every three minutes 
(British Heart Foundation 2020).  
CVDs encompass a variety of disorders that target the cardiovascular system. These include; 
coronary heart disease (CHD), cerebrovascular disease, peripheral arterial disease, rheumatic 
heart disease and venous thromboembolism (WHO 2017, Stewart, Manmathan and 
Wilkinson 2017). Acute events of the heart are mainly caused by occlusions that can in turn 
prevent the blood flowing to the heart and the brain (WHO 2017), this has resulted in serious 
health concerns, physical disabilities and deaths (Nichols et al. 2013). 
The main behavioural risk factors that can lead to the development of CVDs include; an 
unhealthy diet leading to obesity, tobacco use and an unhealthy use of alcohol (WHO 2017). 
These behavioural risk factors can express; a raised blood pressure causing hypertension, a 
raised blood glucose level resulting in diabetes mellitus and increased levels of low density 
lipoproteins (LDLs) and a low level of high density lipoproteins (HDLs) (WHO 2017, Lucero et 
al. 2014).  
Significant primary interventions have evolved in order to manage cardiovascular risks within 
the population and although these are reliable in being able to prevent coronary artery 
occlusion and in turn prevent acute events of a heart attack, it is also imperative that more 
robust and enhanced secondary interventions are put in place, especially after an ischaemic 




1.2  Myocardial Infarction 
 
Myocardial infarction (MI), which can otherwise be termed as a heart attack, can be defined 
as the sudden ischaemic death of myocardial tissue (Neri et al. 2017). A myocardial infarction 
is when atherosclerotic plaque formations occur within the walls of arteries and in turn can 
cause reduced blood flow to the myocardium and therefore cause a lack of oxygen and 
nutrients to the heart (Lu et al. 2015). Atherosclerosis is a condition that can also form due to 
a build-up of fatty deposits in the arterial walls and further causing myocardial infarction 
(Reynold 2012). On commencement of a MI the symptoms consist of; chest pain, arrhythmia 
and shortness of breath, which can lead to permanent damage of the heart muscle (Lu et al. 
2015).  
Research has led to the better understanding of the pathogenesis of acute coronary disorders 
such as angina and MI (Grundy 1999).  Effective treatments that allow for the management 
of these conditions include surgical interventions and also the administration of drug 
therapies such as aspirin (an anti-platelet drug), warfarin (an anticoagulant drug), statins 
(drugs that lower endogenous cholesterol synthesis), beta blockers as well as angiotensin 
converting enzyme (ACE) inhibitors (Anderson et al. 2007). These treatments are all secondary 
treatments in order to manage CHD (Anderson et al. 2007). Ultimately, for those patients who 
have withstood a MI will require treatments during the reperfusion period where medical 
treatments restore the blood flow to any occluded arteries to further restore somewhat 
normal functioning (Kloner and Rezkalla 2004).  
1.3  Myocardial Ischaemia 
 
Myocardial ischaemia can be caused by a deficit in blood supply to the myocardium due to 
the obstruction within arterial flow which can lead to occlusion of the vessels that supply the 
myocardium (Hausenloy and Yellon 2013; Neri et al. 2017). This causes an increase in oxygen 
demand and a decrease in actual oxygen supply due to the lack of blood flow. This is an 
important factor that contributes to heart failure (Hausenloy and Yellon 2013).  
Prolonged ischaemia can result in a metabolic changes due to a lack of oxygen and nutrients 
supply however it can also lead to ultrastructure changes within the cells of myocardium 
tissue. These changes include; alterations in membrane potential and ion distribution, cellular 
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swelling and rupturing, decreased ATP supply to cells, changes in free radical mediated injury, 
disruptions in oxidative phosphorylation, elevated levels of Ca2+ within the mitochondria and 
increased levels of lactic acid causing a decline in intracellular pH and altered metabolism 
(refer to Figure 1.0) (Hausenloy and Yellon 2013; Halestrap et al. 2004; Allen et al. 2008). 
These serious alterations can further lead to cell death via the mechanisms of necrosis, 










Figure 1.1 Schematic diagram that illustrates the components of myocardial ischaemia-
reperfusion injury (IRI). The lack of oxygen present within the cell causes a switch to 
anaerobic respiration which results in the build-up of lactic acid which in turn causes a drop 
in cellular pH. This causes the Na+-H+ exchanger, between the cell and the blood supply, 
extrude H+ out of the cell and cause an overload of intracellular Na+. This process activates 
the 2Na+-Ca2+ exchanger which then extrudes the Na+ out of the cell and causes a further 
overload in intracellular Ca2+. The acidic conditions prevent the MPTP from opening and 
further prevent hyper contracture of the cardiomyocyte cell from occurring. During 
reperfusion, the Na+-H- exchanger is reactivated which causes the lactic acid to wash-out 
and in turn allow for the restoration of the cellular pH. The electron transport chain is also 
reactivated which allows for the development of ROS which can subsequently trigger the 
MPTP opening and allow for myofibril hyper contracture to occur which utilises the Ca2+ 






1.4  Myocardial Reperfusion 
 
Myocardial reperfusion is a vital phenomenon in which cardiomyocyte recovery and 
maintenance is facilitated due to the neutralisation of the lactic acid  build up and the 
reactivation of the Na+-H+ exchanger which then goes on to restore cellular physiological pH 
levels (Hausenloy and Yellon 2013) (refer to Figure 1.1). This occurs due to the reintroduction 
of coronary blood flow to the myocardium after the ischaemic event, however this restoration 
of blood flow can additionally result in reperfusion-induced injury (Kalogeris et al. 2012).  
Reperfusion can therefore been seen as beneficial for the myocardium after an ischaemic 
event as it rescues the myocardium from the deleterious effects as described in Figure 1.1; 
however alongside this, reperfusion of an ischaemic myocardium can also come with 
detrimental consequences which further results in cardiomyocyte injury and death which is 
called ‘ischaemia-reperfusion injury’ (Derek and Hausenloy 2007). 
Previous studies have described reperfusion as a period in which medical interventions can 
be applied in order to reduce injury to myocardium tissue (Yellon and Hausenloy 2013). 
Treatments within reperfusion have resulted in much success and also an effective way of 
managing ischaemia and in the long run very beneficial (Kloner and Rezkalla 2004). Although 
research has provided the information that early reperfusion is the best time period in which 
ischaemic injury can be reduced, the restoration of the blood flow to the ischaemic 
myocardium can consequently cause a burst of reactive oxygen species (ROS) as well as 
inflammatory mediators. This can occur naturally in biological systems and play a major role 
in ischaemia-reperfusion injury (Hausenloy and Yellon 2013; Zhou et al. 2018).  
The event of early myocardial reperfusion with the aid of thrombolytic therapies or primary 
percutaneous coronary interventions are proven to be most successful strategies in managing 
myocardial infarction and in turn improving clinical outcomes (Yellon and Hausenloy 2007).  
Despite the major benefits that comes with reperfusion, the resulting reperfusion injury 
comes with its many negative attributes too. These include;  arrhythmias, myocardial 
stunning which can cause further reversible and/or irreversible cellular damage, as well as the 
release of free radicals within the ischaemia and reperfusion periods (Kalogeris et al. 2012).  
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Previous studies have also mentioned that the progression of a myocardial injury can be 
enhanced by the immune system which include cell types such as neutrophils, macrophages 
and mast cells (Fitridge and Thompson 2012). A previous review written by Epelman and 
Mann (2012) stated that neutrophils are the most abundant leukocyte within the systemic 
circulation thus adding to the myocardial injury causing neutrophil-mediated cardiac injury. 
When a myocardial infarction occurs, the endothelium activates through a variety of 
cytokines and this causes an upregulation of neutrophils to the injury site. These neutrophils 
then bind to ICAM-1 which is a protein expressed by cardiomyocytes thus causing an intense 
trigger of oxidative stress and therefore enhanced myocardial injury (Epelman and Mann 
2012). Neutrophil-mediated myocardial injury increases as the ischaemic period increases 
(Epelman and Mann 2012; Fitridge and Thompson 2012). 
1.5  Oxygen-Derived Free Radicals 
 
Oxygen derived free radicals can be introduced once the coronary blood flow to the 
myocardium is restored after the ischaemic event. This restoration of blood flow leads to a 
further restoration of oxygen to the myocardium thus including the generation of oxygen 
metabolites in the form of ROS (Braunersreuther and Jaquet 2012).  
ROS take the form of chemically reactive ions, radicals and molecules that form from oxygen. 
The majority of free radicals are formed within the mitochondria during the reperfusion 
period (Camara 2009). ROS are small molecules that are generated by oxygen reduction which 
can lead to a presence of unpaired electrons upon the oxygen molecule that has been 
reduced. This addition of an electron to the oxygen molecule (O2) can form a superoxide anion 
radical (O2-); this is considered to be the primary form of ROS (Braunersreuther and Jaquet 
2012). These superoxide radicals have a very short half-life and can interact directly or 
through enzyme- or metal-catalysed reactions with other molecules to generate a secondary 
ROS (Braunersreuther and Jaquet 2012). 
Throughout normal physiological conditions of the myocardium, an enzyme named xanthine 
oxidoreductase is present in a dehydrogenase form and simply acts as a rate-limiting step 
within the purine degradation to uric acid (Jankov et al. 2008). Consequently, once ischaemic 
conditions commence, ATP is broken down into purine hypoxanthine which is a substrate for 
an enzyme named xanthine oxireductase; this further cause’s reversible oxidation or 
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irreversible proteolytic cleavage which causes the conversion of xanthine oxireductase to 
xanthine oxidase. This is primarily causes the deleterious formation of ROS as well as 
hydrogen peroxide (Pritsos 2000; Braunersreuther and Jaquet 2012). 
Throughout ischaemic periods, oxygen-derived free radicals are formed to such destructive 
levels during the reperfusion period of the previously ischaemic region which can cause 
inhibition of contractile function within myocardium tissue thus enhancing myocardial injury 
(Zweier and Talukder 2006). Although ROS possesses such consequential attributes within the 
myocardium and is well documented in favour of cellular damage, it also does participate in 
a range of other roles such as within cell signalling as well as microbial killing (Stowe and 
Camara 2009; Rada and Leto 2008).  
A study carried out by Hoshikawa and colleagues (2001) researched that when male Sprague 
Dawley rat hearts were exposed to hypoxic conditions, there was a constant increased level 
of xanthine oxidase hypoxanthine which is a pathway known to generate oxidative stress in 
vivo (Hoshikawa et al. 2001).  
Although ischaemia reperfusion injury involves the production of ROS, an accumulation can 
result is cellular oxidative stress, dysfunction of the mitochondria, initiation of cell death and 
the activation of the mitochondrial permeability transition pore. In order reduce the effects 
of ROS, antioxidant therapies have been shown to provide positive treatment outcomes to 
reduce ischaemia-reperfusion injury (Zhou et al. 2018). With ROS acting as an important 
signalling molecule to involve the immune system to respond to the injury signals, 
endogenous antioxidants such as catalase, superoxide dismutase (SOD), glutathione and 
glutathione peroxidase (GPx) are important scavengers that are able to maintain ROS at 
normal levels (Zhou et al. 2018). During specific pathological conditions such as an ischaemic 
event, antioxidant defences can be overwhelmed and in turn result in oxidative stress and an 
uncontrollable amount of ROS production (Zuo et al. 2015; Zhou et al. 2018). Investigations 
have been conducted upon antioxidants in alleviating ischaemia-reperfusion injury. A study 
by Adlam and colleagues (2005) investigated mitoQ, a selective mitochondrial ROS inhibitor 
that has the ability to dramatically attenuate heart dysfunction after ischaemia-reperfusion 
in rats (Adlam et al. 2005).  
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1.6  Myocardial Stunning 
 
Myocardial stunning is another negative consequence that can enhance ischaemia-
reperfusion injury (Hausenloy and Yellon 2013). This is when post-ischaemic contractile 
dysfunction is introduced to the myocardium at the onset of reperfusion. This phenomenon 
can be detrimental in terms of initiating oxidative stress and calcium overload (Hausenloy and 
Yellon 2013; Kloner et al 1998).  
 
1.7  No-Reflow Phenomenon 
 
The no-reflow phenomenon essentially occurs at the point of reperfusion when the occluded 
coronary artery becomes free of stress and in an ideal situation, the blood flow to the 
ischaemic tissue is supposed to flow through immediately; however due to detrimental 
changes that have occurred in the cardiac capillaries and arterioles, the blood flow becomes 
impeded (Reffelmann 2002; Hausenloy and Yellon 2013). Sufficient structural damage has 
occurred to the microvasculature and therefore this causes a cease in restoration of normal 
blood flow to the cardiomyocytes. There is inadequate healing of cardiac tissue and therefore 
this can affect future blood flow (Hausenloy and Yellon 2013).  
1.8  Metabolic Changes 
 
Research has currently established that there are multifactorial mechanisms that contribute 
to ischaemia-reperfusion injury when a myocardial infarction occurs (Kalogeris et al. 2012). 
The metabolic changes that occur are important; these include the accumulation of lactic acid 
that results from an increased rate of glycolysis which further decreases the intracellular pH 
within the cardiomyocyte (Halestrap et al. 2007). This occurs due to conditions changing from 
aerobic respiration to anaerobic respiration (Halestrap et al. 2007). A rapid decrease in 
available adenosine triphosphate (ATP) levels occurs which leads to the inhibition of the 
Na+/K+ ATPase, which can then cause a rapid increase in intracellular Na+ which further link 




1.9  Calcium Overload 
 
An increase in cytosolic Ca2+ can contribute to the exacerbated effects of ischaemia-
reperfusion injury. Throughout the ischaemic period, the intracellular levels of Ca2+ rise due 
to the Na+/H+ exchanger extruding H+ ions in exchange for Na+ ions (Hausenloy and Yellon 
2013). The increase in Na+ ions are then exchanged for Ca2+ via the Na+/Ca2+ exchanger within 
the plasma membrane of cardiomyocytes (which usually pumps Ca2+ out of the cell) 
(Hausenloy and Yellon 2013; Kalogeris et al. 2012; Bains 2009). These deleterious effects are 
contracture and death (Kalogeris et al. 2012). The sarcoplasmic reticulum (SR), which is a Ca2+ 
store, is also affected during ischaemia-reperfusion injury and does not allow for the reuptake 
of Ca2+ (Kalogeris et al. 2012).  
Cardiac contractility is regulated by changes in Ca2+concentration and for normal functioning, 
Ca2+ concentrations are sufficiently high in systole and low in diastole. Most of the Ca2+ that 
is needed for contraction comes from the SR (Eisner et al. 2017). The SR functions as a 
dynamic calcium governor in which an automatic feedback control for altering and 
maintaining myoplasmic and SR calcium levels is achieved (Rossi and Dirksen 2005). The way 
in which this automatic feedback is achieved is by the interactions between the terminal 
regions of the SR and the transverse tubular membrane alongside the envelopment of the 
myofibrils from the longitudinal SR (Rossi and Dirksen 2005). The SR plays a central role in 
controlling Ca2+ cycling and with this the SR has developed a detailed set of calcium-regulatory 
proteins that are able to provide a release of Ca2+ upon excitation (systole) and also provide a 
means of Ca2+ reuptake with a maintained calcium storage when muscle is relaxed (diastole) 
(Rossi and Dirksen 2005). This can be referred to as excitation-contraction (EC) coupling 
(Gorski et al. 2015).  
During systole, an action potential causes depolarisation of the sarcolemma which can result 
in the entry of a small amount of extracellular calcium into the cytosol through voltage gated 
L-type calcium channels. The calcium then binds to ryanodine receptors that triggers a larger 
efflux of calcium from the SR and into the cytosol (Gorski et al. 2015). This tenfold increase of 
intracellular calcium activates calcium sensitive contractile proteins like troponin C, which 
further uses ATP to produce tension and muscle contraction. Furthermore, for muscle 
relaxation to occur, calcium is removed from the cytosol by the sodium-calcium exchanger as 
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well as ATPase and pumped back into the SR (Gorski et al. 2015). For heart failure to 
commence there are pronounce cellular changes that occur and this is due to an increase in 
end-diastolic cytosolic calcium levels. This means SR calcium reuptake decreases due to the 
SERCA2a modulate that allows for calcium reuptake becomes dysfunctional (Gorski et al. 
2015). 
It’s the negative alterations of Ca2+ are what contribute towards cell death during ischaemia-
reperfusion injury and one of the ways in which cardiomyocytes can try and deal with the 
lethal increase in Ca2+ is by the mitochondrial Ca2+ uniporter taking up the increased levels of 
Ca2+; this is called the mitochondrial permeability transition (MPT) response (Kalogeris et al. 
2012). This increase in Ca2+ can also cause the activation of the calmodulin-dependent protein 
kinases (CaMKs) which also contribute towards ischaemia-reperfusion injury (Kalogeris et al. 
2012).  
The Ca2+ overload is often accompanied by hyper activation and consistent hyper contracture 
within cardiomyocytes; and with this consecutively occurring cell rupture can occur and in 













Figure 1.2 Schematic diagram of the mechanism of calcium overload that can enhance 
ischaemia-reperfusion injury (Piper 2000). 
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1.10 Cell Death 
 
Cells have the ability to respond to stress in various ways however it is ultimately the 
phenomenon of cell death that eliminates the cells that are damaged due to age or through 
means of injury (Fulda et al. 2010). Cells death is divided up into categories consisting of; 
necrosis, apoptosis and autophagy (Fulda et al. 2010) as referred to in Figure 1.3. Studies have 
gone on to investigate the effects of ischaemia-reperfusion injury upon necrosis and 










Figure 1.3 General modes of cell death which include programmed cell death and necrosis 




Necrosis is known as irreversible injury to cells and can be triggered as a response to physical 
and chemical insults, of which include hypoxia, ischaemia and steep changes in temperature 
(Galluzzi et al. 2014; Konstantindis, Whelan and Kitsis 2012). Necrosis was defined as 
unplanned/accidental cell death however recent studies have developed that necrosis is an 
active form of cell death (Bergh et al. 2014).  
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The process of necrosis has been defined as an oxidation-mediated necrotic pathway, it is ATP 
independent and involves the interactions of multiple regulatory factors. Another pathway of 
cell death includes an ATP dependent pathway called apoptosis (Sancho et al. 2006). A study 
conducted by Lieberthal et al. in 2013 showed that when cultured mouse proximal tubular 
cells showed an increase in cell death, this was negatively proportional to the amount of ATP 
released showing that an increase in cell death was associated with a decrease in ATP 
availability; meaning that necrosis was independent of ATP release (Lieberthal et al. 2013).  
For many years it was proposed that necrosis is the only process of cell death that is 
implicated within cardiomyocytes following ischaemia-reperfusion injury; however since then 
significant research was conducted and other forms of cell death were elucidated. These 
areas being, apoptosis, autophagy and oncosis (Buja and Vela 2008; Kostin et al. 2003). The 
main cause of necrosis occurs when the myocardium is undergoing reperfusion and the 
opening of the MPTP causes dysfunction of the mitochondria and therefore enhances 
cardiomyocyte necrosis (Hausenloy 2012; Hausenloy and Yellon 2013).  
1.12 Apoptosis 
 
Apoptosis in an ATP-dependent, highly conserved biochemical process that becomes 
activated under physiological and pathological circumstances in response to a stimuli (Fulda 
et al. 2010). Apoptosis is also known as programmed cell death (Elmore 2007; Fulda et al. 
2010). When apoptosis occurs, cell morphology changes in such ways that cell shrinkage 
occurs, cytoplasmic condensation and cellular fragmentation into membrane-enclosed 
apoptotic bodies also occur (Fulda et al. 2010; Konstantinidis, Whelan and Kitis 2012). These 
apoptotic bodies are then rapidly phagocytised by macrophages and eliminated (Elmore 
2007; Konstantinidis, Whelan and Kitis 2012).  
Much research has been carried out to identify and elucidate the molecular mechanisms that 
regulate and further execute the process of apoptosis (Kim and Kang 2010). Studies have 
determined that apoptosis is a tightly regulated process and there are various interactions 
between a ranges of pro- and anti-apoptotic molecules. A number of different proposed 
mechanisms have been identified and characterised to define apoptosis. These include the 
intrinsic vs. extrinsic pathway or the caspase-dependent vs. caspase-independent pathway 
(Kim and Kang 2010).  
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Caspases originate from a family of cysteine proteases and are produced as zymogens that 
when become activated, their pro-domains are cleaved off (Nicholson and Thornberry 1997; 
Kim and Kang 2010). There are different categories of caspases and they are grouped together 
based upon their structure which determines their function. Initiator caspases hold long pro-
domains and examples of these are caspase-8 and -9; which are able to initiate apoptosis and 
also downstream themselves to activate effector caspases (Kim and Kang 2010). Effector 
caspases are characterised with short pro-domains, an example of an effector caspase would 
be caspase-3. Caspase-3 would generally depend on an initiator caspase in order to become 
activated (Kim and Kang 2010). The collective results of a number of independent studies 
suggest that caspases can be tissue dependent and specific caspases, when activated can 
mediate apoptosis (Kim and Kang 2010). Caspase-mediated apoptosis recruits either the 
intrinsic or the extrinsic pathway however both include the common effector caspase-3 (Kim 
and Kang 2010). 
 
Figure 1.4 Apoptosis activates through two main pathways, the intrinsic pathway and the 
extrinsic pathway (Loreto 2014) the extrinsic pathway activates via the binding of death 
ligands (TRAIL) to death receptors. The formation of death inducing signalling complex 
(DISC) forms which binds to procaspase-8, this stimulates the activation of caspase-8 and 
further triggers the protease cascade which leads to apoptosis. The intrinsic pathway is 
activated via stress stimuli for example DNA damage, ER stress and hypoxia. The death 
signal is detected by Bcl-2 family proteins (BAD and BAX). This then leads to a 
conformational change in BAX and BAK causing the formation of mitochondrial pores and 
allowing permeability to the outer mitochondrial membrane. This promotes the release of 
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apoptogenic proteins (cytochrome c and SMAC/DIABLO) which interact with Apaf-1 to 
enable the formation of apoptosome complex which then triggers procaspase-9. Activated 
caspase-9 causes a cascade to activate caspase-3, -6 and -7 with the overall objective to 
cause apoptosis (Loreto 2014). 
 
1.12.1 Extrinsic Apoptotic Pathway 
 
The extrinsic pathway of apoptosis can also be termed as the death receptor-mediated 
pathway which initiates via the binding of a death ligand, such as TNF-α, to a cell surface death 
receptor such as Fas (Kiechle and Zhang 2002). This activation can further cause the 
recruitment of the death domain known as Fas-associated death domain (FADD) which 
further activates caspase-8; which then forms the death-inducing signalling complex (DISC) 
(Kim and Kang 2010; Kiechle and Zhang 2002). This complex triggers the auto-catalytic 
activation of caspase-8, which in turn activates the protease cascade (caspase-3,-6 and -7) to 
finally cause apoptosis (Figure 1.3) (Kiechle and Zhang 2002).  
Research has been conducted to show that the Fas pathway is an important mediator of 
apoptosis during ischaemia-reperfusion injury in vivo. Lee and colleagues studied that when 
mice were lacking Fas, they exhibited a reduction in myocardium infarct size after ischaemia-
reperfusion thus making it imperative that Fas be present for apoptosis to occur through the 
extrinsic pathway (Lee et al. 2003; Kim and Kang 2010).  
1.12.2 Intrinsic Apoptotic Pathway 
 
The intrinsic pathway is also known as the mitochondrial-mediated apoptosis pathway and 
can be triggered by various endogenous and exogenous stimuli such as ischaemia, oxidative 
stress and endoplasmic reticulum (ER) stress. The intrinsic pathway plays a major role in the 
removal of damaged cells and caspase activation is closely associated with the 
permeabilisation of the outer mitochondrial membrane by the B-cell lymphoma protein-2 
(Bcl-2) family of proteins (Kim and Kang 2010). The proteins within the Bcl-2 family can be 
categorised into either anti-apoptotic proteins (Bcl-2 and Bcl-xL) or the pro-apoptotic 
members (Bad, Bax and Bak) (Youle and Strasser 2008; Kim and Kang 2010). In regular 
conditions, Bax is located within the cytosol however when responding to an exogenous 
stimuli, Bax then translocates into the outer mitochondrial membrane within the 
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cardiomyocytes (Kim and Kang 2010; Tait and Green 2010; Zhang et al. 2009).  Moreover, the 
injurious stimuli causes a conformational change in Bak which migrates to the outer 
mitochondrial membrane also (Konstantinidis, Whelan and Kitis 2012; Zhang et al. 2009). Due 
to the activation of Bax and Bak at the outer mitochondrial membrane, mitochondrial pores 
form and this then enhances membrane permeability (Sarvothaman et al. 2015). Alongside 
this permeabilisation, the release of apoptogenic proteins is promoted such as: cytochrome 
c and SMAC/Diablo complex, Apoptosis Inducing Factor (AIF) and Endonuclease G (Endo G) 
(Fan et al. 2013; Borutaite et al. 2003; Loreto et al. 2014). Cytochrome c forms an activation 
complex with apoptotic protein activating factor-1 (Apaf-1), this then binds to a complex in 
the cytosol known as the apoptosome which triggers the activation of pro-caspase-9 (Kim an 
Kang 2010; Keoni and Brown 2015). Procaspsae-9 then initiates the activation of effector 
caspases-3, -6 and -7 which then leads to cardiomyocyte apoptosis (Figure 1.3) (Elmore 2007; 
Loreto et al. 2014).  
Studies have been carried out to look into how targeting the intrinsic pathway could reduce 
myocardial ischaemia-reperfusion injury and it has been found that targeting the deletion of 
the pro-apoptotic protein Bax can actually result in a reduction in infarct size and also improve 
myocardial functioning after experimental myocardial infarction has occurred (Hochhauser et 
al. 2007; Kim and Kang 2009). Furthermore, Mocanu, Baxter and Yellon (2000) conducted a 
study that examined the effect of caspase-8, -9 and -3 , when being administered during the 
early stages of reperfusion were able to significantly protect the myocardium from lethal 
reperfusion injury (Mocanu, Baxter and Yellon 2000). This is important to note as several past 
studies have shown caspase-3 to mediate a pivotal role within the development of cellular 
apoptosis namely Namura et al (1998) showing that levels of activated caspase-3 were 
peaking between 30-60 minutes of reperfusion.  
Overall, apoptosis has been researched to play a key part in myocardial infarction damage 
and the use of caspase inhibitors are beneficial to protect  the myocardium from ischaemia-
reperfusion injury however it is feasible to conduct further research to understand the further 
potential mechanisms that can therefore enhance the identification of future potential 
targets to promote cell survival. A study conducted by Mocanu and colleagues (2000) 
investigated caspase activation as being a major events of apoptosis and therefore examined 
how caspase inhibitors (Z-VAD fmk, Z-IETD fmk and Z-LEHD fml and Ac-DEVEcmk), when 
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administered during reperfusion after a myocardial infarction successfully protects isolated 
rat myocardium from lethal reperfusion injury (Mocanu et al. 2000).   
The mitochondrial permeability transition pore (MPTP) which is a transmembrane protein 
that resides in the mitochondrial inner membrane. This pore normally remains closed 
however it can open when stimulated by mitochondrial matrix Ca2+ accumulation which may 
happen in a hypoxic events. With this, oxidative stress can also increase which can further 
lead to apoptosis (Bernardi 2013). 
1.13 Other Forms of Cell Death 
 
Although necrosis can be stated as an uncontrollable process, studies have potentially linked 
necrosis to a process called necroptosis, this process involves a crossover of necrosis and 
apoptosis (Konstantinidis, Whelan and Kitsis 2012; Zhe-Wei, Li-Sha and Yue-Chun 2018). 
Necroptosis has been proposed as an important player in the pathophysiology of heart 
disease and ischaemia-reperfusion injury caused by myocardial infarction (Zhe-Wei, Li-Sha 
and Yue-Chun 2018). Necroptosis, when activated ligands of death receptors bind such as 
receptor-interacting protein 1 (RIP1) mediating the activation of receptor-interacting protein 
3 (RIP3) and mixed lineage kinase domain-like (MLKL); these are two vital downstream 
mediators that inhibit caspase-8 and upstream ischaemia-reperfusion injury via necroptosis 
(Zhe-Wei, Li-Sha and Yue-Chun 2018; Zhou and Yuan 2014; He et al. 2016).  
There are other forms of cell death that can be seen in vitro and in vivo, hence why there is 
such a need to study different forms of cell death (Weerasinghe and Buja 2012). Apoptosis 
manifests by cell shrinkage followed by break down however another form of cell death, 
oncosis, is the total opposite. Oncosis involves cell swelling and coagulation of the cytoplasm 







1.14 Cardioprotective Strategies in Myocardial Infarction 
 
Research suggests that although the period of reperfusion can increase reperfusion injury, it 
simultaneously acts as the key to the management of myocardial infarction injury. By 
exploring strategies that target reperfusion, there is undoubtedly a chance that survival of 
patients can be enhanced (Mocanu et al. 2000; Zhang and Huo 2011; Covinhes et al. 2020).  
1.15 Adenosine Receptors 
 
There are currently four adenosine receptors that are activated by receptor-dependent and 
–independent mechanisms. These receptors belong to the superfamily of G-protein-coupled 
receptors (GPCR); A1, A2A, A2B and A3 receptors and have been categorised in the way that 
they cause stimulatory and inhibitory actions on adenylate cyclase (Figure 1.4) as well as 
selectivity of respective agonists and antagonists (Borea et al. 2016; Fredholm 2014).  
Studies have shown that adenosine A1 receptors are coupled to the pertussis toxin sensitive 
Gi and Go proteins and these inhibit adenylate cyclase activity (and therefore inhibit cyclic 
AMP (cAMP) activation) to activate phospholipase C and the opening of K+ channels as well 
as the inhibition of Ca2+ release (Fredholm 2000; Germack and Dickenson 2004; Borea et al. 
2016). Adenosine A2A and A2B receptors are both shown to couple Gs proteins and these go 
on to stimulate adenylate cyclase and further cause cAMP activation (Germack and Dickenson 
2004; Borea et al. 2016). Adenosine A3 receptors are also coupled to Gi, Go and Gq proteins, 
similar to A1 adenosine receptors, which ensures the inhibition of adenylate cyclase activity is 
achieved. A3 adenosine receptors are also implicated in the activation of phospholipase C and 





Figure 1.5 Schematic diagram of adenosine metabolism mediated through adenosine 
receptors (Boreo et al. 2016). Diagram illustrates an overview of adenosine biosynthesis and 
degradation as well as the second messenger pathways that are coupled to the four 
adenosine receptors.  
Adenosine receptors are shown to be expressed within the cardiovascular system which 
includes the coronary artery, pulmonary artery, aorta and smoother muscle cells; but most 
importantly, adenosine receptors are expressed within cardiomyocytes that make up the 
myocardium (Sheth et al. 2014). Adenosine has the ability to cause vasoconstriction and 
vasodilation (Sheth et al. 2014). Not only are adenosine receptors beneficial for the 
cardiovascular system; they are also activated within the central nervous system to allow for 
neurotransmitter release (Cunha 2001; Sheth et al. 2014) and to regulate T-cell proliferation 
as well as cytokine production to ensure an inflammatory response can be mediated (Hasko 
et al. 2008; Sheth et al. 2014). 
1.16 Adenosine 
 
Adenosine itself is an endogenous nucleoside modulator that is released from almost all cells 
and it is generated by the dephosphorylation of ATP into extracellular AMP and then further 
broken down into adenosine (shown in Figure 1.5 above) (Gessi et al. 2011; Boreo et al. 2016). 
This nucleoside mediated through the activation of the four different adenosine receptors 
(A1, A2A, A2B and A3) that are mediated through GPCRs. There is an estimated level adenosine 
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within the interstitial fluid in the range between 20-200nM (Fredholm 2011). The 
concentration of adenosine can increase when metabolically unfavourable conditions occurs 
such as tissue hypoxia (Fredholm 2010). This can lead to an enhanced breakdown in ATP to 
form more interstitial adenosine in an attempt to protect tissue from damage (Gessi et al. 
2011). Adenosine levels can rise significantly above basal levels with different physiological 
conditions such as asthma, chronic inflammation, neurodegenerative disorders and cancer 
(Gessi et al. 2011). With an increase in adenosine levels, this can play a pivotal role in 
ischaemic injury and can further reduce the damage that occurs from a hypoxic event such as 
ischaemia (Gessi et al. 2011; Gaudry et al. 2020; Effendi et al. 2020). 
Adenosine receptors are widely expressed in human organs and tissue spanning from the 
brain, heart, lungs, liver, bone, kidney, joints and blood cells (Peleli et al. 2017). Studies have 
also been conducted where all four adenosine receptors have been cloned and 
pharmacologically characterised within different specie groups (Gessi et al. 2011). It was 
found that the amino acid composition of adenosine receptors between human and rat 
species was 80-95% similar with more variance within the composition of the A3 receptors 
amongst the other receptors (Ballesteros-Yáñez et al. 2018). In rat, the A1 adenosine receptor 
has shown to be widely expressed within the brain, heart, liver, kidney and aorta (Dixon et al. 
1996; Gessi et al. 2011). Within this same specie group, A3 receptors are widely expressed 
within the heart and the central nervous system (Gessi et al. 2011). The A2A adenosine 
receptors were shown to be expressed within the lungs, heart, kidney and brain and the A2B 
receptors were researched to be expressed within the bowel, bladder, lungs and the brain 
(Dixon et al. 1996; Gessi et al. 2011).  
Adenosine plays a direct role upon the cardiovascular system in terms of regulating blood 
flow, heart rate and pressure and studies have been carried out to determine the effects of 
certain receptor specific agonists on the various adenosine receptors. Activation of the A1 
adenosine receptor has been found to decrease heart rate, a study by Albrecht-Kupper, 
Leineweber and Nell (2012) suggested how A1 agonist 2-Chloro-N6-cyclopentyladenosine 
(CCPA) can significantly reduce heart rate in a concentration-dependent manner. Previous 
research conducted by Hoffman et al. (1997) showed that when A1AR agonist N6- 
cyclopentyladenosine was administered to mammalian embryos it significantly decreased 
heart rate. This group also showed that there was no significant effect upon heart rate via the 
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A2A and A2B adenosine receptors however studies by Berwick et al. (2011) in anesthetized dogs 
and Sanjani et al. (2011) in knockout mice both showed that activation of the A2A and A2B 
receptors enhanced vasodilation and therefore increase coronary blood flow. Activation of A3 
adenosine receptors in mammalian embryos were shown to exert a mild decrease in heart 
rate (Sanjani et al. 2011). Activation of A3 adenosine receptors within different species are 
shown to have different effects upon haemodynamic parameters. Maddock et al. (2002) 
showed that A3AR agonist 2-CL-IB-MECA caused vasodilation and therefore increase coronary 
flow at concentrations of 100nM within rat heart. This is contrasting to earlier studies by 
Lasley et al. (1999) where it was reported that A3AR agonists IB-MECA and CL-IB-MECA had 
no effect upon cardiac function with rat and rabbit with a further zero effect upon coronary 
flow in rabbits.  
Research is being conducted into non-adenosine receptor drugs activating adenosine-related 
mechanisms. Some of these putative modulators include opiods, sildenafil, ketamine and 
creatine (Jacobson and Reitman 2020).  
1.17 Cardioprotection 
 
Several animal models including rat and human cardiomyocytes have demonstrated 
endogenous protective mechanisms to be activated. Ischaemic preconditioning is a 
mechanism of which repeated short cycles of ischaemia (mechanical occlusion) and 
immediate reperfusion are administered to the myocardium prior to the onset of ischaemia 
(Iliodromitis et al. 2007; Singh et al. 2018). Studies have shown that this method of 
cardioprotection has limited myocardial injury and has further provided the myocardium with 
a resistance to ischaemic insult (Skyschally et al. 2008; Tomai et al. 1999).Post-conditioning is 
when brief periods of ischaemia and reperfusion occur after the onset of reperfusion. Studies 
have shown post-conditioning to effectively protect the myocardium and further significantly 
decreasing infarct size (Skyschally et al. 2008). The viable endogenous protective mechanisms 
that can be activated through pre- and post-conditioning can include adenosine production, 
the opening of ATP-sensitive potassium channel as well as the release of nitric oxide (Verma 




1.18 Ischaemic Pre-conditioning  
 
Ischaemic pre-conditioning was first discovered by Murray et al (1986) and research was 
shown to involve short episodes of non-lethal ischaemia which was able to delay necrosis 
upon cardiomyocytes and therefore prevent cell death. Further studies were carried out upon 
a canine model where 4 consistent periods of 5 minute coronary occlusions were shown to 
decrease infarct size by almost 75% when ultimately accompanied by 40 minutes of index 
ischaemia (Murray et al. 1986). Ischaemic pre-conditioning has been shown to confer 
cardioprotection through the reduction of infarct size within the swine model (Schott et al. 
1991) and rabbit model (Liu et al. 1991); however further research has suggested that 
preconditioning has ultimately turned into a universal phenomenon where it can be observed 
in various organs and tissue, not only in the heart, but also in the liver, brain, retina, kidney, 
intestine and skeletal muscle (Yang et al. 2014; Clavien et al. 2000; Simon et al. 1993; Roth et 
al. 1998; Igarashi et al. 2013; Erling Junior et al. 2013; Addison et al. 2003; Stokfisz et al. 2017).  
Ischaemic preconditioning has been researched to protect ischaemic reperfused myocardium 
through the release of endogenous agents that are locally released at the site of injury. These 
include; adenosine, bradykinin, catecholamine’s and opioids that act upon the cell surface 
GPCRs (Cohen et al. 2000; Stokfisz et al. 2017). The activation via these mediators trigger an 
intracellular signal transduction where potentially three parallel pathways may activate (1) 
the mediation of nitric oxide (NO) and nitric oxide synthase (NOS), (2) the reperfusion injury 
salvage kinase (RISK) pathway and the (3) the survival activating factor enhancement (SAFE) 
pathway (Stokfisz et al. 2017). Yellon and colleagues (2002; 2003; 2004) were able to 
experimentally shown that ischaemic preconditioning has the ability to confer myocardial 
protection through the recruitment of the RISK pathway which consists of the PI3K-AKT and 
MEK1/2-ERK1/2 cell survival pathways and it was further shown that when these pathways 
were inhibited, there was also a halt in ischaemic pre-conditioning dependent 
cardioprotection. The activation of protein kinase C through ischaemic pre-conditioning was 
shown to elevate synthesis of various protective proteins and the opening of the ATP-
sensitive K+ channels (Tomai et al. 1999; Healy et al. 2015). One of the latest human clinical 
trials conducted by Candilo and colleagues (2015) showed that ischaemic pre-conditioning 
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showed a positive clinical benefit upon the heart in patients undergoing coronary artery 
bypass graft (CABG) and/or valve surgery (Candilo et al. 2015). 
1.19 Pharmacological Pre-conditioning  
 
The administration of pharmacological agents prior to ischaemia has experimentally shown 
to induce cardioprotection and this is a phenomenon referred to as pharmacological 
preconditioning (Yellon and Downey 2003). Downey and colleagues (2006) discovered that 
when acetylcholine was administered 30 minutes before ischaemia, there was a reduction in 
myocardial infarction damage within isolated rabbit hearts. This group also went on to study 
how protection of the myocardium involved the recruitment of the MEK1/2-ERK1/2 and PI3K-
AKT cell survival pathway.  
A recent study by Sampieri and colleagues (2020) showed that the administration of 
pharmacological agent Diazoxide to conduct pharmacological pre-conditioning in adult rat 
cardiomyocytes was shown to down-regulate store-operated Ca2+ channels which led to 
ensuring cardioprotection following an ischaemia-reperfusion insult (Sampieri et al. 2020). 
Previous studies have elucidated how pharmacological pre-conditioning with adenosine 
agonist analogues have the ability to improve ischaemic ventricular dysfunction and when 
A1AR antagonist was administered alongside, this protection was lost within the rat and rabbit 
species (Lasley et al. 1995). Pharmacological pre-conditioning with A1AR agonist 2-chloro-N6-
cyclopentyladenosine (CCPA) alongside lidocaine (which modulated sodium fast channels) 
had the ability to minimise myocardial damage in in vivo rat models (Canyon and Dobson 205). 
Pharmacological pre-conditioning with A1AR agonist have further shown to mediate 
cardioprotection with rabbit (Tracy et al. 1998) as well as in the rat (Hochhauser et al. 2007). 
A study conducted by Safran et al. (2001) discovered that the administration of A1AR agonist 
CCPA or A3AR agonist CL-IB-MECA prior to ischaemia successfully attenuated cardiomyocyte 
injury and this protection was further abrogated when cardiomyocytes were pre-treated with 
A1 antagonist DPCPX and A3 antagonist MRS 1523, respectively. Pharmacological pre-
conditioning with A3AR agonists were shown to also mediate cardioprotection within rat 
(Hochhauser et al. 2007), mice (Zhao and Kukreja 2002) and rabbit (Takano et al. 2001). 
Previous research has suggested that pharmacological pre-conditioning with both A1AR and 
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A3AR agonists was shown to limit reperfusion injury within the human atrial model of 
ischaemia reperfusion injury (Carr et al. 1997). 
Pharmacological pre-conditioning with A2AR agonists have also potentially shown protection 
to ventricular myocytes from hypoxia/reoxygenation injury (Stickler et al. 2006).  
1.20 Ischaemic Post-conditioning 
 
Ischaemic post-conditioning is when brief episodes of ischaemia are applied to the 
myocardium at the early stages of reperfusion (Pagliaro and Penna 2011). This process has 
been suggested to be just as protective and effective as pre-conditioning against ischaemia-
reperfusion injury. When post-conditioning is applied immediately within 30 minutes after 
the onset of reperfusion, this is referred to as rapid post-conditioning however if post-
conditioning occurs hours or days after the onset of reperfusion then this can be considered 
as delayed post-conditioning (Zhou et al. 2009). Post-conditioning is known as brief cycles of 
ischaemia at the onset of reperfusion (Pagliaro and Penna 2011). Studies have been 
conducted in order to explore the effects of post-conditioning and Galagudza et al. (2004) 
assessed that post-conditioning limited infarct size and improved endothelial functioning 
within rat hearts that were subjected to ischaemia-reperfusion injury (Galagudza et al. 2004). 
Another study conducted by Zhou et al. (2003) discovered that post-conditioning decreased 
infarct size by 44% compared to the same protective effect of pre-conditioning in rat (Zhou 
et al. 2003).  
Post-conditioning has been researched to be a powerful protective process however the 
definite intracellular signalling pathways that are activated in order to mediate protection 
remain to be fully explored (Zhao and Vinten-Johansen 2006). It was reported by Kin et al. 
(2005) that post-conditioning can protect the myocardium via the delayed washout of 
intravascular adenosine in mice. This was further studied and the administration of non-
specific adenosine antagonist 8-SPT abolished any cardioprotective effects meaning that the 
cardioprotection detected when post-conditioning is carried out to the myocardium 
implicating a role for adenosine receptors in mediating cardioprotection (Kin et al. 2005).  
Darling et al. (2005) also discovered that post-conditioning can exert its cardioprotective 
effects via the upregulation of the MEK1/2-ERK1/2 cell survival pathway, where this 
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protection was then blocked by MEK1/2 inhibitor PD98059 (Darling et al. 2005). Similar results 
were also studied by Yang et al. (2004) where they also discovered that the acquired 
protection through the opening of mitochondrial KATP channels was independent of the PI3K-
AKT cell survival pathway (Yang et al. 2004). Further studies also went on to contradict 
previous studies where Yellon and colleagues (2004) discovered that when isolated perfused 
rat hearts underwent ischaemic post-conditioning, protection was acquired by the 
recruitment of the PI3K-AKT-eNOS cell survival pathway; therefore it is feasible to suggest 
that the exact role of the PI3K-AKT cell survival pathway in cardioprotection via post-
conditioning remains elusive.  
Current research has provided a sound basis for the processes of pre-conditioning and post-
conditioning and that it can protect the ischaemic reperfused myocardium from ischaemia 
reperfusion injury within many species (Zhoa and Vinten-Johansen 2006) as well as human 
trials (Straat et al. 2003). The study by Straat et al. (2003) showed that when ischaemic post-
conditioning reduced infarct size by 36% in patients that were admitted for coronary 
angioplasty. This study did show promising preliminary results for the application of ischaemic 
post-conditioning within a clinical setting; however further studies by Lasley and colleagues 
(2005) showed that post-conditioning failed to protect the human heart from ischaemia-
reperfusion injury but they did show that post-conditioning was able to improve the blood 
perfusion to the myocardium.  
1.21 Cardioprotection conferred by the activation of adenosine 
receptors at reperfusion 
 
To date, numerous studies have shown the implication of adenosine to protect the 
myocardium from ischaemia-reperfusion injury. Zhao et al. (1993) conducted a classic 
investigation that demonstrated that when the A1, A2 and A3 adenosine receptors were 
blocked by the non-selective adenosine antagonist 8-(p-sulfophenyl)-theophylline (8-SPT) at 
the onset of reperfusion. This limited endogenous adenosine mediated cardioprotection due 
to the blockade of the receptors suggested that endogenous adenosine played an important 
role to enhance cardioprotection (Yao et al. 1993; Covinhes et al. 2020).  
Zhao et al. (2001) further went on to investigate the administration of adenosine at 
reperfusion to significantly limit infarct development in a series of experiments performed in 
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dogs. They concluded that the limitation of ischaemia reperfusion injury by adenosine was 
mediated by the upregulation of the anti-apoptotic protein Bcl-2 and further downregulated 
by pro-apoptotic protein Bax. There was also a significant decrease in necrosis discovered in 
the myocardium (Zhao et al. 2001). 
Previously, investigators have attempted to implicate the role of adenosine either by pre-
conditioning or administration at reperfusion and Heide et al. (1996) failed to observe 
protection administered at reperfusion in a canine model and failed to observe protection 
when adenosine was administered before coronary artery occlusion at reperfusion within a 
rabbit model of ischaemia-reperfusion injury (Goto et al. 1991). 
Earlier studies focused on the A1AR in terms of cardioprotection due to the lack of 
identification of the A3ARs. Yao and Gross (1993) discovered that when A1AR agonist 
cyclopentyladenosine (CPA) was administered at by the initial coronary artery occlusion, 
cardioprotection was observed (Yao and Gross 1993). Similar findings were also observed by 
Laing and Jacobson (1998).  Lozza at al. (1997) showed that the adenosine A1 receptor subtype 
and the A2A receptors both mediated beneficial properties during ischaemia and reperfusion 
in isolated rat hearts even though the mechanisms of protection were not fully elucidated 
(Lozza et al. 1997). Stambaugh et al. (1997) also investigated the novel cardioprotective 
function of both the A1 and A3 adenosine receptors when undergoing hypoxia within chick 
embryos how they had the ability to attenuate myocyte injury (Stambaugh et al. 1997). Similar 
findings were investigated by Safran et al. (2001) where highly selective A1AR agonist, CCPA 
and A3AR agonist CL-IB-MECA both produced cardioprotective effects against ischaemia 
within isolated cardiac myocytes of new born rats (Safran et al. 2001).  
More recent research showed that the mixed A1/A2A adenosine agonist AMP579 when given 
at reperfusion was protective within animal models of ischaemia-reperfusion injury. A further 
study was conducted to show that AMP579 was neither an A1 nor A2A selective agonist 
however it was then determined to be a potent A2B agonist that also had the ability to protect 
myocardium against infarction through the A2B adenosine receptor (Liu et al. 2010).  
Baltos et al. (2017) have recently conducted a clinical trial on a partial A1AR agonist, 
Capadenoson, which also has the ability to stimulate the A2BAR. It was suggested that 
Capadenoson was a dual A1/A2B adenosine receptor agonist, however it did promote 
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cardioprotection and modulate a decrease in cardiac fibrosis in heart disease (Baltos et al. 
2017).  
Ample amounts of current research has been conducted upon the A3 adenosine receptor 
agonist due to their characteristics being more well known compared to A1 adenosine 
receptor agonists. Maddock et al. (2002) used a highly specific A3AR agonist IB-MECA 
administered at reperfusion and concluded that it protected the myocardium from ischaemia-
reperfusion injury and furthermore limited myocardial stunning in the guinea pig model. This 
protection that was acquired was blocked in the presence of A3AR antagonist MRS1191 
(Maddock et al. 2002) Maddock et al. (2003) also went on to show that another A3AR agonist, 
2-CL-IBMECA, when administered at reperfusion in isolated perfused rat heart as well as the 
cardiomyocyte model of ischaemia reperfusion injury, was able to confer cardioprotection. 
This protection was mediated through the anti-apoptotic and anti-necrotic manner and this 
protection was abrogated in the presence of A3AR antagonist MRS1191 (Maddock et al. 2003). 
It would be feasible to suggest that research into A1AR agonists could potentially confer 
cardioprotection? 
Furthermore, research conducted by Hussain and colleagues (2013) also described the 
molecular mechanisms that were associated with A3AR mediated cardioprotection and they 
indicated that within rat cardiomyocytes, the A3AR agonist 2-CL-IB-MECA (1nM) was able to 
upregulate pro-survival signalling pathways that could lead to a decrease in caspase-3 activity 
to ameliorate ischaemia-reperfusion injury (Hussain et al. 2013).  
Activation of A3ARs have shown to confer cardioprotection within different models however 
these receptors have also been able to stimulate anti-cancer properties (Fishman et al. 2001); 
as well as played a role in cerebral-protection (Von Lubitz et al. 2001); as well as within anti-
apoptotic and anti-necrotic pathways (Maddock et al. 2003). Studies have also shown that 






1.22 Cardioprotection conferred by the activation of adenosine receptors 
post-reperfusion 
 
Previous studies elucidated how pharmacological and non-pharmacological interventions can 
protect the myocardium from ischaemia-reperfusion injury, however it remains an area for 
further research to establish whether postponing the administration of pharmacological 
agents after the onset of reperfusion has the ability to protect the myocardium from 
ischaemia reperfusion injury.  Von Lubitz and colleagues (2001) investigated that when the 
administrations of A3AR agonist IB-MECA was postponed to 20 minutes after the onset of 
reperfusion there was significant protection observed to the brains of mice that were 
subjected to ischaemia-reperfusion. The specific signalling pathway that was recruited was 
not determined (Von Lubitz et al. 2001). Another study conducted by Jonassen et al. (2001) 
investigated that when the administration of the hormone insulin occurred 15 minutes post-
reperfusion, a loss of protection was observed in rat (Jonassen et al. 2000). Bolli et al. (2006) 
further showed that the administration of cytokine therapy 4 hours after the onset of 
reperfusion in order to limit ventricular modelling showed to improve left ventricular 
performance by the promotion of cardiac regeneration within mouse. Caspase inhibitors 
were also researched by Armstrong et al. (2001) that when administered 1 hour after 
reperfusion, they were able to reduce infarct development within the rat heart (Armstrong et 
al. 2001). Research by Hussain and colleagues (2015) also looked into how activation of the 
A3 adenosine receptors at the onset of reperfusion/reoxygenation with the use of 2-CL-IB-
MECA in rat perfused hearts and cardiomyocytes successfully decreased caspase-3 activity by 
the upregulation of pro-survival signalling pathways which included the MEK1/2-ERK1/2 and 
PI3K-AKT cell survival pathways (Hussain et al. 2015).   
The following study may not be related to the myocardium however it does explore post-
reperfusion activation within cerebral ischaemia of brain endothelial cells using two mouse 
models. The two models consisted of; global and focal cerebral ischaemia induced by 
transient occlusion of the carotid arteries, or the middle cerebral artery. The study conducted 
by Yu et al. (2017) investigated how cerebral ischaemia leads to multifaceted injury within the 
brain. This study showed that when a poly-therapeutic drug (lamotrigine and lovastatin) was 
administered after the onset of reperfusion, an increase in protection was observed via the 
targeting of multiple deleterious cascades (Yu et al. 2017).   
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Interestingly, the A3AR agonist 2-CL-IB-MECA has previously been shown to limit infarct 
development within ischaemic reperfused hearts and it has also been shown that 2-CL-IB-
MECA has the ability to mediate cardioprotection when administered at reperfusion and post-
reperfusion via the recruitment of the PI3K-AKT and MEK1/2-ERK1/2 cell survival pathways 
(Hussain 2009). Hussain et al. (2013) further demonstrated that the recruitment of the PI3K-
AKT and MEK1/2-ERK1/2 cell survival pathways was abolished when kinase inhibitors 
Wortmannin and UO126 (respectively) were administered. They also showed that when A3AR 
agonist 2-CL-IB-MECA was administered throughout reoxygenation, there was a significant 
reduction of apoptosis, necrosis, cleaved-caspase 3 activity as well as an increase in BAD 
expression in rat cardiomyocytes (Hussain et al. 2013).  
Collectively, research has tended to show adenosine to confer cardioprotection when 
administered at reperfusion or prior to an ischaemic insult however, no study to date has 
shown the effect of an A1AR agonist being administered post-reperfusion upon infarct 
development as well as upon anti-apoptotic and anti-necrotic processes. No clear link 
between A1 adenosine receptors and the recruitment of cell survival pathways has been 
shown via the delayed reperfusion activation of A1ARs. The aim of this current study was to 
determine whether A1AR agonist 2’-MeCCPA mediated cardioprotection within the 
Langendorff perfused rat heat and adult rat cardiomyocyte model from reperfusion or 
reoxygenation injury via the recruitment of the PI3K-AKT and MEK1/2-ERK1/2 cell survival 
pathways post-reperfusion/reoxygenation. 
 
1.23 Reperfusion Injury Signalling Kinase (RISK) Pathway 
 
Studies by Hausenloy et al. (2005) have previously established the role and recruitment of 
pro-survival kinases; AKT and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2). 
These kinases are commonly termed the RISK pathway and have shown to confer 
cardioprotection against myocardial ischaemia-reperfusion injury. This makes these pro-
survival kinases an important target for cardioprotection. Further studies have also been 
conducted to show that the RISK pathway involves the activation of PI3K-AKT or ERK1/2 as 
two parallel branches of the RISK pathway (Hausenloy et al. 2007). The PI3K-AKT and ERK1/2 
signalling pathways are not independent of each other as a study conducted by Hausenloy et 
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al. (2004) showed that isolated perfused rat hearts that were subjected to LY294008 (PI3K-
AKT inhibitor) at reperfusion induced phosphorylation of ERK1/2-p70S6K; furthermore 
inhibiting MEK1/2-ERK1/2 pathway using PD98059 at reperfusion induced phosphorylation 
of AKT. Therefore this suggests cross talk between the two kinase pathways (Hausenloy and 
Yellon 2004).  
1.23.1 Mitogen-Activated Protein Kinase (MAPK) 
 
Mitogen activated protein kinases (MAPK) are a family of kinases that have the ability to 
respond to extracellular stimuli. MAPKs are serine and threonine kinases and that have been 
investigated by a  number of research groups and found to regulate cell growth, cell 
differentiation, apoptosis and stress responses (Figure 1.6) (Plotnikov et al. 2011). Three 
MAPK families have been clearly characterised and researched, namely, the classic MAPK 
known as ERK, C-Jun C-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38 
kinase. MAPKs lie within protein kinase cascades (Zhang and Liu 2002). Kinases can be 
activated by tyrosine kinase receptors of the activation of GPCRs couple with Gi, Go, Gq and Gs 
(Pearson et al. 2001). 
Once receptor ligand interaction occurs, a sequence of events involving adapter proteins, 
growth factor receptor binding protein (GRB) and Ras guanine exchange factor (SOS), can 
activate Raf (an MAP kinase kinase kinase (MAPKKK), which is also the first of the three MAPK 
module as seen in Figure 1.5 (Zhang and Liu 2002). The phosphorylated Raf has the ability to 
activate downstream MAPKK, MEK1/2 and can further phosphorylate to produce MAPK, 
ERK1/2. The phosphorylation of ERK1/2 at Thr202 and Tyr204 residues can transform ERK1/2 



















Figure 1.6 Diagram to illustrate the MAPK cascade to produce MEK1/2 and ERK1/2 (Zhang 
and Liu 2002). 
 
 
Figure 1.7 Schematic diagram to summarise the functions of the ERK1/2 signalling pathway 




Punn et al. (2000) have shown that an increase in ERK1/2 during ischaemia can further be 
upregulated at the onset of reperfusion within cardiomyocytes. Later studies by Schulte et al. 
(2002) have characterised adenosine receptor agonists to cause the upregulation of 
extracellular regulated kinase (ERK1/2) within Chinese hamster ovary cells (CHO) that 
expressed A3 adenosine receptors.  
Germack and Dickenson (2004) investigated the characteristics of the activation of ERK1/2 via 
adenosine and adenosine analogues within new born cardiomyocytes. They characterised 
that when A1, A2A and A3 adenosine receptor analogues were administered in a time and dose 
dependent manner, there was an increase in ERK1/2 activation however this was not to the 
same extent as with adenosine. This suggests that adenosine has the ability to stimulate all 
adenosine receptors however specific receptor agonists exert their effect on their respective 
receptor subtypes. Nevertheless, a link between adenosine and the upregulation of ERK1/2 
has been investigated.  
Hussain et al. (2013) investigated the role of the MEK1/2-ERK1/2 signalling pathway and the 
effect it had on modifying caspase-3 activity by A3AR agonist 2-CL-IB-MECA mediated 
cardioprotection in rat cardiomyocyte model. It was shown that caspase-3 activity was 
decreased via the recruitment of the MEK1/2-ERK1/2 pathway and MEK1/2 inhibitor UO126 
abrogated this mediation of cardioprotection (Hussain et al. 2014). 
The stress activated protein kinases p38 and JNK are more responsive to a stress stimuli such 
as heat shock, UV radiation, osmotic shock and they also play a part in cell death. Studies have 
been conducted where the inhibition of p38 was shown to reduce myocardial injury following 
infarction within mouse however this protection was not seen in swine (Kaiser et al. 2005). 
JNK has remained a pathway of disagreement on whether it is anti- or pro-apoptotic as recent 
study by Xu et al. (2014) has shown that inhibiting JNK dephosphorylation and activating 







1.23.2 Phosphatidylinositol-3-Kinase (PI3K) 
 
Phosphatidylinositol-3-kinase (PI3K) is a serine/threonine kinase which is a significant player 
in the role of regulating cell growth, differentiation and survival (Ban et al. 2008). The PI3K-
AKT pathway itself has been shown to catalyse the phosphorylation of inositol-containing 
lipids, also known as phosphatidylinositol’s which are then converted to phosphatidylinositol-
3, 4, 5-trisphosphate which are important second messenger molecules. The PI3K 
phosphorylation can lead to subsequent phosphorylation of AKT (also known as protein 
kinase B) via cell signalling cascades which can further lead to cardioprotective effects in a 
myocardial ischaemia-reperfusion setting (Jonassen et al. 2004; Mangi et al. 2003). This cell 
survival pathway was also researched to investigate whether it plays a role within a pre-
conditioning setting (Hausenloy and Yellon 2003). The phosphorylation of AKT via the cell 
signalling cascade leads onto the dual phosphorylation of the ser473 and thr308 residues by 
phosphate-dependent kinase-1 (PDK-1) (Ban et al. 2008).  
The activation of the PI3K-AKT pathway can promote cell survival by the phosphorylation of 
various pro survival molecules such as AKT, endothelial nitric oxide synthase (eNOS) and 
p70S6K (Hausenloy et al. 2004; Mocanu and Yellon 2002). These studies have demonstrated 
a decrease in the activation of apoptotic proteins such as p53, caspase and members of the 
Bcl-2 family (BIM, BAD and BAX). AKT can activate a variety of effector proteins such as 
glycogen synthase kinase 3β (GSK3β) which can stimulate glycogen synthesis as well as other 
proteins involved in cell proliferation and growth (Hausenloy and Yellon 2004; Park et al. 
2006).  
When exploring the context of myocardial ischaemia and reperfusion, studies were carried 
out by Punn et al. (2000) on cardiomyocytes models to simulate ischaemia and reperfusion in 
order to characterise the expression of AKT. It was shown that during ischaemia, p-AKT (ser473) 
was not expressed however expression was enhanced by reperfusion. The PI3K inhibitor 
Wortmannin was also able to abrogate AKT phosphorylation at reperfusion.  
The administration of non-selective adenosine agonist NECA was shown to upregulate 
phosphorylation of AKT and the PI3K inhibitor Wortmannin or LY294002 abrogated the 
phosphorylation of AKT mediated by NECA in rabbit hearts (Yang et al. 2004). The same 
researchers further showed that the phosphorylation of PI3K was sensitive to the Gi/o inhibitor 
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pertussis toxin which therefore implicates the activation of A3 adenosine receptors by NECA 
as well as activation of MAPK p38 and ERK1/2. Kis et al. (2003) also showed the upregulation 
of PDK1-PI3K-AKT cell survival pathway within the rabbit model of ischaemic pre-conditioning 
to allow for protection of the myocardium.  
A more recent study by Hussain et al. (2013) has proposed the recruitment of the PI3K-AKT 
cell survival pathway to enhance cardioprotection by decreasing capase-3 activity through the 
administration of A3AR agonist 2-CL-IB-MECA at the onset of reperfusion in rat cardiomyocyte 
model. This highlight’s the importance of the activation of the PI3K-AKT cell survival pathway 
which mediates protective effects to the myocardium.  
Tian et al. (2015) demonstrated that pre-treatment to the myocardium with A2BAR agonist 
BAY 60-6583 via pre-conditioning had the ability to protect the myocardium from ischaemia-
reperfusion injury through its anti-inflammatory effects that also linked to the PI3K-AKT cell 
survival pathway.  
Hausenloy et al. (2004) previously proposed the strategy of cross talk between the PI3K and 
the ERK1/2 pathways during early reperfusion. This novel study investigated how the 
blockage of the PI3K activity using PI3K inhibitor Wortmannin upregulated ERK1/2 
phosphorylation and the blockage ERK1/2 pathway using PD98059 upregulated the AKT 
phosphorylation. Blockage of both pathways abrogated any protective effect by ischaemic 
pre-conditioning.  
As a collective, data has demonstrated that the release of adenosine during myocardial 
ischaemia and reperfusion plays a punitive role in the activation of adenosine receptor 
dependent cell survival pathways (Sommerchild and Kirkeboen 2000; Hussain et al. 2013). 
Studies have looked into cell lines and rat cardiomyocytes and evidence is apparent to suggest 
that adenosine has the ability to activate AKT and ERK1/2 via adenosine receptors. There has 
been extensive research over the year’s entailed pharmacological and non-pharmacological 
experimental interventions in order to protect the myocardium from ischaemia-reperfusion 
injury. Continued research in the field of cardiovascular research and the continuous 
development of agents could potentially lead to an agent that can one day be successfully 
used in a clinical setting. 
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The aims of this thesis were to: 
- To determine whether the activation of A1AR agonist 2’-MeCCPA, when administered 
at reperfusion or post-reperfusion had the ability to protect the myocardium from 
ischaemia-reperfusion injury via the PI3K-AKT or MEK1/2-ERK1/2 cell survival 
pathways within isolated perfused rat heart. 
- To elucidate the status of cell survival pathway proteins AKT within non-treated 
control ischaemic-reperfused hearts and 2’-MeCCPA treated hearts when 2’-MeCCPA 
was administered at the onset of reperfusion or post-reperfusion in the presence and 
absence of their respective inhibitors by western blot analysis.  
- To fully determine whether the administration of 2’-MeCCPA at the onset of 
reoxygenation or post-reoxygenation can attenuate cell death in the form of caspase-
3 activity, apoptosis and necrosis in an adult rat cardiomyocyte model of 
hypoxia/reoxygenation injury. To also determine the role of the PI3K-AKT and 
MEK1/2-ERK1/2 cell survival pathways within 2’-MeCCPA mediated cardioprotection 




The objectives of this thesis were to: 
- Examine the effects of increasing concentrations of 2’-MeCCPA in an 
ischaemia/reperfusion setting in isolated rat hearts as well as adult rat 
cardiomyocytes; 
- Identify the concentration of the A1AR agonist 2’-MeCCPA that provides the 




- Investigating the effects of administrating 2’-MeCCPA at the onset of reperfusion, 15 
or 30 minutes post-reperfusion to explore the protective effects.  
- Investigate the effects of A1 adenosine antagonism to confirm the protective role of 
the A1 adenosine receptor in the model of ischaemia/reperfusion and 
hypoxia/reoxygenation, at the onset of reperfusion/reoxygenation, 15 and 30 
minutes post-reperfusion/reoxygenation; 
- Investigate the effects of 2’-MeCCPA on the PI3K-AKT intracellular signalling pathway 
in heart tissue, at the onset of reperfusion/reoxygenation, 15 and 30 minutes post-
reperfusion/reoxygenation; 
- Investigate the effects of 2’-MeCCPA on the MEK1/2-ERK1/2 intracellular signalling 





The hypotheses of this thesis are as follows: 
- The administrations of the A1AR agonist 2’-MeCCPA will provide a cardioprotective 
effects to the myocardium in the ischaemia/reperfusion and hypoxia/reoxygenation 
model. 
- This cardioprotective effect will be observed by a decrease in infarct size, an 
improvement to cardiac functioning, and a decrease in cell death and caspase-3 
activity and an increase in the PI3K and MEK1/2 survival pathways at the onset of 











Chapter 2: Materials and Methods 
 
2.1 Experimental Animals 
 
Adult male Sprague Dawley rats (350±50g body weight) were obtained within this study from 
Charles River (Margate, UK) and were kept within the institutional animal house under 
humane conditions in order to acclimatise with free access to a standard pelleted diet and 
water. All care and procedures were carried out in accordance with the Guidance on the 
Operation of the Animals Act (Scientific Procedures Act 1986). Ethical approval was obtained 
from Coventry University Research ethics committee in order for the study to be carried out; 
ethics was regularly assessed throughout the project (Reference P76726). 
2.2 Materials 
 
The following chemicals 2-Chloro-N-cyclopentyl-2'-methyladenosine (2’-MeCCPA) (selective 
A1 agonist), 1S,6bR,9aS,11R,11bR)11-(Acetyloxy)1,6b,7,8,9a,10,11,11b-octahydro-1-
(methoxymethyl)-9a,11b-dimethyl-3H-furo[4,3,2de]indeno[4,5,-h]-2-h]-2-benzopyran-3,6,9-
trione (Wortmannin) (selective irreversible PI3K inhibitor), 1,4-Diamino-2,3-dicyano-1,4-
bis[2-aminophenylthio]butadiene (U0126)  (selective inhibitor of MEK1/2), 8-Cyclopentyl-1,3-
dipropylxanthine (DPCPX) (selective A1 antagonist), 4-(2-[7-Amino-2-(2-
furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385) (highly selective 
A2a antagonist), N-(4-Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-
purin-8-yl)phenoxy]-acetamide (MRS 1754) (selective A2b antagonist), N-[2-(2-Furanyl)-8-
propyl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N'-(4-methoxyphenyl)urea 
(MRE 3008F) (selective A3 antagonist), 8-(p-Sulfophenyl)theophylline (8-SPT) (Unselective 
adenosine antagonist) and Hydrogen Peroxide were supplied supplied by Tocris (Bristol, UK).  
 
All drugs were dissolved in dimethyl sulfoxide (DMSO) with the final concentration of DMSO 
being less than 0.02% as this does not affect haemodynamic data or infarct size (data not 
included) which is then stored at -20 °C. Bliksøen et al. (2016) investigated that when DMSO 
was administered under 0.02% to a Langendorff experiment, no effect was detected upon 




All salts and chemicals that were used in order to prepare buffers for the Langendorff 
technique and cardiomyocyte isolation were purchased from Fischer Scientific 
(Loughborough, UK).  
 
All equipment and reagents used for the Western blot technique were purchased from Bio-
Rad (Watford, UK).  
 
All antibodies including: Cleaved Caspase-3 (Asp175) Antibody (Alexa Fluor® 488 Conjugate), 
phospho-AKTser473, total-AKT, phosphor-p44/42 MAPK (ERK1/2)(Thr202/Try204), p44/42 MAPK 
(ERK1/2) antibodies and GAPDH, (HRP) conjugated Rabbit monoclonal antibodies and 
antibiotin were purchased from Cell Signalling (UK). SuperSignal West Femto® enhanced 
chemiluminescent substrates were purchased from ThemoFisher (UK). Dead Cell Apoptosis 
Kit with Annexin V FITC and PI was purchased from ThermoFisher (UK). 
 
2.3 Langendorff Technique – Isolated Perfused Rat Heart Model 
 
2.3.1 Heart Extraction and Perfusion Procedure 
 
Following the rapid sacrifice of the rat by cervical dislocation in accordance to the Schedule 1 
Home Office Procedure, hearts were dissected and then placed in ice cold Krebs Henseleit 
buffer (KHB) solution (118.5mM NaCl, 25mM NaHCO3, 4.8mM KCl, 1.2mM MgSO4, 1.2mM 
KH2PO4, 12mM Glucose, 1.7mM CaCl2.2H2O) <4oC and at pH 7.4 (Hussain et al. 2013). 
The hearts were removed by a process called thoracotomy (Bell et al. 2011). This process 
involves a trans-abdominal skin incision is carried out at the xyphoid- sternum and further 
expanded to the lateral ends of the right and left costal sides (Bell et al. 2011). The surgical 
procedure was then continued up to the ribs at the left and right anterior axillary lines in order 
to generate the clamshell thoracotomy (Bell et al. 2011). Following on from this, the 
pericardium was opened and the thoracic cage was detached to expose the heart for 




The hearts were removed by promptly excising the descending aorta and immediately 
transferred to ice cold KHB so that ischaemic damage was prevented (Skrzypiec-Spring et al. 
2007). The aorta of the rat hearts were attached onto the aortic cannula by the aortic clip and 
perfused with KHB in a retrograded manner (Bell et al. 2011; Gharanei et al. 2013). The aorta 
was fastened to the aortic cannula by thread which secured the heart to the Langendorff 
system after which the aortic clip was removed. The KHB was administered retrogradely at a 
constant hydrostatic pressure, stable flow rate and at a constant pH of 7.4 by continuous 
gassing with 95% O2 and 5% CO2 (BOC gases). Extra care needed to be taken to ensure that 
the cannula was not inserted too deep into the aorta as this would cause mechanical fissure 
or obstruction to the coronary ostia (Bell et al. 2011). The temperature was also maintained 
at 37oC with the use of a water jacketed heat exchange coil to allow for the heart to stabilise 
upon the Langendorff system (Skrzypiec-Spring et al. 2007; Bell et al. 2011). It has been 
researched that the optimal time needed for the heart to stabilise functioning is 5-10 minutes 
after the cannulation period (Skrzypiec-Spring et al. 2007; Bell et al. 2011). 
The Langendorff model was first pioneered by Oscar Langendorff in 1895 and ever since 
evolved as a technique in which the understanding of the physiology of the heart which 
includes contractile function, coronary blood flow and cardiac metabolism could be 
understood (Bell et al. 2011). This model has been included within many research studies 
where the Langendorff model was used to probe and identify the pathophysiology of 
ischaemia and reperfusion as well as other disease states. This model can also study the 
effects of pharmacological agents and their physiological impact upon the heart as well as 
upon intracellular signalling pathways (Bell et al. 2011). Within a normal in vivo heart, it has 
been found that the coronary system relies upon the pressure within the heart in order to 
pump blood; however within a Langendorff system, the model itself pumps directly into the 
coronary system which then allows for a constant pressure within the heart. Whilst this is 
occurring, a steady ejection of KH buffer is maintained through the heart chambers. This way, 





2.3.2 Measurement of Haemodynamic Cardiac Parameters: Left 
Ventricular Developed Pressure (LVDP), Heart Rate (HR) and Coronary 
Flow (CF) 
 
A pressure transducer was calibrated prior to every Langendorff experiment using the 
software LabChart 7 with the PowerLab (AD Instruments Ltd. Chalgrove, UK). Before each 
experiment commenced, the pressure transducer was set to the zero point by the bridge amp 
and desired calibration values were applied and values were recorded in the software with 
applicable units (mmHg) for the whole experiment.  
As soon as the heart contracted consistently, the left atrium was removed and a latex balloon 
was inserted into the left ventricle and inflated with water to a set preload of 5-10mmHg 
(Skrzypiec-Spring et al. 2007); Bell et al. 2011). The balloon was connected to a pressure 
transducer which allowed for the LVDP and HR to be recorded constantly and further 
examined through the PowerLab system (Figure 2.1) (Gharanei et al. 2013).  
The haemodynamic parameters of LVDP and HR were observed and recorded at regular time 
intervals. To measure the CF rate, the effluent from the heart attached onto the Langendorff 
system was collected for 1 minute at each time point of regular intervals. All three of the 
haemodynamic parameters were recorded every 5 minutes in the stabilisation and ischaemia 









Figure 2. 1 Diagram illustrating a Langendorff trace that includes the heart rate and left 
ventricular developed pressure using the PowerLab system.  
All haemodynamic parameters were graphed using Microsoft Excel where LVDP and HR were 
calculated as a percentage of the mean stabilisation period; whereas CF was adjusted to the 
heart weight and calculated as a percentage of the mean stabilisation period. Any hearts that 
had a high coronary flow rate (>20ml/min) or any arrhythmic episode throughout the 20 
minutes to stabilisation period were excluded from the study.  
 
2.3.4 Induction of Ischaemia 
 
Regional ischaemia was induced by ligation where a surgical needle (also known as a suture) 
obstructed the main left coronary artery which further obstructed the flow to the left 
coronary artery. The occlusion point was established to be above the coronary artery branch. 
The ends of the suture were then passed through plastic tubes to form a tight snare to initiate 
ischaemia. Reperfusion was initiated by the removal of the plastic tubes to release the thread 
ends of the suture. After the completion of the reperfusion period, the surgical threads were 
tightened to obstruct the left coronary artery and a further 1ml of saline solution containing 
0.25% Evans Blue was administered slowly through the aorta to delineate the viable areas 
from the infarct areas. Figure 2.2 shows a perfused rat heart before ischaemia, after 
ischaemia and then at the end of reperfusion when the heart is infused with Evans blue 
solution. 
 




Figure 2. 2 The Langendorff setup illustrating a Sprague-Dawley rat heart throughout the 
stabilisation before ischaemia (A); regional ischaemia was induced by the tightening of a snare 
to ligate the left anterior descending artery (B); the end of reperfusion where the surgical 
thread was tightened and Evans blue was perfused through the aortic cannula (C) 
 
2.3.5 Experimental Groups in Langendorff Protocol  
 
Normoxic Control Group: 
 
The normoxic control group consisted of the heart stabilising for 20 minutes followed by 155 minutes 
of perfusion with KHB as seen in Figure 2.3. Hearts were then weighed and stored at -20oC for 





Figure 2. 3 Diagram showing the experimental protocol for isolated perfused rat hearts within 
the normoxic control group undergoing 20 minutes of stabilisation and 155 minutes of 




Ischaemia-Reperfusion (IR) Control Group: 
 
Within the ischaemia/reperfusion (IR) control group, hearts underwent 20 minutes 
stabilisation, 35 minutes of induced regional ischaemia and a further 120 minutes of 
reperfusion as seem in Figure 2.4. On completion of reperfusion, surgical threads were 
tightened to obstruct the left coronary artery and a further 1ml of saline solution containing 
0.25% Evans Blue was administered slowly through the aorta to delineate the viable areas 
from the infarct areas. Hearts were then weighed and stored at -20oC for triphenyltetrazolium 




Figure 2. 4 Diagram showing the experimental protocol for isolated perfused rat hearts within 
the ischaemia/reperfusion (IR) control group undergoing 20 minutes of stabilisation, 35 
minutes of induced regional ischaemia and a further 120 minutes of reperfusion with KHB. 
 
Experimental Groups at Reperfusion Studies: 
 
Hearts all underwent 20 minutes of stabilisation, 35 minutes of induced ischaemia and a 
further 120 minutes of reperfusion. As seen on Figure 2.5 at the onset of reperfusion, hearts 
were concomitantly infused with either:  
a) KHB (IR control). 
b) A1AR agonist 2’-MeCCPA (0.1nM, 1nM, 10nM, 10nM and 1µM) (To determine 
cardioprotective effects of A1AR agonist 2’-MeCCPa and 10nM was shown to be the 
most cardioprotective and used for further studies). 
c) A1AR agonist 2’-MeCCPA (10nM) in the presence of cell signalling cascade inhibitors – 
PI3K inhibitor Wortmannin (100nM); MEK1/2 inhibitor UO126 (10µM) (To determine 
the effects of 2’-MeCCPA (10nM) via the activity of the PI3K-AKT and MEK1/2-ERK1/2 
cell signalling pathways).  
d) A1AR agonist 2’-MeCCPA (10nM) in the presence of selective A1AR antagonist DPCPX 







Figure 2. 5 Diagram showing the experimental protocol for isolated perfused rat hearts when 
subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes of reperfusion. 
Drug treatments were administered at the onset of reperfusion.  
 
Upon completion of reperfusion, surgical threads were tightened to obstruct the left coronary 
artery and a further 1ml of saline solution containing 0.25% Evans Blue was administered 
slowly through the aorta to delineate the viable areas from the infarct areas. Hearts were 
then weighed and stored at -20oC for triphenyltetrazolium chloride (TTC) staining. 
 
Experimental Groups at Post-Reperfusion Studies: 
 
As seen from Figure 2.6, hearts underwent 20 minutes stabilisation, 35 minutes ischaemia 
and 120 minutes of reperfusion. Hearts were concomitantly infused with drug treatment at 
either 15 minutes or 30 minutes post-reperfusion with: 
a) 2’-MeCCPA (10nM) at 15 or 30 minutes post-reperfusion. 
b) 2’-MeCCPA (10nM) in the presence of PI3K inhibitor Wortmannin (100nM) or MEK1/2 
inhibitor UO126 (10µM) at 15 of 30 minutes post-reperfusion. 
c) 2’-MeCCPA (10nM) in the presence of either selective A1 (DPCPX-200nM) or 












Figure 2. 6 Diagram showing the experimental protocol for isolated perfused rat hearts when 
subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes of reperfusion. 
Drug treatments were administered 15 or 30 minutes post-reperfusion.   
 
Upon completion of reperfusion, surgical threads were tightened to obstruct the left coronary 
artery and a further 1ml of saline solution containing 0.25% Evans Blue was administered 
slowly through the aorta to delineate the viable areas from the infarct areas. Hearts were 
then weighed and stored at -20oC for triphenyltetrazolium chloride (TTC) staining. 
 
2.3.6 Triphenyltetrazolium Chloride Analysis (TTC) 
 
At the end of the reperfusion period, all hearts including controls and experimental group 
hearts were de-cannulated and then weighed and frozen at -20oC. Next, frozen hearts were 
cut in a transverse manner into slices of approximately 2mm thick and then incubated in 
triphenyltetrazolium chloride (TTC) solution (1% of TTC in phosphate buffer, pH 7.3 at 37oC) 
for 10 minutes (Bell et al. 2011). This way of TTC staining is dependent upon the capacity of 
intracellular dehydrogenase enzymes that react with the tetrazolium salts to produce 
formazan (Bell et al. 2011). As a result of TTC staining, the viable cells which contained 
preserved NADPH were stained in a brick red colour. The non-viable cells (infarct cells) 
showed as pale white-yellow colour (Bell et al. 2011). Any non-risk areas were further stained 
dark blue from the Evans blue solution that was administered. Furthermore, the heart tissue 
slices were incubated in 10% formaldehyde for 4 hours prior to analysis. This allowed for 






Figure 2. 7 TTC stained heart slice placed between two Perspex sheets that were 
compressed with the bulldog clips showing the left ventricle as the non-risk area (dark blue), 
viable risk area (brick-red) and infarcted area (pale white/yellow). 
 
2.3.7 Infarct Size to Risk Ratio (%) Assessment  
 
In order to assess the infarct size to risk ratio (%), the transversal heart slices were placed 
between two glass plates in order to expand the tissue slices and were then held together by 
clips. The viable area, non-risk area (dark blue), risk area (brick red) and infarct area (pale 
white yellow) (as represented in Figure 2.7) were then traced on an acetate paper with each 
trace then being examined using the ImageJ tool program (N.I.H Software, Bethesda, USA). 
The ratio of the infarct area within the risk area was evacuated for each heart slice. The viable, 
risk and infarct area within each heart slice was traced in a double blinded manner by an 
unconnected individual to ensure that there was no bias in results. A selection of samples 
were also double analysed to ensure all results were obtained in an accurate manner.  
The infarct size (IS) for each slice within each group was calculated as a percentage of the area 
at risk (AAR) (IS/AAR %). The area at risk is the area free from Evans blue solution which 
corresponds to the myocardial perfusion bed distal to the occluded left anterior descending 








2.4 Adults Rat Ventricular Cardiomyocyte Isolation 
 
Adult ventricular rat myocytes were isolated from male Sprague Dawley rats (350±50g body 
weight) via enzymatic dissociation (Maddock et al. 2002; Hussain et al. 2014). Once excision 
occurred, the hearts were place within ice cold KH buffer for a short period of time before 
being mounted upon the Langendorff apparatus and then perfused with modified calcium 
free Krebs buffer containing (in mM): 116 NaCl, 5.4 KCl, 0.4 MgSO4.7H20, 10 glucose, 20 
taurine, 5 pyruvate, 0.9 Na2HPO4. 12H2O and 25 NaHCO3 dissolved in RO water. The buffer 
was further oxygenated with 95% O2 and 5% CO2 and also maintained at 37oC at a pH 7.4, to 
ensure contractions of the heart stop. 
Hearts then underwent the perfusion stage with modified KH digestion buffer (1mg/ml Gibco 
type II collagenase isolated from Clostridium histolyticum, 1mM CaCl2). Throughout this 
period of perfusion with collagenase (Gibco, UK), the effluent was recirculated through the 
experiment to ensure a successful isolation took place (Louch et al. 2011). Once the enzyme 
digestion of the heart occurred, the ventricles of the heart were fragmented and incubated 
for 5 minutes in the orbital shaker containing digestion buffer. The supernatant was then 
centrifuged for 2 minutes at 600rpm and the pellet obtained was re-suspended in fresh 
restoration buffer (116 mM NaCl, 5.4mM KCl, 0.4mM MgSO4.7H20, 10mM glucose, 20 mM 
taurine, 5mM sodium pyruvate, 25 mM NaHCO3, 11.75mM KH2PO4, 1% bovine serum albumin 
(BSA), 1% Pen-Strep, 5mM creatine monohydrate and 100mM CaCl2, pH 7.4). 
The cell viability was monitored and strictly assessed through the visualization of the 
cardiomyocyte cells under the inverted microscope as seen in Figure 2.8. The final 
concentration of calcium that needed to be added to the restoration buffer containing the 
cells was added gradually to a final concentration of 1.25mM. This gradual addition was to 
ensure calcium overload didn’t occur which may damage the cells. Only cell isolations that 





Figure 2. 8 Viable rat cardiomyocytes being observed under the inverted microscope. 
 
2.4.1 Hypoxia Induced Isolated Rat Ventricular Cardiomyocytes 
 
The isolated adult rat cardiomyocytes were centrifuged for 2 minute at 600rpm where the 
supernatant was gently removed and the pellet that contained the viable cardiac myocytes 
were gently redistributed in Esumi ischaemic buffer (11.95 mM KCl, 1.04mM MgCl2, 1.7mM 
CaCl2, 4mM HEPES, 10mM deoxyglucose and 20mM sodium pyruvate, pH 6.2). Cells were then 
transferred into a culture dish and incubated for 1 hour in a hypoxic chamber (New Brunswick 
Biosciences, UK) at 37oC in 5% CO2 and 0.01-1% O2 to induce hypoxia.  
Following hypoxic treatment, cells were centrifuged for 2 minutes at 600rpm where the 
supernatant was removed and cardiomyocytes were gently redistributed with 24ml 
restoration buffer at 37oC. The pellet was redistributed and 1ml aliquots were pipetted into a 
24 well sterile plate. Each well contained the necessary drug treatment and underwent a 








2.4.2 Experimental Groups in Isolated Rat Cardiomyocyte Protocol  
 
Normoxic Control Group: 
 
Isolated rat cardiomyocytes underwent 4 hours of reoxygenation at 37oC, 5% CO2 and 95% 





Figure 2. 9 Diagram showing the experimental protocol of the normoxic control. Isolated rat 
cardiomyocytes underwent 4 hours of reoxygenation. 
 
 
Hypoxia/Reoxygenation (Hyp/Reox) Control Group: 
 
Isolated rat cardiomyocytes underwent 1 hour of hypoxia at 37oC, 5% CO2 and 0.01-1% O2 






Figure 2. 10 Diagram showing the experimental protocol of the Hyp/Reox control. Isolated rat 







Experimental Groups at Reoxygenation: 
 
Isolated rat cardiomyocytes underwent 1 hour of hypoxia at 37oC, 5% CO2 and 0.01-1% O2 
followed by 3 hours of reoxygenation at 37oC, 5% CO2 and 95% O2. The following drugs were 
administered at the onset of reoxygenation to isolated rat cardiomyocytes as seen in Figure 
2.11: 
a) Hydrogen Peroxide was administered as a positive control. 
b) A1AR agonist 2’-MeCCPA (1nM, 10nM, 10nM and 1µM) (To determine the effects of 
caspase-3 activity and cell death effects of A1AR agonist 2’-MeCCPA).  
c) A1AR agonist 2’-MeCCPA (10nM) in the presence of cell signalling cascade inhibitors – 
PI3K inhibitor Wortmannin (100nM); MEK1/2 inhibitor UO126 (10µM) (To determine 
the effects of 2’-MeCCPA (10nM) via the regulation of the PI3K-AKT and MEK1/2-
ERK1/2 cell signalling pathways on caspase-3 activity and cell death).  
d) A1AR agonist 2’-MeCCPA (10nM) in the presence of selective A1AR antagonist DPCPX 





Figure 2. 11 Diagram showing the experimental protocol of the administration of all drug 
groups at the onset of reperfusion. Isolated rat cardiomyocytes underwent 1 hour of hypoxia 
and 3 hours of reoxygenation. 
 
Experimental Groups Post-Reoxygenation: 
 
Isolated rat cardiomyocytes underwent 1 hour of hypoxia at 37oC, 5% CO2 and 0.01-1% O2 
followed by 3 hours of reoxygenation at 37oC, 5% CO2 and 95% O2. The following drugs were 
administered at 15 minutes or 30 minutes into the onset of reoxygenation to isolated rat 
cardiomyocytes, as seen in Figure 2.12: 




b) 2’-MeCCPA (10nM) at 15 or 30 minutes post-reoxygenation. 
c) 2’-MeCCPA (10nM) in the presence of PI3K inhibitor Wortmannin (100nM) or MEK1/2 
inhibitor UO126 (10µM) at 15 of 30 minutes post-reoxygenation. 
d) 2’-MeCCPA (10nM) in the presence of either selective A1AR antagonist DPCPX (200nM) 







Figure 2. 12 Diagram showing the experimental protocol of the administration of all drug 
groups at 15 or 30 minutes post-reoxygenation. Isolated rat cardiomyocytes underwent 1 
hour of hypoxia and 3 hours of reoxygenation. 
 
2.5 Flow Cytometry Analysis  
 
2.5.1 Experiment Protocol and Quantitative Analysis of Cleaved 
Caspase-3 Activity 
 
The flow cytometry technique was used in order to evaluate caspase 3 activity following drug 
treatment. Once the drug treatment incubation period was completed, treated cells were 
transferred into labelled Eppendorf tubes and centrifuged at 1200rpm for 2 minutes. The 
pellet obtained was re-suspended in phosphate buffer saline (PBS) (140 mM NaCl, 5mM KCl, 
1.8mM CaCl2) and further fixed with 6% formaldehyde for 10 minutes at room temperature. 
Cardiomyocyte cells were then permeabilised by being incubated in ice cold 90% methanol 
for 30 minute at 4oC and then stored at -20oC ready for analysis. 
Cells were centrifuged at 1200rpm for 2 minutes and washed twice with incubation buffer 
(0.5% BSA in PBS) at room temperature. The Cleaved Capase-3 (Asp175) Antibody (Alexa Fluor 
488 conjugate) was prepared to a 1:100 final dilution using incubation buffer and incubated 
at room temperature for 1 hour in the dark. Furthermore, cells were then centrifuged at 
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1200rpm for 2 minutes and supernatant was discarded. The pellet was redistributed in PBS 
and ready for analysis. 
Analysis occurred using the FL-1 channel on the BD Accuri C6 Plus Flow Cytometer. The mean 
fluorescence for 10 000 cell counts were investigated which indicated the cleaved-caspase 3 
activity. Protocol was carried out in accordance with manufacturer’s instructions (New 
England Biolabs, Hitchin UK).  
 
2.5.2 Experiment Protocol and Quantitative Analysis of Cell Death 
using Dead Cell Apoptosis Kit with Annexin V FITC and Propidium 
Iodide (PI) 
 
In preparation for flow cytometry analysis of cell death, live cardiomyocytes underwent a set 
of processes as recommended by the manufacturer (ThermoFischer, UK).  
Cells were harvested after their incubation period and centrifuged at 1200rpm for 2 minutes. 
They were further washed with cold phosphate-buffered saline (PBS). The 1X annexin-binding 
buffer and a working solution of propidium iodide (PI) was prepared according to the 
manufacturer’s protocol. Once cardiomyocytes had been washed, the supernatant was 
discarded and cells were re-suspended in 1X annexin-binding buffer. 5µl of Alexa Fluor 488 
annexin V and 1 µl of pre-prepared PI working solution was added to 100 µl of cell suspension. 
Cells were then incubated at room temperature for 15 minutes. Next, 400 µl of 1X annexin-
binding buffer was added and mixed gently and samples were then kept on ice.  
Soon after, stained cells were analysed using the BD Accuri C6 Plus Flow Cytometer measuring 
fluorescence emission on the FL-1 channel.  
 
2.6 Western Blotting  
 
2.6.1 Introduction to Western Blotting  
 
Western blotting, also known as immunoblotting, is commonly used as an analytical 
technique which can detect, identify and quantify fractioned proteins based on their 
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molecular weight, charge and conformation. The protein itself is extracted from a tissue or 
cell homogenate. The proteins are separated based on their size by gel electrophoresis and 
then further transferred onto a Polyvinyl Di Fluoride (PVDF) membrane by immunoblot 
transfer (Mahmood and Yang 2012; Kim 2017).  
This technique is split up into four stages. Stage 1) Electrophoresis is where the separation of 
proteins occurs depending on their size, structure and charge; Stage 2) the transfer of the 
proteins onto a Polyvinyl Di Fluoride membrane (PVDF); Stage 3) incubation with the primary 
and secondary antibody to detect the protein of interest; Stage 4) visualisation of proteins 
bands of interest and analysis of their relative abundance. The molecular weight of a protein 
band can be compared to a reference marker. The effectiveness of this technique can be 
limited in a way that high levels of nonspecific background staining and limit the identification 
and quantification of band intensity (Olle et al. 2005). 
2.6.2 Tissue Preparation and Experimental Protocols 
 
For Western blot tissue preparation, isolated rat hearts underwent stabilisation, ischaemia 
and reperfusion for a specific amount of time and 2’-MeCCPA (10nM) was administered at 
reperfusion, 15 minutes or 30 minutes post-reperfusion in the presence and absence of PI3K 
inhibitor Wortmannin (100nM) or MEK1/2 inhibitor UO126 (10µM). Each protocol is 
described below.  
At the end of specific reperfusion periods, hearts were removed from the Langendorff 
apparatus and the left ventricle of each heart was trimmed away using a sterile scalpel. The 
heart tissue was immediately wrapped in foil, labelled accordingly and snap frozen in liquid 





2.6.3 Experimental Groups for Western Blotting  
 
Normoxic Control Group: 
Within the normoxic control group, hearts were subjected to 20 minutes of stabilisation and 
135 minutes of perfusion with KHB. Heats were then taken off the Langendorff apparatus as 
seen in Figure 2.13. 
 
Figure 2. 13 Protocol used to isolate heart tissue within normoxic control group for Western 
blot analysis.  
 
Experimental Groups at Reperfusion Studies: 
 
Hearts underwent 20 minutes of stabilisation, 35 minutes of ischaemia and then a further 10 
minutes of reperfusion. Drug administration occurred at the onset of reperfusion and hearts 
were harvested for Western blot analysis after 10 minutes of reperfusion as seen in Figure 
2.14. Drug groups consisted of the following: 
a) Ischaemia/reperfusion control group – at the onset of reperfusion only KHB was 
perfused through the heart at reperfusion. 
b) A1AR agonist 2’-MeCCPA (10nM) at the onset of reperfusion. 
c) A1AR agonist 2’-MeCCPA (10nM) in the presence of cell signalling cascade inhibitor – 






Figure 2. 14 Protocol used to isolate heart tissue with drug treatments administered at 
reperfusion for Western blot analysis.  
 
Experimental Groups at 15 minutes Post-Reperfusion Studies: 
 
Hearts underwent 20 minutes of stabilisation, 35 minutes of ischaemia and then a further 25 
minutes of reperfusion or 35 minutes of reperfusion. Drug administration occurred at 15 
minutes post-reperfusion and hearts were harvested either 25 minutes or 35 minutes post-
reperfusion, as seen in Figure 2.15. Drug groups consisted of the following: 
a) Ischaemia/reperfusion control group at 25 minutes – KHB was perfused through the 
hearts for 25 minutes after the onset of reperfusion. 
b) Ischaemia/reperfusion control group at 35 minutes – KHB was perfused through the 
hearts for 35 minutes after the onset of reperfusion. 
c) 2’-MeCCPA (10nM) was administered at 15 minutes post-reperfusions and hearts 
were harvested 25 minutes post-reperfusion. 
d) 2’-MeCCPA (10nM) was administered at 15 minutes post-reperfusion and hearts were 
harvested 35 minutes post-reperfusion. 
e) 2’-MeCCPA (10nM) was administered at 15 minutes post-reperfusion in the presence 
of Wortmannin (100nM). Hearts were harvested at 25 minutes post-reperfusion.  
f) 2’-MeCCPA (10nM) was administered at 15 minutes post-reperfusion in the presence 






Figure 2. 15 Protocol used to isolate heart tissue with drug treatments administered at 15 
minutes post-reperfusion for Western blot analysis.  
 
Experimental Groups at 30 minutes Post-Reperfusion Studies: 
 
Hearts underwent 20 minutes of stabilisation, 35 minutes of ischaemia and then a further 40 
minutes of reperfusion or 50 minutes of reperfusion. Drug administration occurred at 30 
minutes post-reperfusion and hearts were harvested either 25 minutes or 35 minutes post-
reperfusion, as seen in Figure 2.16. Drug groups consisted of the following: 
a) Ischaemia/reperfusion control group at 40 minutes – KHB was perfused through the 
hearts for 40 minutes after the onset of reperfusion. 
b) Ischaemia/reperfusion control group at 50 minutes – KHB was perfused through the 
hearts for 50 minutes after the onset of reperfusion. 
c) 2’-MeCCPA (10nM) was administered at 30 minutes post-reperfusions and hearts 
were harvested 40 minutes post-reperfusion. 
d) 2’-MeCCPA (10nM) was administered at 30 minutes post-reperfusion and hearts were 
harvested 50 minutes post-reperfusion. 
e) 2’-MeCCPA (10nM) was administered at 30 minutes post-reperfusion in the presence 
of Wortmannin (100nM). Hearts were harvested at 40 minutes post-reperfusion.  
f) 2’-MeCCPA (10nM) was administered at 30 minutes post-reperfusion in the presence 




Figure 2. 16 Protocol used to isolate heart tissue with drug treatments administered at 30 
minutes post-reperfusion for Western blot analysis.  
 
2.6.4 Protein Extraction 
 
The extraction of proteins was conducted from the stored frozen samples that were obtained 
previously. Approximately 60mg of the ventricular tissue sample was placed in a sterile 
cryogenic vial which that contained 250μl of lysis buffer (0.1M NaCl, 10mM Tris Base, 1mM 
EDTA (pH 8.0), 2mM Sodium phosphate, 2mM NaF, 2mM β-glycerophosphate, 1 protease 
cocktail tablet/100ml lysis buffer and 1 PhosSTOP tablet/10 ml lysis buffer). Following this, 
tissue homogenisation was carried out using IKA Ultra-Turrax Labortechnik T25 WERKE 
homogeniser. The homogenized samples were then centrifuged at 11 000rpm at 4oC for 10 
minutes. The supernatant was isolated and collected at which point it was then assessed for 
its protein concentration using the colorimetric Pierce™ Bicinchoninic Acid (BCA) assay kit 
(Thermo Fisher Scientific, UK). The sampled obtained were further diluted (2X) in sample 
buffer (250mM Tris-HCl pH 6.8, 10% glycerol, 0.0006% bromophenol blue, 4% SDS, 2% β-
mercaptoethanol-pH 6.8) and incubated for 5 minutes at 100oC before being stored at -80oC. 
All samples were defrosted at room temperature before being used and diluted with sample 







2.6.5 Protein Quantification using the BCA Protein Assay 
 
The BCA protein assay is an accurate technique of which the colorimetric detection and 
measurement of total protein occurs (Olson and Markwell 2007). This technique of protein 
quantification is based upon the chemical reduction of Cu2+ to Cu+ by the protein in an alkaline 
environment using a precise and selective colorimetric exposure of cuprous cation by 
bicinchoninic acid. The purple colour achieved in a result from the reaction of two particles 
of BCA with one Cu1+ ion.  
To fully determine the protein concentration of samples, a standard curve was created with 
the use of bovine serum albumin (BSA) as a reference reagent. A set of standards were 
prepared from 2mg/ml BSA provided within the assay. These standards were prepared as 
dilutions ranging from 2000µl/ml to 25µl/ml using H2O as a diluent. Next, 25µl of each 
standard was added to 96 well flat-bottomed micro-titre plates and a blank standard was 
required also. 2µl of unknown sample protein was pipetted into distilled H2O to obtain a 
dilution of 1:12.5. The overall working reagent (WR) was prepared by adding 50 parts of BCA 
reagent A with 1 part of reagent B (both reagent A and B were provided within the kit). 200µl 
of WR was pipetted into each well and mixed thoroughly using a plate shaker for around 30 
seconds. The plate was incubated in the dark to eliminate any light interference in order to 
maximize the rate of reaction and incubated for 30 minutes at 37oC. The plate was then 
cooled to room temperature and the absorbance was measured at 562nm using a UV/Vis 
plate reader. The responses received of the standards allowed for the standard curve to be 
calculated and plotted. Absorbance values of the unknown sampled were inserted into the 
standard curve created on Excel in order to determine their exact protein concentration.  
 
2.6.6 Gel Electrophoresis 
 
To begin the process of gel electrophoresis, 60µg of protein sample was loaded into the 
Biorad 4-15% Tris/Glycine precast gradient gels (Biorad, Hertfordshire, UK). The gel was then 
attached onto the Mini-PROTEAN 3 electrode assembly system (Biorad PowerPac 3000) and 
then ran at 130 volts for 90 minutes. The electrode frame was then placed within the clamping 
frame and the system was secured tightly and closed. The inner chamber was then lowered 
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into the Mini Tank which was then placed into the Biorad mini protean III system (Biorad, UK) 
which then went onto separate out the samples. There was approximately 125ml of 1X 
running buffer (glycine 14.42 g/l, SDS 1.0 g/l, TrisBase 3.0 g/l) that was added to the inner 
chamber of the system and approximately 200ml was added to the outer chamber of the 
system. The plastic combs were removed in order to expose the wells and the samples were 
then loaded into the appropriate wells. This was carried out by using gel loading tips (Fisher 
Scientific Ltd, UK). One of the wells were allocated with 2.5µl of biotinylated protein ladder 
(Cell Signalling Technologies, UK) which contained bands of specific molecular weight which 
aided in the identification of the target protein. The gel was then run using electrical leads 
from the Mini-PROTEAN 3 apparatus to the Power-Pac 9 (Bio-Rad, UK) at 130 volts for 90 
minutes at room temperature. 
2.6.7 Protein Transfer 
 
Once the electrophoresis step was conducted and protein bands had separated, the gel was 
carefully removed from the glass plates and placed into the Trans-Blot Turbo transfer pack 
(Bio-Rad, UK), which consisted of a Polyvinyl Di Fluoride (PVDF) membrane and buffer. The 
transfer cassette was firmly assembled together and closed according to the manufacturer’s 
instruction (Bio-Rad, UK) and placed into the Trans-Blot Turbo transfer system (Bio-Rad, UK). 
The settings on the transfer system was selected for the transfer at 25V, 1.3A for 7 minutes 
using two gels.  
2.6.8 Immunoblotting Procedure 
 
Once the protein transfer procedure was conducted, the PVDF membrane was incubated with 
freshly prepared blocking buffer (5% w/v milk powder in 1X TrisBase Tween20 (TBS-T) buffer 
(2.42 g/l Tris-Base, 8g/l NaCl, 1ml/l Tween20) for one hour facing upwards. The membrane 
was then further washed 3 times for 5 minutes in 1X TBST buffer and then incubated overnight 
with the primary antibody diluted to 1:1000 in antibody buffer (5% w/v BSA in 1XTBS-T) on 
an orbital shaker at 4oC.  
Primary antibodies included: phosphorylated and total-AKTser473, phosphorylated and total-
p44/42 MAPK (ERK1/2) (Thr202/Try204) and GAPDH. GAPDH was used an internal loading control 
in all experiments to ensure that uniform loading of gel samples and uniform transfer of 
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proteins occurred during the immunoblotting stage. The relative variation levels of 
monoclonal rabbit phosphorylated-AKTser473 were normalized to the total form of AKTser473. 
This was also conducted for the monoclonal rabbit phosphorylated-p44/42 MAPK (ERK1/2) 
(Thr202/Try204) being normalized to the total form of the rabbit monoclonal p44/42 MAPK 
(ERK1/2) (Thr202/Try204). 
The membranes were then washed 3 times for 5 minutes in 1X TBST and incubated with 
secondary anti-rabbit antibody HRP (1:1000 dilution in antibody buffer) linked IgG and HRP 
linked with anti-biotin antibody (in order to visualize the biotinylated protein marker) for 1 
hour on an orbital shaker. After this last stage of incubation, the membrane was washed 3 
times again for 5 minutes in 1X TBST before analysis of membranes could occur using the 
Biorad ChemiDoc imaging system.  
In order to normalise phosphorylated-AKTser473 and phosphorylated-p44/42 MAPK 
(ERK1/2)(Thr202/Try204) to their total forms, membranes were placed in stripping buffer for 5 
minutes and to start the re-probing process for total forms of the antibodies, membranes 
were incubated in blocking buffer (5% milk powder in TBST) for an hour. Then incubated 
overnight with the Total antibodies at a dilution of 1:1000 upon the orbital shaker at 4oC. 
After the overnight incubation period, membranes were washed 3 times in 1X TBST and then 
incubated in 1:1000 dilution and incubated with secondary anti-rabbit antibody linked IgG 
and HRP linked with anti-biotin antibody (in order to visualize the biotinylated protein marker) 
Membrane blots were then visualized under the ChemiDoc imaging system (BioRad, UK). 
2.6.9 Visualisation and Quantification of Band Density 
 
Furthermore, membranes were placed on acetate film where 1ml of Super Signal West Femto 
Maximum Sensitivity Substrate solution (ThermoFischer Scientific, UK) was prepared by 
combining reagent A and B in a 1:1 dilution, and then added onto the membranes. This 
solution is an ultra-sensitive substrate that contains luminol which is a widely used 
chemiluminescent reagent. This solution covered the entire surface of the membrane within 
excess for 5 minutes before it was placed within the Biorad™ ChemiDoc imaging system (Bio-
Rad, UK). With the aid of the Bio-Rad Quantity One software, the membrane was exposed for 
10-30 seconds which allowed for the protein bands to be visualized. Band density was then 
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analysed by assessing the background exposure for the blot with the aid of ImageJ (N.I.H, 
Bethesda, USA). The target protein was then accurately identified.  
Data was presented as a mean±SEM. Statistical differences were calculated using the IBM 
SPSS programme where one-way ANOVA with LSD post-hoc test was conducted. Significance 
was considered at p<0.05.  
 
2.7 Statistical Analysis of All Techniques Used 
 
All data that was presented in this project is expressed at the mean ± standard error of the 
mean (SEM). IBM Statistical Package for Social Sciences (SPSS®v21) software was used to 
statistically analyse the data. The statistical tests currently used to analyse infarct sizes, band 
densities and cell population data was by one-way ANOVA accompanied by Fishers Protected 
Least Significant Difference (LSD) test for multiple comparisons. To assess the difference in 
the data sets, a p-value of p<0.05 was used to consider statistical significance.  


















Chapter 3: Profiling of A1 adenosine receptor agonist, 2’-MeCCPA 
within the ischaemia-reperfusion injury model in isolated rat heart 




3.1.1 Adenosine and Adenosine Receptors 
 
Adenosine is an endogenous nucleoside modulator and it is released from almost all cells. It 
is generated by the dephosphorylation of ATP into AMP which is further broken down into 
adenosine. Adenosine has the ability to be released as a response to an injurious effect that 
has occurred for example in response to an ischaemic insult (Gessi et al. 2011; Boreo et al. 
2016). 
There are currently four different adenosine receptors that belong to a superfamily of G-
protein coupled receptors (GPCR). These receptors can be categorised as A1, A2A, A2B and A3 
receptors and each of them cause’s stimulatory and inhibitory actions on adenylate cyclase. 
Each receptor is selective to their respective agonists and antagonists (Boreo et al. 2016; 
Fredholm 2014; Covinhes et al. 2020; Gaudry et al. 2020).  
The A1 adenosine receptor itself is coupled to the pertussis toxin sensitive Gi and Go proteins 
that go on to inhibit adenylate cyclase activity which can further inhibit cAMP activation as 
therefore activate the opening to K+ ion channels and the inhibition of Ca2+ release (Germack 
and Dickenson 2004). The A3 adenosine receptor is also coupled to Gi and Go as well as Gq 
proteins which in turn makes their functioning very similar to the A1 adenosine receptor. The 
A1 adenosine receptor has been well researched to decrease heart rate in many studies 
(Albrecht-Kupper, Leineweber and Nell 2012; Hoffman et al. 1997). 
3.1.2 A1 Adenosine Mediated Cardioprotection 
 
Previous research has been conducted to express how pharmacological pre-conditioning with 
A1AR agonist can mediate cardioprotection, for example Hill et al. (1998) were able to 
mediate cardioprotection within the rabbit heart model with the administration of adenosine. 
This study was able to identify and support studies in showing that selective A1 adenosine 
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receptor agonists were able to pharmacologically mimic ischemic pre-conditioning to ensure 
cardioprotection within the rabbit heart through the A1 adenosine receptor (Hill et al. 1998). 
To further support the essence of cardioprotection in animal models, Hochhauser et al. (2007) 
were able to mediate cardioprotection with pre-ischaemic pharmacological preconditioning 
(PC) in the perfused rat isolated heart model with the use of A1 adenosine receptor agonist, 
2-Chloro-N6-cyclopentyladenosine (CCPA), the protection that occurred partially related to 
the increased phosphorylation of p38 MAPK (Hochhauser et al. 2007).  
Post-conditioning is another phenomenon in which the A1 adenosine receptor, when 
activated, has the ability to induce infarct limiting cardioprotection (Xi et al. 2008). Post-
conditioning is a concept of briefs periods of coronary occlusion performed at the beginning 
of reperfusion which have shown to be successful (Pagliaro and Penna 2011); however 
confounding research has also been established by Kin et al. (2005) who have suggested that 
post-conditioning protection to the myocardium is not via the A1AR subtypes but more so via 
the A2A and A3AR subtypes.  
The phenomenon of post-conditioning differs from post-reperfusion activation in a way that 
in post-reperfusion activation, rat hearts are undergoing 35 minutes of simulated ischaemia 
and then 120 minutes of reperfusion in which A1 adenosine receptor agonist 2’-MeCCPA is 
administered at the onset of reperfusion and 15 or 30 minutes into reperfusion. Whereas 
post-conditioning would include brief periods of ischaemia to be simulated after the 35 
minutes of simulated ischaemia with A1 agonist 2’-MeCCPA being administered throughout 
reperfusion to assess the effects of it. This makes the current study different from post-
conditioning. This idea of post-reperfusion activation can also be supported by Von Lubitz and 
colleagues (2001) who found that A3 adenosine receptor agonist IB-MECA, when 
administered 20 minutes post-reperfusion to the brain was able to significant increase 
protection after an ischaemic injury. Further research conducted by Hussain (2009) showed 
that the post-reperfusion activation of A3 adenosine receptors using Cl-IB-MECA successfully 
attenuated infarct size to risk ratio (%) as well as cell death and caspase-3 activity. With such 
extensive research conducted into the post-reperfusion A3AR activation as well as the 
similarities between the A3 and the A1 adenosine receptors, this became a basis for the 




Taking into consideration the previous research conducted into the A3AR itself, this current 
study was conducted to look into the cardioprotective effects of activation of the A1ARs at 
reperfusion and post-reperfusion rather than through the pre-conditioning and post-
conditioning phenomenon’s. This idea of post-reperfusion activation of A1 adenosine 
receptors is an area of research that has not currently been fully explored. 
3.1.3 Aims and Objectives 
 
1. To determine the cardioprotective effects of A1 adenosine receptor (A1AR) agonist, 2’-
MeCCPA (0.1nM - 1µM) in a dose-dependent manner on infarct size to risk ratio (%), 
cell death (apoptosis and necrosis) and caspase-3 activity when administered at the 
onset of reperfusion/reoxygenation.  
2. To determine the post-reperfusion/reoxygenation activation effects of A1 adenosine 
receptors using A1AR agonist 2’-MeCCPA (10nM) when administered at the onset of 
reperfusion compared to the administration 15 minutes and 30 minutes post-
reperfusion/reoxygenation; and the effects upon infarct size to risk ratio (%), cell 






2’-MeCCPA was purchased from Tocris Cookson (Bristol, UK). Working concentrations of the 




Adult male Sprague-Dawley rats (350 ± 50g) were sacrificed via cervical dislocation outlined 
in the Schedule 1 Home Office Procedure using the process of thoracotomy, previously 




3.2.4 Langendorff Protocol – Isolated Perfused Rat Heart Preparation 
 
Briefly, for studies using the Langendorff model of ischaemia-reperfusion (details in Chapter 
2, Section 2.3.5), the experiments were carried out for 175 minutes in total. Hearts were 
allowed a 20 minutes stabilisation period, followed by 35 minutes of simulated regional 
ischaemia and 120 minutes of reperfusion. Hearts were random allocated to the following 
control and treatment groups: 
a) Normoxic control – Rat hearts perfused with KH buffer for 175 minutes (no ischaemia 
was induced). 
b) Ischaemia-Reperfusion (IR) Control – Rats hearts were perfused with KH buffer for 20 
minutes followed by 35 minutes of simulation regional ischaemia and then 120 
minutes of reperfusion. 
c) Concentration response – Rats were perfused with KH buffer for 20 minutes, 35 
minutes of simulated regional ischaemia and 120 minutes of reperfusion. Throughout 
the reperfusion stage, hearts were allocated with various concentrations of A1AR 
agonist, 2’-MeCCPA (0.1nM, 1nM, 10nM, 100nM and 1µM).  
d) Time-point response – Rats were perfused with KH buffer for 20 minutes, 35 minutes 
of simulated regional ischaemia and 120 minutes of reperfusion were 2’-MeCCPA 
(10nM) was administered at the onset of reperfusion or 15 minutes post-reperfusion 
or 30 minutes post-reperfusion  
Throughout the course of the experiments, the stability of the hearts were monitored through 
the heart rate (HR), left ventricular developed pressure (LVDP) and coronary flow (CF) 
parameters (as described in Chapter 2, Section 2.3.2).  
At the end of the reperfusion period, the infarct size to risk ratio was assessed with the use 
of Evans blue triphenyltetrazolium chloride (TTC) staining procedures as described in Chapter 






3.2.5 Isolation of Adult Rat Ventricular Cardiomyocytes 
 
Adult rat ventricular cardiomyocytes were isolated by enzymatic digestion as previously 
described in Chapter 2, Section 2.4. All details of the heart digestion protocol and conditions 
in order to conduct a successful isolation of primary adult rat cardiomyocytes are described 
in Chapter 2, Section 2.4.  
 
3.2.6 Induction of Hypoxia and Reoxygenation Conditions in Adult Rat 
Cardiomyocytes 
 
As described in Chapter 2, Section 2.4.1, freshly isolated ventricular myocytes were incubated 
in Esumi hypoxic buffer for 1 hour in a hypoxic chamber at 37oC, in 5% CO2 and 0.01-1% O2 to 
induce hypoxia. 
 
3.2.7 Experimental Drug Treatment Protocol in Adult Rat Ventricular 
Cardiomyocytes 
 
Isolated rat ventricular cardiomyocytes were exposed to differing control and drug 
treatments. All conditions are detailed below: 
a) Normoxic control – Isolated myocytes were exposed to normoxic conditions for a total 
of 4 hours at 37oC, 5% CO2 and 95% O2.  
b) Hypoxia-Reoxygenation control – Isolated myocytes were exposed to 1 hour of 
hypoxia conditions followed by the onset of reoxygenation for 3 hours.  
c) Concentration response – Isolated myocytes were exposed to 1 hour of hypoxia 
conditions followed by treatment with 2’-MeCCPA (1nM, 10nM, 100nM and 1µM) at 
the onset of reoxygenation for 3 hours at 37oC, 5% CO2 and 95% O2.  
d) Time-point response – Isolated myocytes were exposed to 1 hour of hypoxia 
conditions followed by treatment with 2’-MeCCPA (10nM) at either; the onset of 
reoxygenation, 15 minutes post-reoxygenation or 30 minutes post-reoxygenation for 




3.2.8 Quantitative Analysis of Cell Death using Dead Cell Apoptosis Kit with 
Annexin V FITC with Propidium Iodide (PI) in Adult Rat Cardiomyocytes 
 
Followed by the drug treatment protocols as described above, isolated rat cardiomyocytes 
were assess for their levels of apoptosis and necrosis using the Dead Cell Apoptosis Kit with 
Annexin V FITC and PI was purchased from ThermoFisher (UK) (previously detailed in Chapter 
2, Section 2.5.2). Data was normalised against the cell only control and the values obtained 
were calculated as a relative change in apoptosis and necrosis activity of the mean 
absorbance of the control group. 
 
3.2.9 Analysis of Cleaved Caspase-3 Activity in Adult Rat Cardiomyocytes 
 
Following the drug treatment protocol as described above, the rat cardiomyocytes were 
probed with cleaved caspase-3 antibody as described in Chapter 2, Section 2.5.1. Data 
obtained was normalised to the cell only control by subtracting the mean fluorescence 
background recorded in untreated samples. Data was presented as a relative change in 
fluorescence activity. 
 
3.2.10 Data analysis 
 
All data that was presented in this project is expressed at the mean ± standard error of the 
mean (SEM). IBM Statistical Package for Social Sciences (SPSS®) software was used to 
statistically analyse the data. The statistical tests currently used to analyse infarct sizes, band 
densities and cell population data was by one-way ANOVA accompanied by Fishers Protected 
Least Significant Difference (LSD) test for multiple comparisons. To assess the difference in 
the data sets, a p-value of p<0.05 was used to consider statistical significance.  






3.3  Results  
 
3.3.2 Profiling of various concentrations of 2’-MeCCPA (0.1nM - 1µM) in 
myocardial ischaemia reperfusion injury within isolated perfused rat 
hearts. 
 
3.3.2.1 The effects of 2’-MeCCPA (0.1nM-1µM) when administered at the 
onset of reperfusion on haemodynamic parameters (left ventricular 
developed pressure, heart rate and coronary flow). 
 
Haemodynamic parameters such as the left ventricular developed pressure, heart rate and 
coronary flow were consistently monitored in Langendorff studies. Hearts were subjected to 
20 minutes of stabilisation, then 35 minutes of ischaemia followed by 120 minutes of 
reperfusion with 2’-MeCCPA (0.1nM, 1nM, 10nM, 100nM and 1µM) administered throughout 
the reperfusion period.  
A general decrease in left ventricular developed pressure (LVDP) was observed after 5 
minutes of regional ischaemia in the ischaemia-reperfusion (IR) control and 2’-MeCCPA 
(0.1nM-1µM) groups. It was found that there was a significant increase in LVDP within the 
normoxic group compared to all other treatment groups (P>0.05) (Figure 3.1). No significant 
difference between the groups at any of the time-points throughout reperfusion was 




















Figure 3. 1 Assessing the effects of 2’-MeCCPA (0.1nM-1µM) on left ventricular developed 
pressure on isolated rat hearts that were subjected to 20 minutes stabilisation, 35 minutes 
ischaemia and 120 minutes of reperfusion. 2’-MeCCPA (0.1nM-1µM) was administered 
throughout reperfusion. Data presented as Mean±SEM. n=6-8. * p<0.05 normoxia vs. all 
treatment group (ischaemia).  
 
A significant decrease in heart rate was detected when hearts were administered with 2’-
MeCCPA (100nM) at each time point within reperfusion compared to the normoxia group 




















Figure 3. 2 Assessing the effects of 2’-MeCCPA (0.1nM-1µM) on heart rate within isolated rat 
hearts subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes of 
reperfusion. 2’-MeCCPA groups (0.1nM-1µM) was administered at the onset and throughout 
reperfusion. Data was presented as Mean±SEM. n=6-8. * p<0.05 normoxia vs. 100nM.  
 
Following left coronary artery occlusion, the coronary flow decrease vastly after 5 minutes of 
ischaemia within all groups. When 2’-MeCCPA (0.1nM-1µM) was administered throughout 
reperfusion, no significant effect upon coronary flow was detected compared with the time 
matched control (p>0.05, Figure 3.3). Interestingly, 2’-MeCCPA (0.1nM - 1µM) treated hearts 
did all increase the coronary flow in comparison to the time matched IR control heart. No 
statistical significance was observed.  
Throughout the period of ischaemia, all treatment groups significantly decreased the 




Figure 3. 3 Assessing the effects of 2’-MeCCPA (0.1nM-1µM) on coronary flow in isolated rat 
hearts that were subjected to 20 minutes stabilisation, 35 minutes of ischaemia and 120 
minutes of reperfusion. 2’-MeCCPA (0.1nM - 1µM) was administered at the onset of 
reperfusion. Data was presented as Mean±SEM. n=6-8. * p<0.05 normoxia vs. all treatment 
group (ischaemia). 
 
3.3.2.2 Profiling effects of 2’-MeCCPA (0.1nM-1µM) on infarct size to risk 
ratio within isolated hearts subjected to ischaemia reperfusion 
injury. 
 
All hearts were subjected to 20 minutes of stabilisation, 35 minutes of ischaemia and 120 
minutes of reperfusion in the presence and absence of the varying concentrations of 2’-
MeCCPA (0.1nM-1µM). These concentrations were administered throughout reperfusion and 
followed by TTC staining to determine the infarct size to risk ratio (%).  
The area at risk (ischaemic area) was quantified for each heart to ensure the values do not 
vary significantly between the groups. This allows for better assessment and quantification of 
the % of infarcted tissues as well as for more reliable quantification of drug treatment. 
Quantifying infarct size as a percentage of area of risk between the groups corrects for 




There was a significant increase in infarct size to risk ratio (%) when the ischaemia-reperfusion 
control (IR) was compared to the Normoxic control (55 ± 6% IR control vs. 7 ± 2% Normoxic 
control, p<0.001) (Figure 3.4).  
The administration of various concentrations of 2’-MeCCPA (0.1nM-1µM) to the myocardium 
had different effects upon the infarct size to risk ratio (%). From Figure 3.4 the administration 
of 2’-MeCCPA (10nM) in particular throughout reperfusion showed the most significant 
decrease in infarct size to risk ratio (%) when compared to the IR control (28 ± 4% vs. 55 ± 6%, 
p<0.001), this concentration was then taken on for further study throughout this chapter. A 
significant decrease in infarct size to risk ratio, when compared to the IR control, was also 
observed at the concentrations of 1nM (42 ± 8% vs. 55 ± 6%, p<0.01), as well as at the 












Figure 3. 4 Infarct size to risk ratio (%) within isolated perfused hearts subjected to 20 minutes 
stabilisation, 35 minutes ischaemia and 120 minutes reperfusion in the presence and absence 
of either 2’-MeCCPA (0.1nM, 1nM, 10nM, 100nM and 1µM) throughout the reperfusion 
period. Data presented as Mean±SEM. n=6-8. *** p<0.001 vs. normoxic, ## p<0.01 vs. IR, ## 




3.3.2.3 Profiling effects of 2’-MeCCPA (0.1nM-1µM) on apoptosis and 
necrosis when administered at reoxygenation within adult rat 
cardiomyocytes subjected to hypoxia-reoxygenation 
 
Isolated rat cardiomyocytes were subjected to different protocols as described in Chapter 2. 
Isolated cardiomyocytes were then either allowed to reoxygenate for a total of 4 hours 
(normoxic control group) or exposed to 1 hour of hypoxia followed by 3 hours of 
reoxygenation (Hyp/Reox control group) in the presence and absence of A1AR agonist, 2’-
MeCCPA (1nM-1M) at the onset of reoxygenation within this section. After the cells 
underwent reoxygenation they were assessed on the flow cytometer to further determine 
the percentage levels of live, apoptotic and necrotic cells out of 10000 cells.  
Isolated adult rat myocytes were subjected to 1 hour of hypoxia followed by 3 hours of 
reoxygenation which then resulted in a 261% increase within the number of apoptotic cells 
compared to the normoxic group (346% Hyp/Reox vs. 135% Normoxia, p<0.001) (Figure 
3.5). The isolated rat cardiomyocytes subjected to 1 hour of hypoxia followed by 3 hours of 
reoxygenation also resulted in a 280% increase within the number of necrotic cells compared 
























Figure 3. 5 The assessment of apoptosis and necrosis within isolated adult rat cardiomyocytes 
subjected to 4 hours of oxygenation (Normoxia) or 1 hour of hypoxia and 3 hours of 
reoxygenation (Hyp/Reox). Results are shown as MeanSEM and are expressed as a 
percentage of 10000 cells counted from 6 individual experiments. *** p<0.001 Hyp/Reox vs. 
Normoxia. 
 
Studies were conducted to ascertain the role of A1ARs in limiting the deleterious 
consequences of reoxygenation injury within adult rat cardiomyocytes that were subjected 
to 1 hour of hypoxia and 3 hours of reoxygenation where A1AR agonist 2’-MeCCPA (1nM, 
10nM, 100nM and 1M) was administered at the onset and throughout the reoxygenation 
period. Differing concentrations of 2’-MeCCPA (1nM, 10nM, 100nM and 1µM) was 
administered at reperfusion in order to determine the cytoprotective effects of 2’-MeCCPA 
and if cytoprotective effects increased as the concentrations of 2’-MeCCPA increased. 
The administration of A1 adenosine receptor agonist 2’-MeCCPA (1nM) throughout 
reoxygenation significantly decreased the percentage of apoptotic cardiomyocytes when 
compared to the Hyp/Reox group (18±2% 2’-MeCCPA (1nM) vs. 34±6% Hyp/Reox, p<0.001) 
(Figure 3.6). The administration of 2’-MeCCPA (2nM) throughout reoxygenation also 
significantly decreased the percentage of necrotic cardiomyocytes when compared to the 
Hyp/Reox control group (15±3% 2’-MeCCPA (1nM) vs. 28±7% Hyp/Reox, p<0.001) (Figure 3.6). 
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At higher concentrations of 2’-MeCCPA (10nM, 100nM and 1µM), significant protection from 
hypoxia-reoxygenation injury was observed through an anti-apoptotic and anti-necrotic 
manner. The administration of 2’-MeCCPA (10nM) throughout reoxygenation significantly 
decreased the percentage of apoptotic cardiomyocytes compared to Hyp/Reox (17±4% 2’-
MeCCPA (10nM) vs. 34±6% Hyp/Reox, p<0.001). When 2’-MeCCPA (10nM) was administered 
throughout reoxygenation, it also significantly decreased necrotic cardiomyocytes (13±2% 2’-
MeCCPA (10nM) vs. 28±7% Hyp/Reox, p<0.001) (Figure 3.6). Administration of 2’-MeCCPA 
(100nM) throughout the duration of reoxygenation significantly decreased the number of 
apoptotic cardiomyocytes compared to the Hyp/Reox group (19±2% 2’-MeCCPA (100nM) vs. 
34±6% Hyp/Reox, p<0.001). The administration of 2’-MeCCPA (100nM) also significantly 
decreased the number of necrotic cells when compared to Hyp/Reox group (15±2% 2’-
MeCCPA (100nM) vs. 28±7% Hyp/Reox, p<0.001). Lastly, the administration of 2’-MeCCPA 
(1µM) significantly decreased the number of apoptotic myocytes in comparison with the 
Hyp/Reox group (17±7% 2’-MeCCPA (1µM) vs. 34±6% Hyp/Reox, p<0.001). Furthermore, the 
administration of 2’-MeCCPA (1µM) also significantly decreased the number of necrotic cells 
compared to the Hyp/Reox group (16±2% 2’-MeCCPA (1µM) vs. 28±7% Hyp/Reox, p<0.001) 
(Figure 3.6).  
Due to the number of apoptotic and necrotic cardiomyocytes being the least within the 2’-
MeCCPA (10nM) group, the concentration of 10nM of 2’-MeCCPA was used in all further 




Figure 3. 6 The assessment of apoptosis and necrosis within isolated rat cardiomyocytes 
subjected to 1 hour hypoxia and 4 hours of reoxygenation. The A1AR agonist 2’-MeCCPA 
(1nM, 10nM, 100nM and 1M) was added at the onset of reoxygenation. Results are shown 
as MeanSEM and are also expressed as a percentage of 10000 cells counted from 6 individual 
experiments. *** p<0.001 vs Normoxia. ### p<0.001 vs. Hyp/Reox. 
 
3.3.2.4 Profiling effects of 2’-MeCCPA (1nM-1µM) when administered at 
reoxygenation on cleaved caspase-3 activity in isolated rat 
cardiomyocytes when subjected to 1 hour of hypoxia and 3 hours of 
reoxygenation 
 
Isolated adult rat cardiomyocytes were subjected to 1 hour of hypoxia and a further 3 hours 
of reoxygenation resulted in a 313% increase in cleaved-caspase 3 activity when compared 
with the normoxic group which consisted of a 4 hours of oxygenation (31335% Hyp/Reox vs. 
10026% Normoxia, p<0.001) (Figure 3.7). Administration of 2’-MeCCPA (1nM) throughout 
reoxygenation significantly decreased cleaved-caspase 3 activity when compared to the 
Hyp/Reox control (22438% 2’-MeCCPA (1nM) vs. 31335% Hyp/Reox, p<0.01) (Figure 3.7). 
When 2’-MeCCPA (10nM) was administered throughout reoxygenation, a significant decrease 
was also seen in cleaved-caspase 3 activity compared to the Hyp/Reox control group 
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(18144% 2’-MeCCPA (10nM) vs. 31335% Hyp/Reox, p<0.001) (Figure 3.7). Another 
significant decrease was detected when 2’-MeCCPA (100nM) was administered at the onset 
of reoxygenation in comparison to Hyp/Reox group (23733% 2’-MeCCPA (100nM) vs. 
31335% Hyp/Reox, p<0.05) (Figure 3.7). When 2’-MeCCPA (1M) was administered 
throughout reoxygenation, there was a decrease in cleaved-caspase 3 activity when 
compared to Hyp/Reox group however this was not a significant change (27747% 2’-
MeCCPA (1M) vs. 31335% Hyp/Reox, p>0.05) (Figure 3.7). 
 
Figure 3. 7 Cleaved-caspase 3 activity within isolated adult rat cardiomyocytes subjected to 4 
hours of oxygenation (Normoxia) or 1 hours of hypoxia followed by 3 hours of reoxygenation 
(Hyp/Reox). The A1 adenosine receptor agonist 2’-MeCCPA (1nM, 10nM, 100nM and 1M) 
was administered at the onset of reoxygenation. *** p<0.001 vs. Normoxia. * p<0.05 vs. 
Normoxia. ## p<0.01 vs. Hyp/Reox. ### p<0.001 vs. Hyp/Reox. # p<0.05 vs. Hyp/Reox. Data is 







3.3.3 The administration of 2’-MeCCPA (10nM) at various time-points within 
reperfusion in myocardial ischaemia reperfusion injury. 
 
3.3.3.1 The effects of 2’-MeCCPA (10nM) at various time-points within 
reperfusion on haemodynamic parameters (left ventricular 
developed pressure, heart rate and coronary flow). 
 
Isolated hearts were subjected to 20 minutes of stabilisation, then 35 minutes of ischaemia 
followed by 120 minutes of reperfusion where 2’-MeCCPA (10nM) was administered at the 
onset of reperfusion compared to 2’-MeCCPA (10nM) being administered at 15 minutes into 
the onset of reperfusion and 30 minutes into the onset of reperfusion.  
A decrease in LVDP was detected in the following 5 minutes of regional ischaemia within non-
treated IR control hearts as well as 2’-MeCCPA (10nM) groups administered at different time-
points. Once reperfusion commenced, an increase in LVDP was detected with a gradual 
decline within all groups compared to the non-treated IR control group (Figure 3.8).  
Throughout the ischaemic period, all treatment groups had a significantly decreased LVDP in 





Figure 3. 8 The effect of 2’-MeCCPA (10nM) on left ventricular developed pressure on isolated 
rat hearts when subjected to 20 minutes stabilisation, 35 minutes of ischaemia and 120 
minutes of reperfusion. 2’-MeCCPA (10nM) was administered at the onset of reperfusion, 15 
minutes post-reperfusion and 30 minutes post-reperfusion. Data was presented as 











Minimum fluctuation in heart rate was observed throughout the Langendorff protocol with 
no statistical significance shown from 2’-MeCCPA (10nM) groups at any time-points when 
compared to time matched controls (p>0.05) (Figure 3.9) 
 
Figure 3. 9 The effects of 2’-MeCCPA (10nM) on heart rate on isolated rat hearts when 
subjected to 20 minutes stabilisation, 35 minutes of ischaemia and 120 minutes of 
reperfusion. 2’-MeCCPA (10nM) was administered at the onset of reperfusion, at 15 minutes 
post-reperfusion and at 30 minutes post-reperfusion. Data was presented as Mean±SEM. 
n=6-8. 
 
When 2’-MeCCPA (10nM) was administered at the onset of reperfusion, 15 minutes post-
reperfusion and 30 minutes post-reperfusion there was a steady decline in coronary flow 
detected when compared to the IR control. No significant differences were detected between 
2’-MeCCPA (10nM) groups compared to the IR control at any time-points within the 
reperfusion period (p>0.05) (Figure 3.10). 
Throughout the ischaemic period, all treatment groups had a significantly decreased the 





Figure 3. 10 The effects of 2’-MeCCPA (10nM) on heart rate on isolated rat hearts when 
subjected to 20 minutes stabilisation, 35 minutes of ischaemia and 120 minutes of 
reperfusion. 2’-MeCCPA (10nM) was administered at the onset of reperfusion, at 15 minutes 
post-reperfusion and at 30 minutes post-reperfusion. Data was presented as Mean±SEM. 
n=6-8. 
 
3.3.3.2 Time-profiling effects of 2’-MeCCPA (10nM) on infarct size to risk 
ratio within isolated hearts subjected to ischaemia reperfusion 
injury 
 
All hearts were subjected to 20 minutes stabilisation, 35 minutes of ischaemia and a further 
120 minutes of reperfusion. 2’-MeCCPA (10nM) was administered at the onset of reperfusion 
and the infarct size to risk ratio was compared to when 2’-MeCCPA (10nM) was administered 
15 minutes into the onset of reperfusion as well as 30 minutes into the onset of reperfusion.  
A significant decrease in infarct size to risk ratio was detected when 2’-MeCCPA (10nM) was 
administered at the onset of reperfusion when compared to the IR control (28 ± 4% vs. 55 ± 
6%, p<0.001). A significant decrease in infarct size to risk ratio was also observed when 2’-
MeCCPA (10nM) was also administered at 15 minutes into the onset of reperfusion (30 ± 10% 
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vs. 55 ± 6%, p<0.001) as well as when 2’-MeCCPA was administered 30 minutes into the onset 











Figure 3. 11 Infarct size to risk ratio (%) within isolated perfused hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion in the presence and 
absence of 2’-MeCCPA (10nM) administered at the onset of reperfusion as well as 
administered 15 minutes into the onset of reperfusion, 30 minutes into the onset of 
reperfusion and 60 minutes into the onset of reperfusion. Data presented as Mean±SEM. n=6-
8. *** p<0.001 vs. normoxic, ### p<0.001 vs. IR.  
 
3.3.3.3 Time-point profiling effects of 2’-MeCCPA (10nM) when 
administered at the onset of reoxygenation, 15 minutes post-
reoxygenation and 30 minutes post-reoxygenation in adult rat 
cardiomyocytes subjected to hypoxia-reoxygenation on apoptosis 
and necrosis. 
 
Isolated adult rat myocytes were exposed to 1 hour of hypoxia and 3 hours of reoxygenation. 
It was observed that when 2’-MeCCPA (10nM) was administered at the onset of 
reoxygenation there was a significant decrease in apoptotic cardiomyocytes compared to the 
Hyp/Reox group (17±4% 2’-MeCCPA at onset of reoxygenation vs. 34±6% Hyp/Reox, p<0.001). 
A significant decrease in necrotic cardiomyocytes was observed when 2’-MeCCPA (10nM) was 
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administered at the onset of reoxygenation compared to the Hyp/Reox group (13±2% 2’-
MeCCPA at onset of reperfusion vs. 28±7% Hyp/Reox, p<0.001) (Figure 3.12). 
When 2’-MeCCPA (10nM) was administered at 15 minutes post-reoxygenation, a significant 
decrease in apoptotic cardiomyocytes was seen in comparison to the Hyp/Reox group (14±5% 
2’-MeCCPA 15mins Post-R vs. 34±6% Hyp/Reox, p<0.001). Similarly, when 2’-MeCCPA (10nM) 
was administered at 15 minutes post-reoxygenation, a significant decrease in necrotic cardiac 
myocytes was seen compared to the Hyp/Reox group (16±4% 2’-MeCCPA 15mins Post-R vs. 
28±7% Hyp/Reox, p<0.001) (Figure 3.12). 
The administration of 2’-MeCCPA (10nM) at 30 minutes post-reoxygenation showed a 
significant decrease in apoptotic cardiomyocytes in comparison to the Hyp/Reox group 
(15±5% 2’-MeCCPA 30mins Post-R vs. 34±6% Hyp/Reox, p<0.001). A significant decrease in 
necrotic cardiomyocytes was observed when 2’-MeCCPA was administered 30 minutes post-
reoxygenation in comparison to the Hyp/Reox group (17±3% 2’-MeCCPA 30mins Post-R vs. 









Figure 3. 12 The assessment of apoptosis and necrosis within isolated rat cardiomyocytes 
subjected to 1 hour hypoxia and 4 hours of reoxygenation. The A1AR agonist 2’-MeCCPA 
(10nM) was administered at the onset of reoxygenation, 15 minutes post-reoxygenation 
and 30 minutes post-reoxygenation. Results are shown as MeanSEM and are also 
expressed as a percentage of 10000 cells counted from 6 individual experiments. *** 
p<0.001 vs. Normoxia. ### p<0.001 vs. Hyp/Reox. 
 
3.3.3.4 Time-point profiling effects of 2’-MeCCPA (10nM) when 
administered at the onset of reoxygenation, 15 minutes post-
reoxygenation and 30 minutes post-reoxygenation on cleaved 
caspase-3 activity in isolated rat cardiomyocytes when subjected to 
1 hour of hypoxia and 3 hours of reoxygenation 
 
Isolated adult rat cardiomyocytes were subjected to 1 hour of hypoxia and 3 hours of 
reoxygenation. It was observed that when 2’-MeCCPA (10nM) was administered upon the 
onset of reoxygenation as well as 15 minutes into the onset of reoxygenation, a significant 
decrease in cleaved-caspase 3 was detected compared to the Hyp/Reox group (181±35% 2’-
MeCCPA at the onset of reoxygenation p<0.001, 262±63% 2’-MeCCPA at 15 minutes Post-
Reox p<0.05 vs. 313±35% Hyp/Reox) (Figure 3.13). A non-significant decrease in cleaved-
caspase 3 activity was detected when 2’-MeCCPA was administered at 30 minutes post-
reoxygenation in comparison to Hyp/Reox group (p>0.05) (Figure 3.13).  
99 
 
A significant increase in cleaved-caspase 3 activity was detected when 2’-MeCCPA was 
administered 15 minutes post-reperfusion compared to when 2’-MeCCPA was administered 
at the onset of reoxygenation (retrospectively, 262±63% vs 181±35%, p<0.01) (Figure 3.13). 
A significant increase in cleaved-caspase 3 activity was also detected when 2’-MeCCPA was 
administered at 30 minutes post-reperfusion compared to when 2’-MeCCPA was 
administered at the onset of reoxygenation (retrospectively, 306±77% vs. 181±35%, p<0.05) 
(Figure 3.13).  
 
Figure 3. 13 Cleaved-caspase 3 activity in isolated rat cardiomyocytes subjected to 4 hours of 
reoxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of reoxygenation 
(Hyp/Reox). 2’-MeCCPA (10nM) was administered at the onset of reoxygenation, 15 minutes 
post-reoxygenation as well as 30 minutes post-reoxygenation. *** p<0.001 vs. Normoxia. ### 
Vs. Hyp/Reox. # p<0.05 vs. Hyp/Reox. $$ p<0.01 vs. 2’-MeCCPA (10nnM) Onset of Reox. $ 









3.4  Discussion  
 
In this current investigation, we demonstrated that altering the concentration of 2’-MeCCPA 
from 0.1nM - 1µM within isolated perfused rat heart had little effect upon haemodynamic 
parameters HR, LVDP and CF except at the concentration of 100nM where 2’-MeCCPA 
showed a significant decrease in HR after the onset of reperfusion (Figure 3.2.). This is can be 
supported by published research by Schindler and colleagues (2005) who observed that when 
the A1 agonist, CPA (0.3mg/kg) was administered to the rat heart model, a significant decrease 
in heart rate and blood pressure was observed (Schindler et al. 2005). The findings of the 
current study can also be compared to a study by Koeppen et al. (2009) where they presented 
in vivo evidence in anaesthetised mice heart models to support how the A1 adenosine 
receptor plays a selective role in slowing heart rate (Koeppen et al. 2009). This current 
investigation only showed the slowing of the HR when 2’-MeCCPA (100nM) was administered 
at reperfusion, this could potentially be useful within a clinical setting. 
The way in which the A1 adenosine receptor decreases HR is by atrioventricular block (AV) 
upon activation (Albrecht-Kupper et al. 2012). They inhibit the pacemaker current which 
decreases the pacemaker action potential and therefore causes negative chronotropy 
(Mustafa et al. 2009). The A1 adenosine receptor activation can act upon the presynaptic 
purinergic receptors that are located on the sympathetic nerve terminals which furthermore 
inhibit the release of noradrenaline and in turn decrease HR (Mustafa et al. 2009). This could 
be the effect occurring when 2’-MeCCPA (100nM) is being administered to activate the A1 
adenosine receptors.  
When 2’-MeCCPA (100nM) was administered at the onset of reperfusion, a decrease in heart 
rate was detected however there was no difference to LVDP within this current study, which 
Schindler and colleagues (2005) had observed. This could have been due to the fact that 
optimal concentration to affect LVDP may not have been reached and higher concentrations 
of 2’-MeCCPA could have been investigated and explored. 
From this current study, it can be implied that when 2’-MeCCPA (10nM) was administered at 
15 minutes and 30 minutes post-reperfusion, there was no significant difference in LVDP 
which is also surprising. This could be due to the fact that such a low concentration of 2’-
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MeCCPA was administered and this could have been investigated using a higher 
concentration of 2’-MeCCPA rather than 10nM for haemodynamic parameters only.  
Although the concentration of 2-MeCCPA (100nM) was observed to slow the HR, this current 
study observed that the concentration of 2’-MeCCPA (10nM) was shown to decrease infarct 
size to risk ratio (%) the most compared to the other concentrations of 2’-MeCCPA (0.1nM, 
1nM, 100nM and 1µM); and therefore taken forward within this study for further 
investigation. The lower concentration of 2’-MeCCPA (10nM) was further used as it provided 
the most significant amount of protection to the isolated rat heart and rat cardiomyocyte 
models. Using such a low concentration of 2’-MeCCPA (10nM) ensured that infarct size to risk 
ratio (%), cell death and caspase-3 activity data remained significantly less. One of the main 
purposes of this current study was to investigate the cardioprotective effects of the A1 
adenosine receptor when activated and this aim was achieved.  
The concentration dependent effects of 2’-MeCCPA (0.1nM - 1µM) were assessed on the 
isolated rat heart model to further determine the effects on infarct size to risk ratio. This 
method of investigation was useful and can be compared to the methodology conducted by 
Maddock et al. (2002) where they also studied the concentration dependent effects of the A3 
adenosine receptor agonist 2-CI-IB-MECA within the isolated rat heart model upon infarct size 
to risk ratio (%) (Maddock et al. 2002). With similar methodology used to assess an A3 
adenosine receptor agonist, it was only beneficial to apply it when investigating an A1 
adenosine receptor agonist such as 2’-MeCCPA. 
This current investigation can imply that the A1 adenosine receptor agonist 2’-MeCCPA 
between the concentrations of 1nM - 1µM were able to confer cardioprotection within the 
ischaemia reperfusion rat heart model via a decrease in infarct size to risk ratio (%). This is 
useful and can be compared to previous literature that have also used heart models within 
rabbits, canine and mouse to confer cardioprotection (Baxter et al. 2000; Yao and Gross 1993; 
Urmaliya et al. 2010). Baxter et al. (2000) showed that when an A1 adenosine receptor agonist, 
GR79236 (30 μg kg−1), was administered to an ischaemic reperfused myocardium within the 
rabbit heart model, it limited lethal reperfusion injury via infarct size (Baxter et al. 2000). Yao 
and Gross (1993) also suggested that the stimulation of the myocardial A1 adenosine 
receptors with A1AR agonist CPA, within an ischaemia reperfusion model of a stunned canine 
model, had the ability to confer cardioprotection through repetitive but brief periods of 
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coronary artery occlusion (Yao and Gross 1993). A more recent study by Urmaliya et al. (2010) 
showed that when A1AR agonist CPA (100nM) was administered to wild-type mouse cardiac 
cell ischaemia model that were subjected to global ischaemia, there was a significant 
reduction in infarct size due to the activation of the A1 adenosine receptor. An interesting 
point from this study is that 100nM concentration was used and if this was administered to 
mice, the effects on haemodynamic parameters could have been assessed and compared to 
our current study. A further study by Bibli and colleagues (2014) showed that the A1 
adenosine receptor activation with CCPA in rabbit heart is essential for triggering 
cardioprotection through the post-conditioning phenomenon and on this basis, our current 
study can imply that the activation of A1 adenosine receptors with 2’-MeCCPA (10nM) in rat 
heart can trigger cardioprotection through the post-reperfusion activation phenomenon.   
Due to the fact that various concentrations of A1AR agonist 2’-MeCCPA (0.1nM - 1µM) were 
assessed in the isolated rat heart model with the Langendorff technique, the same 
assessment was carried out in isolated rat ventricular cardiomyocytes to investigate cell death 
by apoptosis and necrosis as well cleaved caspase-3 activity. These elements were 
investigated to imply which concentration limited cell death and cleaved caspase-3 activity. 
Assessment of these markers is important as they allow for the determination of the 
cardioprotective effects of 2’-MeCCPA on a cellular level.  
This current study found that when concentrations of 2’-MeCCPA (1nM - 1µM) were 
administered to isolated rat cardiomyocytes, there was an overall decrease in apoptosis and 
necrosis of cardiomyocytes at all nanomolar concentrations. This meant that receptor 
activation of the A1 adenosine receptors has shown to decrease apoptotic injury that has been 
induced by ischaemia. This can be linked with previously published data by Maddock et al. 
(2002) that researched to imply that the activation of the A3 adenosine receptor also had the 
ability to decrease apoptotic injury at nanomolar concentrations of CL-IB-MECA. Although an 
A3 adenosine agonist was investigated by Maddock et al (2002), it did imply that lower 
concentrations of the A3 adenosine agonist had an effect upon apoptotic injury and this could 
also be similar with the A1 adenosine activation; and from our findings, it was.  
With limited published research conducted into the A1 adenosine receptor through post-
reperfusion activation, further research has suggested that the A3 adenosine receptor 
functions in a similar manner to the A1 adenosine receptor to mediate cardioprotection 
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(Safran et al. 2001; Liang et al. 2001, Mangoni 2004), therefore similarities could potentially 
be drawn upon due to the way in which both receptor subtypes are activated. Both the A1 
and the A3 adenosine receptor subtypes are coupled to the Gi and Go pertussis toxin sensitive 
proteins which makes them different to the A2A and A2B adenosine receptor subtypes 
(Germack and Dickenson 2004; Hoffman et al. 1997).  
This current study implied that the A1 adenosine receptor agonist 2’-MeCCPA had the ability 
to decrease cleaved caspase-3 activity between the concentrations of 1nM – 100nM which 
decreased cardiomyocyte apoptosis. Current literature has not been able to clearly decipher 
the link between the activation of A1 adenosine receptors and a decrease in cleaved caspase-
3 within the cardiovascular system through the post-reperfusion activation phenomenon 
however it has been in the pre-conditioning phenomenon (Germack and Dickenson 2005). 
Interestingly Dastjerdi et al. (2016) have shown that the expression of the A1 adenosine 
receptor within breast tissue was able to significantly down-regulate caspase-3 activity within 
MCF-7 cells and when A1 adenosine receptor antagonist DPCPX was administered, the down-
regulation of caspase-3 was reversed. This therefore implies that the activation of the A1 
adenosine receptors does play a part in the decrease in cleaved caspase-3 activity.  
Apoptosis is divided into 2 distinct signalling pathways which include the intrinsic pathway 
(also known as the mitochondrial cell death pathway) and the extrinsic pathway (also known 
as the death receptor pathway) (Fulda 2010; Kim and Kang 2010). Many investigations have 
shown that upon the activation of either the intrinsic or extrinsic pathway, there are initiator 
caspases that become activated that go on to trigger executioner caspases -3, -6 and -7 (Singh 
and Kang 2011; Zhang et al 2017). Within this current study, when 2’-MeCCPA (1nM - 1µM) 
was administered to isolated rat cardiomyocytes to activate the A1 adenosine receptor 
subtype, it was shown that apoptosis was decreased however cleaved caspase-3 activity was 
also decreased. The activation of caspase-3 is linked with mitochondrial oxidative stress which 
can also lead to an increase in cytochrome c release into the cytosol thus producing 
apoptosome complexes (Eefting et al. 2004; Gottlieb et al. 1994; Wan and Yim 2005). Due to 
the decrease in apoptosis with 2’-MeCCPA (1nM - 1µM) administration, this also meant a lack 
of mitochondrial oxidative stress and therefore a lack of apoptosome complex formation. This 
implies that the A1 adenosine receptor agonist, 2’-MeCCPA possesses cardioprotective 
qualities at a cellular level. Further study by Germack and colleagues (2004; 2005) showed by 
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A1 activation can cause protection to neonatal rat cardiomyocytes via the upregulation of the 
MEK/ERK1/1 and PI3K-AKT signalling pathways causing the decrease in caspase-3 activity and 
therefore a decrease in apoptosis.  
Previous research has shown that the activation of the A1 adenosine receptor prior to 
ischaemia (known as pre-conditioning) within the rabbit and rat model has expressed 
cardioprotective effects (Hill et al. 1998; Hochhauser et al. 2007). There has, however, been 
little, if any, research on activating A1 adenosine receptors post-reperfusion to determine 
their cardioprotective effects. Postponing the administration of cardioprotective agents after 
the onset of reperfusion is still considered as a novel hypothesis and is still being extensively 
researched. Data from this current study implies that activation of the A1 adenosine receptors 
using selective A1 adenosine agonist, 2’-MeCCPA (10nM), and administering it at the onset of 
reperfusion, 15 minutes and 30 minutes post-reperfusion all have the ability to mediate 
cardioprotection in the form of reducing infarct size to risk ratio in the isolated rat model. This 
post-reperfusion administration also has the ability to decrease apoptosis and necrosis as well 
as caspase-3 activity at different time-points. An article written my Piper, Abdallah and 
Schäfer (2004) implied that the first few minutes of reperfusion constituted as a critical phase 
in which lethal tissue injury can occur and therefore this window of opportunity can lead to 
cardioprotection (Piper, Abdallah and Schäfer 2004). This therefore supports the findings of 
this current study when 2’-MeCCPA (10nM) has been administered at the onset of 
reperfusion/reoxygenation and at 15 minutes post-reperfusion/reoxygenation to provide a 
cardioprotective effect. Interestingly, this study also implies that the cardioprotective effect 
is also observed at 30 minutes post-reperfusion/reoxygenation which has never been 
detected before. This could be useful within a clinical setting as 30 minutes after an ischaemic 
myocardial event, the A1 adenosine receptor agonist 2’-MeCCPA could provide 
cardioprotective effects.  
This study demonstrated and therefore implied that postponing the administration of 2’-
MeCCPA to 15 minutes and 30 minutes post-reperfusion still conferred cardioprotection via 
the reduction of infarct size in isolated perfused rat hearts. Postponing the administration of 
this cardioprotective agent until after the onset of reperfusion has not actually been 
extensively researched. Interestingly, Von Lubitz et al. (2001) showed how the A3AR agonist 
IB-MECA, when administered at 20 minutes post-reperfusion, successfully attenuated infarct 
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development in mice brain that were subjected to ischaemia-reperfusion. This post ischaemic 
treatment resulted in an improved neuronal preservation and therefore protection of 
neuronal activity in mice brain (Von Lubitz et al. 2001). This technique of post-reperfusion 
activation of the A3 adenosine receptor was very interesting and applied to this current 
project into the post-reperfusion activation of the A1 adenosine receptor and found that 
protective effects were observed.  
3.5  Summary of Findings 
 
In summary, the present study represents the evidence that the A1 adenosine receptor 
agonist, 2’-MeCCPA, may be able to reduce myocardial ischaemia reperfusion injury in 
Sprague Dawley rat model. Our results show that: 
- Activation of the A1 adenosine receptor at the onset of reperfusion using various 
concentrations of selective A1 adenosine receptor agonist, 2’-MeCCPA (1nM, 10nM, 
100nM and 1µM), offers cardioprotection. 
- When the A1 adenosine receptor is activated using selective A1AR agonist 2’-MeCCPA 
(1nM, 10nM, 100nM and 1µM), there was a reduction in infarct size to risk ratio (%) 
observed in ischaemic-reperfused myocardium.  
- The administration of 2’-MeCCPA (1nM, 10nM, 100nM and 1µM) to rat ventricular 
cardiomyocytes caused a decrease in apoptosis and necrosis which in turn decreased 
caspase-3 activity, an effector enzyme of the apoptotic cell death cascade. 
- The activation of A1 adenosine receptors using the selective A1AR agonist 2’-MeCCPA 
(10nM) when administered at 15 minutes and 30 minutes post-reperfusion 
conferred cardioprotection. 
- The administration of the A1AR agonist 2’-MeCCPA (10nM) at 15 minutes and 30 
minutes post-reperfusion caused a decrease in infarct size to risk ratio (%) in 
ischaemic-reperfused myocardium.  
- The administration of A1AR agonist 2’-MeCCPA (10nM) to isolated rat ventricular 
cardiomyocytes at 15 minutes and 30 minutes post-reperfusion both causes a 





Chapter 4: Adenosine Antagonist Profiling with A1 Adenosine 
Receptor (A1AR) Agonist alongside Selective A1 and Non-Selective 




Considerable research has been conducted into the four different adenosine receptors (A1, 
A2A, A2B and A3). They have been cloned and characterised within several mammalian species. 
Adenosine itself is the preferred endogenous agonist that targets all four different receptor 
subtypes. Adenosine levels throughout an injurious period such as ischaemia has the ability 
to activate all receptors, even when expressed at low levels (Fredholm et al. 2001; Covinhes 
et al. 2020). Previous studies have investigated receptor antagonism within knock out mice 
to investigate adenosine A1, A2 and A3 receptor expression and how they respond under 
physiological and pathophysiological conditions (Fredholm et al. 2001). Previous research has 
been conducted into these receptor subtypes where selective agonists have been used to 
activate certain receptor subtypes and selective antagonist have been used in order to 
identify the specific role of that receptor. Both agonists and antagonist are being developed 
as potential drug therapies. This current study explores the role of the A1 adenosine receptor 
and if there is a potential interaction from other adenosine receptor subtypes for 
cardioprotection.  
Numerous studies have explored the protective qualities of adenosine in myocardial 
reperfusion injury (Yao and Gross 1993) and have shown that the administration of adenosine 
can limit infarct size (Yao and Gross 1993). There have also been many studies that have 
investigated the activation of the A1 adenosine receptor through the phenomenon of 
preconditioning to enhance cardioprotection in animal models such as rat neonatal myocytes 
and canine models (Germack and Dickenson 2004; Yao and Gross 1993). Further research is 
required in order to elucidate exact activation of the A1 adenosine receptor throughout post-
reperfusion activation and if alternative adenosine receptor subtypes could potentially play a 
part towards the cardioprotection expressed in rat myocardium. 
The role of an antagonist is to obstruct the preferred effect of an agonist. A very common and 
well documented A1 adenosine antagonist, DPCPX, has been administered alongside many 
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selective A1 adenosine agonists in order to block the effect of the A1AR agonist. Urmaliya et 
al. (2010) administered DPCPX alongside A1AR agonist CPA causing successful attenuation of 
CPA-mediated cardioprotection. This allowed for the confirmation of the A1 receptor to play 
an important part in cardioprotection. 
 
4.1.1. Aims and Objectives 
 
1. The aim of this investigation was to determine the explicit effects of A1 adenosine 
receptor activation at the onset of reperfusion as well as delayed receptor activation 
of the A1 adenosine receptor at 15 minutes and 30 minutes post-reperfusion by 
activation with A1 adenosine receptor agonist 2’-MeCCPA (10nM) and then blocking 
the A1 adenosine receptor subtype with the co-administration with A1 adenosine 
antagonist DPCPX (200nM) within the isolated perfused rat heart model and isolated 
rat cardiomyocyte model. Effects on infarct size (%), apoptosis, necrosis and cleaved 
caspase-3 activity were assessed.  
2. The second aim of this investigation was to determine the effects of p-AKT (Ser473) 
phosphorylation when 2’-MeCCPA was administered in the presence and absence of 
A1AR antagonist DPCPX at the onset of reperfusion, 15 minutes or 30 minutes post-
reperfusion through western blot analysis. This was carried out to determine the 
explicit effects of the A1 adenosine receptor towards the regulation of the PI3K-AKT 
and pro-survival pathway.  
3. Another aim of this investigation was to assess the effects of A1 adenosine receptor 
activation at the onset of reperfusion but also as delayed receptor activation at 15 
minutes and 30 minutes post-reperfusion by the administration of the A1 adenosine 
agonist 2’-MeCCPA (10nM). 2’-MeCCPA (10nM) was then co-administered alongside 
non-selective adenosine antagonist 8-SPT (1µM) to assess the effects upon infarct size 
(%), apoptosis, necrosis and cleaved caspase-3 activity. This investigation was carried 
out to assess the effects upon the explicit activation of the A1 adenosine receptor 









2’-MeCCPA and DPCPX were both purchased from Tocris Cookson (Bristol, UK). 8-SPT was 
purchased from Carbosynth (Berkshire, UK). Working concentrations of the drug used within 
this chapter were freshly prepared each day as described in Chapter 2, Section 2.2.  
4.2.1 Animals 
 
Adult male Sprague-Dawley rats (350 ± 50g) were sacrificed via cervical dislocation in 
accordance to the Schedule 1 Home Office Procedure using the process of thoracotomy, 
previously described in Chapter 2, Section 2.1. 
4.2.3 Langendorff protocol - Isolated perfused rat heart preparation 
 
For studies involving the Langendorff model of ischaemia-reperfusion (details stated in 
Chapter 2, Section 2.3.5), all experiments were carried out for 175 minutes. Isolated rat hearts 
were given 20 minutes for stabilisation followed by 35 minutes of simulated regional 
ischaemia and 120 minutes of reperfusion. Hearts were random allocated to the following 
control and treatment groups: 
a) Normoxic control – Rat hearts perfused with KH buffer for 175 minutes (no ischaemia 
was induced). 
b) Ischaemia-Reperfusion (IR) Control – Rats hearts were perfused with KH buffer for 20 
minutes followed by 35 minutes of simulation regional ischaemia and then 120 
minutes of reperfusion. 
c) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of A1AR 
antagonist DPCPX (200nM) at the onset of reperfusion - Rats were perfused with KH 
buffer for 20 minutes, 35 minutes of simulated regional ischaemia followed by 120 
minutes of reperfusion where drug administration occurred at the onset of 
reperfusion. 
d) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of A1AR 
antagonist DPCPX (200nM) at 15 minutes post-reperfusion - Rats were perfused with 
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KH buffer for 20 minutes, 35 minutes of simulated regional ischaemia followed by 120 
minutes of reperfusion where drug administration occurred at 15 minutes post-
reperfusion. 
e) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of A1AR 
antagonist DPCPX (200nM) at 30 minutes post-reperfusion - Rats were perfused with 
KH buffer for 20 minutes, 35 minutes of simulated regional ischaemia followed by 120 
minutes of reperfusion where drug administration occurred at 30 minutes post-
reperfusion. 
f) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of non-
selective adenosine antagonist 8-SPT (1µM) at the onset of reperfusion - Rats were 
perfused with KH buffer for 20 minutes, 35 minutes of simulated regional ischaemia 
followed by 120 minutes of reperfusion where drug administration occurred at the 
onset of reperfusion. 
g) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of non-
selective adenosine antagonist 8-SPT (1µM) at 15 minutes post-reperfusion - Rats 
were perfused with KH buffer for 20 minutes, 35 minutes of simulated regional 
ischaemia followed by 120 minutes of reperfusion where drug administration 
occurred at 15 minutes post-reperfusion. 
h) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of non-
selective adenosine antagonist 8-SPT (1µM) at 30 minutes post-reperfusion - Rats 
were perfused with KH buffer for 20 minutes, 35 minutes of simulated regional 
ischaemia followed by 120 minutes of reperfusion where drug administration 
occurred at 30 minutes post-reperfusion. 
Throughout all Langendorff experiments, the stability of the hearts were consistently 
monitored through haemodynamic parameters such as: heart rate (HR), left ventricular 
developed pressure (LVDP) and coronary flow (CF) (as described in Chapter 2, Section 2.3.2). 
After the reperfusion period, the infarct size to risk ratio was assessed with the use of Evans 
blue triphenyltetrazolium chloride (TTC) staining procedures as described in Chapter 2, 




4.2.4 Isolation of adult rat ventricular cardiomyocytes 
 
Isolation of adult rat ventricular cardiomyocytes was previously described in Chapter 2, 
Section 2.4.  
4.2.5 Induction of hypoxia and reoxygenation conditions in adult rat 
cardiomyocytes 
 
Fully described in Chapter 2, Section 2.4.1. 
 
4.2.6 Experimental drug treatment protocol in adult rat ventricular 
cardiomyocytes 
 
The isolated rat cardiomyocytes were exposed to differing control and drug treatments. All 
experimental conditions are detailed as below: 
a) Normoxic control – Isolated myocytes were exposed to normoxic conditions for a total 
of 4 hours at 37oC, 5% CO2 and 95% O2.  
b) Hypoxia-Reoxygenation control – Isolated cardiomyocytes were exposed to 1 hour of 
hypoxia conditions followed by the onset of reoxygenation for 3 hours.  
c) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of A1AR 
antagonist DPCPX (200nM) at the onset of reoxygenation - Isolated cardiomyocytes 
were exposed to 1 hour hypoxia conditions followed by drug treatment at the onset 
of reoxygenation for 3 hours at 37oC, 5% CO2 and 95% O2.  
d) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of A1AR 
antagonist DPCPX (200nM) at 15 minutes post-reoxygenation - Isolated 
cardiomyocytes were exposed to 1 hour hypoxia conditions followed by drug 
treatment at 15 minutes post-reoxygenation for 3 hours at 37oC, 5% CO2 and 95% O2.  
e) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of A1AR 
antagonist DPCPX (200nM) at 30 minutes post-reoxygenation - Isolated 
cardiomyocytes were exposed to 1 hour hypoxia conditions followed by drug 
treatment at 30 minutes post-reoxygenation for 3 hours at 37oC, 5% CO2 and 95% O2.  
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f) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of non-
selective adenosine antagonist 8-SPT (1µM)  at the onset of reoxygenation - Isolated 
cardiomyocytes were exposed to 1 hour hypoxia conditions followed by drug 
treatment at the onset of reoxygenation for 3 hours at 37oC, 5% CO2 and 95% O2.  
g) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of non-
selective adenosine antagonist 8-SPT (1µM) at 15 minutes post-reoxygenation - 
Isolated cardiomyocytes were exposed to 1 hour hypoxia conditions followed by drug 
treatment at 15 minutes post-reoxygenation for 3 hours at 37oC, 5% CO2 and 95% O2.  
h) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of non-
selective adenosine antagonist 8-SPT (1µM) at 30 minutes post-reoxygenation - 
Isolated cardiomyocytes were exposed to 1 hour hypoxia conditions followed by drug 
treatment at 30 minutes post-reoxygenation for 3 hours at 37oC, 5% CO2 and 95% O2. 
4.2.7 Quantitative Analysis of Cell Death using Dead Cell Apoptosis Kit with 
Annexin V FITC with Propidium Iodide (PI) in Adult Rat Cardiomyocytes 
 
Followed by the drug treatments described above, isolated rat ventricular cardiomyocytes 
were assess for their levels of apoptosis and necrosis using the Dead Cell Apoptosis Kit with 
Annexin V FITC and PI was purchased from ThermoFisher (UK) (previously detailed in Chapter 
2, Section 2.5.2). Data was normalised against the cell only control and the values obtained 
were calculated as a relative change in apoptosis and necrosis activity of the mean 
absorbance of the control group. 
 
4.2.8 Analysis of Cleaved Caspase-3 Activity in Adult Rat Cardiomyocytes 
 
Following the drug treatment protocol as described above, the rat cardiomyocytes were 
probed with cleaved caspase-3 antibody as described in Chapter 2, Section 2.5.1. Data 
obtained was normalised to the cell only control by subtracting the mean fluorescence 





4.2.9 Western blot analysis 
 
Western blot analysis was performed as described in Chapter 2, Section 2.6. Following the 
stages of separation and protein transfer procedure; membrane blots were probed for 
phosphorylated and total form of the monoclonal rabbit AKT (Ser473) protein (Cell Signalling, 
UK) as stated in Section 2.6.7. Protein detection was quantified with the use of Super Signal 
West Femto Maximum Substrate Solution (ThermoFisher Scientific, UK) to perform an 
enhanced chemiluminescence assay (as detailed in Chapter 2, Section 2.6.8) and proteins 
bands were visualised with the use of Bio-Rad Quantity One programme. The relative 
variations of the levels of phosphorylated monoclonal rabbit AKT (Ser473) protein were 
normalised to the total form of the monoclonal rabbit AKT protein. GAPDH was also used as 
an internal loading control within all experiments as explained in Chapter 2, Section 2.6.7.  
 
4.2.10 Data Analysis 
 
All data that was presented in this project is expressed at the mean ± standard error of the 
mean (SEM). IBM Statistical Package for Social Sciences (SPSS®) software was used to 
statistically analyse the data. The statistical tests currently used to analyse infarct sizes, band 
densities and cell population data was by one-way ANOVA accompanied by Fishers Protected 
Least Significant Difference (LSD) test for multiple comparisons. To assess the difference in 
the data sets, a p-value of p<0.05 was used to consider statistical significance.  











4.3 Results  
 
4.3.1 The effects of co-administration of 2’-MeCCPA (10nM) with A1 
adenosine antagonist, DPCPX (200nM) at various time-points within 
reperfusion in myocardial ischaemia reperfusion injury. 
 
4.3.1.1 The co-administration effects of 2’-MeCCPA (10nM) + DPCPX (200nM) 
when administered at the onset of reperfusion on haemodynamic parameters 
(left ventricular developed pressure, heart rate and coronary flow). 
 
All hearts were subjected to 20 minutes stabilisation, 35 minutes ischaemia followed by 120 
minutes of reperfusion where A1 adenosine receptor agonist, 2’-MeCCPA (10nM), was 
administered in conjunction with A1 adenosine receptor antagonist, DPCPX (200nM). This co-
administration was conducted at the onset of reperfusion within this section. Overall, it was 
found that there was no significant difference between the groups at any of the time-points 
within the reperfusion period (p>0.05) (Figure 4.1). 
Throughout the ischaemic period, all treatment groups had a significantly decreased LVDP in 







Figure 4. 1 Effects of 2’-MeCCPA (10nM) in the presence and absence of DPCPX (200nM) on 
the left ventricular developed pressure within isolated rat hearts when subjected to 20 
minutes stabilisation, 35 minutes of ischaemia and 120 minutes of reperfusion. 2’-MeCCPA 
(10nM) was administered at the onset of reperfusion in the presence and absence of DPCPX 













The co-administration of 2’-MeCCPA (10nM) in the presence and absence of DPCPX (200nM) 
had no significant difference upon heart rate at all time-points post reperfusion when 
compared to the IR control (p>0.05) (Figure 4.2).  
 
Figure 4. 2 The effects of 2’-MeCCPA (10nM) in the presence and absence of DPCPX (200nM) 
on heart rate within isolated rat hearts subjected to 20 minutes stabilisation, 35 minutes of 
ischaemia and 120 minutes of reperfusion. 2’-MeCCPA (10nM) was administered at the onset 












2’-MeCCPA (10nM) when administered in the presence of absence of DPCPX (200nM) has no 
significant effect upon coronary flow when compared to the IR control hearts post-
reperfusion (p>0.05, Figure 4.3).  
Throughout the ischaemic period, all treatment groups had a significantly decreased coronary 




Figure 4. 3 Effects of 2’-MeCCPA (10nM) administered in the presence and absence of DPCPX 
(200nM) on coronary flow in isolated rat hearts subjected to 20 minutes stabilisation, 35 
minutes of ischaemia and 120 minutes of reperfusion. 2’-MeCCPA (10nM) was administered 
at the onset of reperfusion in the presence and absence of DPXPC (200nM). Data was 







4.3.1.2 The effects of co-administration of 2’-MeCCPA (10nM) with A1 
adenosine antagonist, DPCPX (200nM) on infarct size to risk ratio within 
isolated hearts subjected to ischaemia reperfusion injury at the onset of 
reperfusion. 
 
A significant decrease in infarct size to risk ratio (%) was detected when 2’-MeCCPA (10nM) 
was administered at the onset of reperfusion compared to the IR control (28 ± 4% vs. 55 ± 
6%, p<0.001). When 2’-MeCCPA (10nM) + DPCPX (200nM) was administered together at the 
onset of reperfusion, a significant increase in infarct size to risk ratio (%) was detected when 
compared to the administration of 2’-MeCCPA (10nM) alone (52 ± 7% vs. 28 ± 4%, p<0.001) 
(Figure 4.4). 
 
Figure 4. 4 Infarct size to risk ratio (%) within isolated perfused rats’ hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Hearts were 
subjected to 2’-MeCCPA (10nM) administered at the onset of reperfusion in the presence and 
absence of DPCPX (200nM). Data presented as Mean±SEM. n=6-8. *** p<0.001 vs. normoxic, 




4.3.1.3 The co-administration effects of 2’-MeCCPA (10nM) + DPCPX (200nM) 
when administered at 15 minutes post-reperfusion on haemodynamic 
parameters (left ventricular developed pressure, heart rate and coronary 
flow). 
 
All hearts were subjected to 20 minutes stabilisation, 35 minutes ischaemia followed by 120 
minutes of reperfusion where A1 adenosine receptor agonist, 2’-MeCCPA (10nM), was 
administered in conjunction with A1 adenosine receptor antagonist, DPCPX (200nM). This co-
administration was administered 15 minutes pot-reperfusion within this section. Overall, it 
was found that there was no significant difference between the groups at any of the time-
points (p>0.05). 
The co-administration of 2’-MeCCPA (10nM) in conjunction with DPCPX (200nM) had no 
significant effect upon LVDP at all time-points post reperfusion when compared to the IR 
control (p<0.05) (Figure 4.5). 
Throughout the ischaemic period, all treatment groups had a significantly decreased LVDP in 







Figure 4. 5 Effects of 2’-MeCCPA (10nM) administered in the presence and absence of DPCPX 
(200nM) on left ventricular developed pressure within isolated rat hearts when subjected to 
20 minutes stabilisation, 35 minutes of ischaemia and 120 minutes of reperfusion. 2’-MeCCPA 
(10nM) was administered at 15 minutes post-reperfusion in the presence and absence of 













When 2’-MeCCPA (10nM) and DPCPX (200nM) were administered together at 15 minutes 
post-reperfusion, no significant difference was detected upon heart rate at all time-points 
post reperfusion in comparison to the IR control (Figure 4.6).  
 
Figure 4. 6 Effects of 2’-MeCCPA (10nM) administered in the presence and absence of DPCPX 
(200nM) on heart rate within isolated rat hearts when subjected to 20 minutes stabilisation, 
35 minutes of ischaemia and a further 120 minutes of reperfusion. 2’-MeCCPA (10nM) was 
administered at 15 minutes post-reperfusion in the presence and absence of DPCPX (200nM). 










When 2’-MeCCPA (10nm) and DPCPX (200nM) was administered in conjunction, no significant 
difference was detected on coronary flow at all time points within the reperfusion period 
(p<0.05) (Figure 4.7).  
Throughout the ischaemic period, all treatment groups had a significantly decreased coronary 
flow in comparison to the normoxic control (p<0.05) (Figure 4.7).  
 
 
Figure 4. 7 Effects of 2’-MeCCPA (10nM) administered in the presence and absence of DPCPX 
(200nM) o heart rate within isolated rat hearts when subjected to 20 minutes stabilisation, 
35 minutes of ischaemia and 120 minutes of reperfusion. 2’-MeCCPA (10nM) was 
administered at 15 minutes post-reperfusion in the presence and absence of DPCPX (200nM). 
Data was presented at Mean±SEM. n=6-8. * p<0.05 vs. Normoxia. 
 
4.3.1.4 The effects of co-administration of 2’-MeCCPA (10nM) with A1 
adenosine antagonist, DPCPX (200nM) on infarct size to risk ratio in isolated 
hearts subjected to ischaemia reperfusion injury at 15 minutes post-
reperfusion 
 
A significant decrease in infarct size to risk ratio (%) was observed when 2’-MeCCPA (10nM) 
alone was administered at 15 minutes post-reperfusion in comparison to the IR control (30 ± 
10% vs. 55 ± 6%, p<0.001) (Figure 4.8). When 2’-MeCCPA (10nM) + DPCPX (200nM) was 
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administered in conjunction with one another at 15 minutes post-reperfusion, a significant 
increase in infarct size to risk ratio (%) was detected in comparison to when 2’-MeCCPA 
(10nM) was administered alone at 15 minutes post-reperfusion (56 ± 7% vs. 30 ± 10%, p<0.01) 
(Figure 4.8). Administration of DPCPX had no significant effect upon infarct size to risk ratio 
(%) when compared to the IR control.  
 
Figure 4. 8 Infarct size to risk ratio (%) within isolated perfused hearts subjected to 20 minutes 
stabilisation, 35 minutes ischaemia and 120 minutes reperfusion subjected to 2’-MeCCPA 
(10nM) administered at 15 minutes post-reperfusion alone as well as DPCPX (200nM) 
administered at 15 minutes post-reperfusion alone and the co-administration of 2’-MeCCPA 
(10nM) + DPCPX (200nM) administered at 15 minutes post-reperfusion. Data presented as 
Mean±SEM. n=6-8. *** p<0.001 vs. normoxic, ### p<0.001 vs. IR and $$ p<0.01 vs. 2’-MeCCPA 






4.3.1.5 The co-administration effects of 2’-MeCCPA (10nM) + DPCPX (200nM) 
when administered at 30 minutes post-reperfusion on haemodynamic 
parameters (left ventricular developed pressure, heart rate and coronary 
flow). 
 
Hearts were all subjected to a 20 minute stabilisation period, 35 minutes of ischaemia 
followed by 120 minutes of reperfusion where A1 adenosine receptor agonist, 2’-MeCCPA 
(10nM) was administered in conjunction with A1 adenosine receptor antagonist, DPCPX 
(200nM). 2’-MeCCPA was administered alone, DPCPX was administered alone and both were 
also co-administered together at 30 minutes post-reperfusion.  
The co-administration of 2’-MeCCPA in the presence and absence of DPCPX at 30 minutes 
post-reperfusion had no significant difference between the groups at any of the time-points 
within the reperfusion period (p>0.05) (Figure 4.9). 
Throughout the ischaemic period, all treatment groups had a significantly decreased LVDP in 
comparison to the normoxic control (p<0.05) (Figure 4.9).  
 
Figure 4. 9 Effects of 2’-MeCCPA (10nM) administered in the presence and absence of DPCPX 
(200nM) on left ventricular developed pressure within isolated rat hearts when subjected to 
20 minutes stabilisation, 35 minutes of ischaemia and 120 minutes of reperfusion. 2’-MeCCPA 
(10nM) was administered at 30 minutes post-reperfusion in the presence and absence of 
DPCPX (200nM). Data was presented as Mean±SEM. n=6-8. * p<0.05 vs. Normoxia.  
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No significant effect was detected upon heart rate when 2’-MeCCPA and DPCPX was 
administered in conjunction at 30 minutes post-reperfusion at any time-points in comparison 
to IR control and normoxic control (p>0.05) (Figure 4.10).  
 
Figure 4. 10 Effects of 2’-MeCCPA (10nM) administered in the presence and absence of 
DPCPX (200nM) on heart rate within isolated rat hearts when subjected to 20 minutes 
stabilisation, 35 minutes of ischaemia and a further 120 minutes of reperfusion. 2’-MeCCPA 
(10nM) was administered at 30 minutes post-reperfusion in the presence and absence of 












When 2’-MeCCPA (10nM) was administered alongside DPCPX (200nM) as well as when each 
of these treatments were administered separately too, there was no significant difference 
detected between groups and when compared to the IR control within the reperfusion period 
(p>0.05) (Figure 4.11).  
Throughout the ischaemic period, all treatment groups had a significantly decreased coronary 
flow in comparison to the normoxic control (p<0.05) (Figure 4.11).  
 
Figure 4. 11 Effects of 2’-MeCCPA (10nM) administered in the presence and absence of 
DPCPX (200nM) on heart rate within isolated rat hearts when subjected to 20 minutes 
stabilisation, 35 minutes of ischaemia and 120 minutes of reperfusion. 2’-MeCCPA (10nM) 
was administered at 30 minutes post-reperfusion in the presence and absence of DPCPX 
(200nM). Data was presented at Mean±SEM. n=6-8. * p<0.05 vs. Normoxia.  
 
4.3.1.6 Effects of co-administration of 2’-MeCCPA (10nM) with A1 adenosine 
antagonist, DPCPX (200nM) on infarct size to risk ratio within isolated hearts 
subjected to ischaemia reperfusion injury at 30 minutes post-reperfusion. 
 
When 2’-MeCCPA (10nM) was administered alone at 30 minutes post reperfusion, a 
significant decrease in infarct size to risk ratio (%) was detected when compared to the IR 
control (35 ± 6% vs. 55 ± 6%, p<0.001) (Figure 4.12). When DPCPX (200nM) was administered 
alone at 30 minutes post-reperfusion, no significant effect was observed. When 2’-MeCCPA 
(10nM) + DPCPX (200nM) were administered together at 30 minutes post-reperfusion and a 
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significant increase in infarct size to risk ratio was observed when comparing to when 2’-
MeCCPA was administered alone at 30 minutes post-reperfusion (57 ± 11% vs. 35 ± 6%, 











Figure 4. 12 Infarct size to risk ratio (%) within isolated perfused hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion subjected to 2’-
MeCCPA (10nM) administered at 30 minutes post-reperfusion alone as well as DPCPX 
(200nM) administered at 30 minutes post-reperfusion alone and the co-administration of 2’-
MeCCPA (10nM) + DPCPX (200nM) administered at 30 minutes post-reperfusion. Data 
presented as Mean±SEM. n=6-8. *** p<0.001 vs. normoxic, ** p<0.01 vs normoxic ### 
p<0.001 vs. IR and $ p<0.05 vs. 2’-MeCCPA administered 30 minutes post-reperfusion 
(10nM).  
 
4.3.1.7 Profiling effects of co-administration of 2’-MeCCPA (10nM) alongside 
A1 adenosine antagonist, DPCPX (200nM) at the onset of reoxygenation, 15 
minutes post-reoxygenation and 30 minutes post-reoxygenation in adult rat 
cardiomyocytes subjected to hypoxia-reoxygenation on apoptosis and 
necrosis 
 
Isolated adult rat cardiac myocytes were subjected to 1 hour of hypoxia and 3 hours of 
reoxygenation and treated with 2’-MeCCPA (10nM) in the presence and absence of DPCPX 
(200nM). Cardiomyocytes were then assessed for apoptosis and necrosis.  
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When 2’-MeCCPA (10nM) + DPCPX (200nM) was administered in conjunction at the onset of 
reoxygenation, there was an increase in cellular apoptosis compared to when 2’-MeCCPA 
(10nM) was administered alone however this was not a significant change (21±4% 2’-MeCCPA 
+ DPCPX at onset of Reox vs. 17±4% 2’-MeCCPA@onset of Reox, p<0.05) (Figure 4.13). When 
DPCPX (200nM) was administered alone at the onset of reoxygenation, an increase in 
apoptosis was detected when compared to the non-treated Hyp/Reox group however this 
was not significant (p>0.05) (Figure 4.3). An increase in apoptotic cells was detected when 
DPCPX (200nM) was administered alone in comparison to when 2’-MeCCPA (10nM) was 
administered alone, this was not a significant change (Figure 4.13). 
When 2’-MeCCPA (10nM) + DPCPX (200nM) was co-administered at the onset of 
reoxygenation, a significant increase in necrosis was observed when compared to 2’-MeCCPA 
(10nM) being administered alone (22±6% 2’-MeCCPA + DPCPX vs. 13±2% 2’-MeCCPA, p<0.01) 
(Figure 4.13). A decrease in necrotic cells was observed when DPCPX (200nM) was 
administered alone at reoxygenation in comparison to the non-treated Hyp/Reox group 








Figure 4. 13 The assessment of necrosis and apoptosis within isolated rat cardiomyocytes 
subjected to 1 hour of hypoxia and 3 hours of reoxygenation. 2’-MeCCPA (10nM) was 
administered at the onset of reoxygenation in the presence and absence of A1 adenosine 
receptor antagonist, DPCPX (200nM) b. Results were shown as Mean±SEM and were 
expressed as a percentage of 10 000 cells counted from 6 individual experiments. *** p<0.001 
vs. Normoxia. ### p<0.001 vs. Hyp/Reox. $$ p<0.01 vs. 2’MeCCPA at onset of Reox. 
 
A significant increase in cellular apoptosis was also detected when 2’-MeCCPA (10nM) + 
DPCPX (200nM) was administered together at 15 minutes post-reoxygenation compared to 
when 2’-MeCCPA (10nM) was administered alone at 15 minutes post-reoxygenation (25±3% 
2’-MeCCPA + DPCPX@15mins Post-R vs. 14±5% 2’-MeCCPA@15min Post-R, p<0.01) (Figure 
4.14). An increase in cellular apoptosis was detected when DPCPX (200nM) was administered 
alone at 15 minutes post-reperfusion in comparison to when 2’-MeCCPA (10nM) was 
administered alone, this was not a significant effect (p<0.05) (Figure 4.14).  
When 2’-MeCCPA (10nM) + DPCPX (200nM) was administered in conjunction at 15 minutes 
post-reoxygenation an increase in cellular necrosis was observed in comparison to when 2’-
MeCCPA (10nM) was administered alone at 15 minutes post-reoxygenation, this was not a 
significant change (21±4% 2’-MeCCPA + DPCPX@15mins Post-R vs. 16±4% 2’-













Figure 4. 14 The assessment of necrosis and apoptosis within isolated rat cardiomyocytes 
subjected to 1 hour of hypoxia and 3 hours of reoxygenation. 2’-MeCCPA (10nM) was 
administered at 15 minutes post-reoxygenation in the presence and absence of A1 adenosine 
receptor antagonist, DPCPX (200nM). Results were shown as Mean±SEM and were expressed 
as a percentage of 10 000 cells counted from 6 individual experiments. *** p<0.001 vs. 
Normoxia. * p<0.05 vs. Normoxia. ### p<0.001 vs. Hyp/Reox. $$ p<0.01 vs. 2’-MeCCPA 
15mins Post-Reox.  
 
When 2’-MeCCPA (10nM) + DPCPX (200nM) was administered together at 30 minutes post-
reoxygenation, an increase in cellular apoptosis was detected when compared to when 2’-
MeCCPA (10nM) was administered alone at 30 minutes post-reoxygenation however this was 
not a significant change (21±7% 2’-MeCCPA +DPCPX@30min Post-R vs. 15±6% 2’-
MeCCPA@30mins Post-R, p<0.05) (Figure 4.15).  
When 2’-MeCCPA (10nM) + DPCPX (200nM) was administered together at 30 minutes post-
reoxygenation, a significant increase in cellular necrosis was detected when compared to 
when 2’-MeCCPA (10nM) was administered alone at 30 minutes post-reoxygenation (23±7% 





Figure 4. 15 The assessment of necrosis and apoptosis within isolated rat cardiomyocytes 
subjected to 1 hour of hypoxia and 3 hours of reoxygenation. 2’-MeCCPA (10nM) was 
administered at 15 minutes post-reoxygenation in the presence and absence of A1 
adenosine receptor antagonist, DPCPX (200nM). Results were shown as Mean±SEM and 
were expressed as a percentage of 10 000 cells counted from 6 individual experiments. *** 
p<0.001 vs. Normoxia. ** p<0.01 vs. Normoxia. ### p<0.001 vs. Hyp/Reox. $$ p<0.01 vs. 2’-
MeCCPA 30mins Post-Reox. 
 
4.3.1.8 Profiling effects of co-administration of 2’-MeCCPA (10nM) with A1 
adenosine antagonist, DPCPX (200nM) at the onset of reoxygenation, 15 
minutes post-reoxygenation and 30 minutes post-reoxygenation on cleaved 
caspase-3 activity within isolated rat cardiomyocytes when subjected to 1 
hour of hypoxia and 3 hours of reoxygenation 
 
Isolated adult rat cardiomyocytes were subjected to 1 hour of hypoxia and 3 hours of 
reoxygenation. It was found when 2’-MeCCPA (10nM) + DPCPX (200nM) was administered in 
conjunction together, there was a significant increase in cleaved-caspase 3 activity in 
comparison to when 2’-MeCCPA (10nM) was administered alone at the onset of 
reoxygenation (retrospectively, 238±20% vs. 181±35%, p<0.05) (Figure 4.16). 
When 2’-MeCCPA + DPCPX was administered at 15 minutes post-reoxygenation, there was a 
significant increase in cleaved-caspase 3 activity when compared to 2’-MeCCPA being 
131 
 
administered alone at 15 minutes post-reoxygenation (retrospectively, 313±37% vs. 
232±33%, p<0.05) (Figure 4.17). When DPCPX was administered alone, there was an increase 
in cleaved-caspase 3 activity when compared to 2’-MeCCPA being administered alone 
however this was not a significant change.  
When 2’-MeCCPA + DPCPX was administered in conjunction at 30 minutes post-reperfusion, 
there was a slight increase in cleaved-caspase 3 activity when compared to 2’-MeCCPA being 
administered alone at 30 minutes post-reoxygenation however this was not a significant 
change (retrospectively, 283±31% vs. 263±68%, no significance p>0.05).  
 
 
Figure 4. 16 Cleaved-caspase 3 activity in isolated rat cardiomyocytes subjected to 4 hours 
of reoxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of reoxygenation 
(Hyp/Reox). 2’-MeCCPA (10nM) was administered in the presence and absence of A1 
adenosine receptor antagonist, DPCPX (200nM) at the onset of reoxygenation. Data 
presented as percentage of Normoxia±SEM n=6. *** p<0.001 vs. Normoxia. ** p<0.01 vs. 








Figure 4. 17 Cleaved-caspase 3 activity in isolated rat cardiomyocytes subjected to 4 hours 
of reoxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of reoxygenation 
(Hyp/Reox). 2’-MeCCPA (10nM) was administered in the presence and absence of A1 
adenosine receptor antagonist, DPCPX (200nM) at 15 minutes post-reoxygenation. Data 
presented as percentage of Normoxia±SEM n=6. *** p<0.001 vs. Normoxia. ## p<0.0 vs. 


























Figure 4. 18 Cleaved-caspase 3 activity in isolated rat cardiomyocytes subjected to 4 hours of 
reoxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of reoxygenation 
(Hyp/Reox). 2’-MeCCPA (10nM) was administered in the presence and absence of A1 
adenosine receptor antagonist, DPCPX (200nM) at 30 minutes post-reoxygenation. Data 
presented as percentage of Normoxia±SEM n=6. *** p<0.001 vs. Normoxia.  
 
4.3.1.9 Administration of A1AR agonist 2’-MeCCPA (10nM) in the presence 
and absence of A1AR antagonist DPCPX (200nM) at the onset of reperfusion, 
15 minutes and 30 minutes post-reperfusion and the effects upon p-AKT (Ser473) 
phosphorylation in western blots 
 
It has previously been shown that when 2’-MeCCPA (10nM) is administered at the onset of 
reperfusion, 15 minutes and 30 minutes post-reperfusion, there is a significant decrease in 
infarct size to risk ratio however when 2’-MeCCPA (10nM) is administered in the presence of 
the A1AR antagonist DPCPX (200nM), there is a significant increase in infarct size to risk ratio 




In order to furthermore determine if the protection shown by the administration of 2’-
MeCCPA (10nM) at the onset of reperfusion, 15 minutes and 30 minutes into the onset of 
reperfusion explicitly involved the PI3K-AKT pro-survival pathway, all heart tissue was treated 
with 2’-MeCCPA (10nM) in the presence and absence of DPCPX (200nM) either at the onset 
of reperfusion, 15 minutes post-reperfusion or 30 minutes post-reperfusion. Heart tissue was 
treated with drug intervention and then further assessed for p-AKT (ser473) protein 
phosphorylation which was normalised against the total AKT (Ser473) protein phosphorylation 
through western blot analysis. 
The western blot analysis indicated that when 2’-MeCCPA (10nM) was administered at the 
onset of reperfusion, there was a significant upregulation in the levels of p-AKT (Ser473) when 
compared to the control group (284 ± 10% vs. 116 ± 14%, p<0.001). Furthermore the 
administration of 2’-MeCCPA (10nM) with DPCPX (200nM) significantly decreased the levels 
of phosphorylated AKT when compared to the 2’-MeCCPA (10nM) alone group (103 ± 15% vs. 
284 ± 10%, p<0.001) (Figure 4.19). 
Furthermore western blot analysis showed that the administration of 2’-MeCCPA (10nM) at 
15 minutes post-reperfusion indicated a significant increase in levels of p-AKT(Ser473) when 
compared to the control group (267 ± 16% vs 163 ± 13%, p<0.001). It was also found that 
when 2’-MeCCPA (10nM) was co-administered with DPCPX (200nM), there was a significant 
downregulation in p-AKT levels in comparison to the 2’-MeCCPA alone at 15 minutes post-
reperfusion group (99 ± 27% vs. 267 ± 16%, p<0.001) (Figure 4.20).  
When 2’-MeCCPA (10nM) was administered alone at 30 minutes post-reperfusion, the 
western blot analysis determined that there was a significant upregulation in p-AKT (Ser473) 
levels compared to the control group (206 ± 18% vs. 124 ± 11%, p<0.001). When 2’-MeCCPA 
(10nM) was administered alongside DPCPX (200nM) at 30 minutes post-reperfusion, there 
was a significant downregulation in p-AKT phosphorylation compared to the 2’-MeCCPA alone 










Figure 4. 19 Western blot analysis showing the effects of A1AR agonist 2’-MeCCPA (10nM) 
administered in the presence and absence of A1AR antagonist DPCPX (200nM) at the onset 
of reperfusion. Reperfusion time went on for 10 minutes after the onset and heart tissue 
was then stored. Results were shown as Mean ± SEM of 4 experiments. ***p<0.001 vs. 














Figure 4. 20 Western blot analysis showing the effects of A1AR agonist 2’-MeCCPA (10nM) 
administered in the presence and absence of A1AR antagonist DPCPX (200nM) when 
administered 15 minutes post-reperfusion. Reperfusion time went on for a further 10 
minutes after drug administration making a total 25 minutes reperfusion period and then 
heart tissue was stored. Results were shown as Mean ± SEM of 4 experiments. ***p<0.001 












Figure 4. 21 Western blot analysis showing the effects of A1AR agonist 2’-MeCCPA (10nM) 
administered in the presence and absence of A1AR antagonist DPCPX (200nM) when 
administered 30 minutes post-reperfusion. Reperfusion time went on for a further 10 
minutes after drug administration making a total 40 minutes reperfusion period and then 
heart tissue was stored. Results were shown as Mean ± SEM of 4 experiments. ***p<0.001 












4.3.2 The effects of co-administration of 2’-MeCCPA (10nM) with unselective 
adenosine antagonist, 8-SPT (1µM) at various time-points within reperfusion 
in myocardial ischaemia reperfusion injury. 
 
4.3.2.1 The effects of co-administration of 2’-MeCCPA (10nM) + 8-SPT (1µM) 
on infarct size to risk ratio within isolated hearts subjected to ischaemia 
reperfusion injury at the onset of reperfusion. 
 
When 2’-MeCCPA (10nM) was administered alone at reperfusion, there was a significant 
decrease in infarct size to risk ratio (%) compared to the IR control (28 ± 4% vs. 55 ± 6%, 
p<0.001) (Figure 4.22). When unselective adenosine antagonist 8-SPT (1µM) was 
administered alongside 2’-MeCCPA (10nM) at the onset of reperfusion, no significant change 
was observed in comparison to when 2’-MeCCPA (10nM) was administered alone at 
reperfusion (39 ± 3% 2’-MeCCPA + 8-SPT vs. 28 ± 5% 2’-MeCCPA, p>0.05) (Figure 4.22). When 
2’-MeCCPA (10nM) + 8-SPT (1µM) was administered together, this showed a significant 
decrease in infarct size to risk ratio in comparison to the IR control (39 ± 3% 2’-MeCCPA+8-







Figure 4. 22 Infarct size to risk ratio (%) within isolated perfused rats’ hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Hearts were 
subjected to A1AR agonist 2’-MeCCPA (10nM) administered at the onset of reperfusion in 
the presence and absence of unselective adenosine antagonist 8-SPT (1µM). Data presented 
as Mean±SEM. n=6-8. *** p<0.001 vs. normoxic, ### p<0.001 vs. IR and # p<0.05 vs. IR.  
 
4.3.2.2 The effects of co-administration of 2’-MeCCPA (10nM) + 8-SPT (1µM) 
on infarct size to risk ratio within isolated hearts subjected to ischaemia 
reperfusion injury at 15 minutes post-reperfusion. 
 
2’-MeCCPA (10nM) administered alone at 15 minutes post-reperfusion showed a significant 
decrease in infarct size to risk ratio (%) compared to the IR control (30 ± 8% 2’-MeCCPA 
15mins Post-R vs 55 ± 6% IR control, p<0.001) (Figure 4.23). When 2’-MeCCPA (10nM) was 
administered alongside 8-SPT (1µM) at 15 minutes post-reperfusion, there was a significant 
increase in infarct size to risk ratio (%) in comparison to when 2’-MeCCPA (10nM) was 
administered alone at 15 minutes post-reperfusion (45 ± 3% 2’-MeCCPA + 8-SPT 15mins Post-
R vs. 30 ± 8% 2’-MeCCPA 15mins Post-R, p<0.05) (Figure 4.23). When 8-SPT (1µM) was 
administered alone at 15 minutes post-reperfusion, there was a significant increase in infarct 
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size to risk ratio (%) compared to when 2’-MeCCPA (10nM) was administered alone at 15 
minutes post-reperfusion (56 ± 5% 8-SPT 15mins Post-R vs. 30 ± 8% 2’-MeCCPA 15mins Post-
R, p<0.05) (Figure 4.23).  
 
Figure 4. 23 Infarct size to risk ratio (%) within isolated perfused rats’ hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Hearts were 
subjected to A1AR agonist 2’-MeCCPA (10nM) administered at 15 minutes post-reperfusion 
in the presence and absence of unselective adenosine antagonist 8-SPT (1µM). Data 
presented as Mean±SEM. n=6-8. *** p<0.001 vs. normoxic, ### p<0.001 vs. IR and $ p<0.05 
vs. 2’-MeCCPA 15mins Post-R. 
 
4.3.2.3 Effects of co-administration of 2’-MeCCPA (10nM) + 8-SPT (1µM) on 
infarct size to risk ratio within isolated hearts subjected to ischaemia 
reperfusion injury at 30 minutes post-reperfusion. 
 
When 2’-MeCCPA (10nM) was administered alone at 30 minutes post-reperfusion, there was 
a significant decrease in infarct size to risk ratio (%) compared to the IR control (35 ± 6% 2’-
MeCCPA 30mins Post-R vs. 55 ± 6% IR control, p<0.001) (Figure 4.24). When 2’-MeCCPA 
(10nM) and 8-SPT (1µM) was administered in conjunction, there was a significant increase in 
infarct size to risk ratio compared to when 2’-MeCCPA (10nM) was administered alone at 30 
minutes post-reperfusion (48 ± 4 2’-MeCCPA + 8-SPT 30mins Post-R vs. 2’-MeCCPA 30mins 
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Post-R, p<0.05) (Figure 4.24). When 8-SPT (1µM) was administered alone at 30 minutes post-
reperfusion, there was a significant increase in infarct size to risk ratio compared to when 2’-
MeCCPA (10nM) was administered alone at 30 minutes post-reperfusion (53 ± 5% 8-SPT 
30mins Post-R vs. 35 ± 6% 2’-MeCCPA 30mins Post-R, p<0.05) (Figure 4.24). 
Figure 4. 24 Infarct size to risk ratio (%) within isolated perfused rats’ hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Hearts were 
subjected to A1AR agonist 2’-MeCCPA (10nM) administered at 30 minutes post-reperfusion 
in the presence and absence of unselective adenosine antagonist 8-SPT (1µM). Data 
presented as Mean±SEM. n=6-8. *** p<0.001 vs. normoxic, ### p<0.001 vs. IR and $ p<0.05 








4.3.2.4 Profiling effects of co-administration of 2’-MeCCPA (10nM) alongside 
A1 adenosine antagonist, DPCPX (200nM) at the onset of reoxygenation, 15 
minutes post-reoxygenation and 30 minutes post-reoxygenation in adult rat 
cardiomyocytes subjected to hypoxia-reoxygenation on apoptosis and 
necrosis 
 
4.3.2.4a Effects of administration of A1AR agonist 2’-MeCCPA (10nM) + 8-SPT 
(1µM) on apoptosis and necrosis at the onset of reperfusion 
 
When 2’-MeCCPA (10nM) was administered alongside unselective adenosine antagonist, 8-
SPT (1µM), there was a significant increase in apoptosis (27 ± 4% 2’-MeCCPA + 8-SPT vs. 17 ± 
4% 2’-MeCCPA, p<0.01) and necrosis (23 ± 3% 2’-MeCCPA + 8-SPT vs. 13 ± 2% 2’-MeCCPA, 
p<0.05) compared to when 2’-MeCCPA (10nM) was administered alone (Figure 4.25). 
No significant differences in apoptosis and necrosis were detected when 8-SPT (1µM) was 
administered alone at the onset of reperfusion (p>0.05).  
 
Figure 4. 25 Assessment of necrosis and apoptosis within isolated rat cardiomyocytes 
subjected to 1 hour of hypoxia and 3 hours of reoxygenation. 2’-MeCCPA (10nM) was 
administered at the onset of reoxygenation in the presence and absence of unselective 
adenosine antagonist (1µM). Results were shown as Mean±SEM and were expressed as a 
percentage of 10 000 cells counted from 6 individual experiments. *** p<0.001 vs. 
Normoxia.** p<0.01 vs. Normoxia. ### p<0.001 vs. Hyp/Reox. # p<0.05 vs. Hyp/Reox.  
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4.3.2.4b Effects of administration of A1AR agonist 2’-MeCCPA (10nM) + 8-SPT 
(1µM) on apoptosis and necrosis at 15 minutes post-reoxygenation 
 
When 2’-MeCCPA (10nM) was administered at 15 minutes post-reoxygenation, a significant 
decrease in apoptosis was observed compared to the Hyp/Reox control group (14 ± 5% 2’-
MeCCPA 15mins Post-R vs. 34 ± 6% Hyp/Reox control, p<0.001) (Figure 4.26); a significant 
decrease in necrosis was also observed when 2’-MeCCPA (10nM) was administered alone at 
15 minutes post-reoxygenation (16 ± 4% 2’-MeCCPA 15mins Post-R vs. 28 ± 7%, p<0.001) 
(Figure 4.26).  
An increase in necrosis was detected when 2’-MeCCPA (10nM) and 8-SPT (1µM) were 
administered at 15 minutes post-reoxygenation compared to when 2’-MeCCPA (10nM) was 
administered alone at 15 minutes post-reoxygenation however this was not a significant 
change (p>0.05) (Figure 4.26). An increase in apoptosis was detected when 2’-MeCCPA 
(10nM) and 8-SPT (1µM) were administered at 15 minutes post-reoxygenation compared to 
when 2’-MeCCPA (10nM) was administered alone at 15 minutes post-reoxygenation, 
however this was also not a significant change (p>0.05) (Figure 4.26).  
No significant difference in apoptosis and necrosis was detected when 8-SPT (1µM) was 
administered at 15 minutes post-reoxygenation compared to the Hyp/Reox control group 





Figure 4. 26 Assessment of necrosis and apoptosis within isolated rat cardiomyocytes 
subjected to 1 hour of hypoxia and 3 hours of reoxygenation. 2’-MeCCPA (10nM) was 
administered at 15 minutes post-reoxygenation in the presence and absence of unselective 
adenosine antagonist (1µM). Results were shown as Mean±SEM and were expressed as a 
percentage of 10 000 cells counted from 6 individual experiments. *** p<0.001 vs. 
Normoxia.** p<0.01 vs. Normoxia. ### p<0.001 vs. Hyp/Reox. 
 
4.3.2.4c Effects of administration of A1AR agonist 2’-MeCCPA (10nM) 
alongside unselective adenosine antagonist 8-SPT (1µM) on apoptosis and 
necrosis at 30 minutes post-reoxygenation 
 
When 2’-MeCCPA (10nM) was administered at 30 minutes post-reoxygenation there was a 
significant decrease in apoptosis compared to the Hyp/Reox control (15 ± 5% 2’-MeCCPA 
15mins Post-R vs. 34 ± 6% Hyp/Reox, p<0.001) (Figure 4.27). When 2’-MeCCPA (10nM) was 
administered at 30 minutes post-reoxygenation, there was a significant decrease in necrosis 
compared to the Hyp/Reox control group (17 ± 3% 2’-MeCCPA 15mins Post-R vs. 28 ± 7 
Hyp/Reox, p<0.001) (Figure 4.27). 
No significant change was detected in apoptosis and necrosis when 2’-MeCCPA (10nM) was 
administered alongside 8-SPT (1µM) at 30 minutes post-reoxygenation compared to when 
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2’-MeCCPA (10nM) was administered alone at 30 minutes post-reoxygenation (p>0.05 
(Figure 4.27).  
Furthermore, no significant difference was detected in apoptosis and necrosis was when 8-
SPT (1µM) was administered at 30 minutes post-reoxygenation compared to the Hyp/Reox 
control group (p>0.05) (Figure 4.27).  
 
Figure 4. 27 Assessment of necrosis and apoptosis within isolated rat cardiomyocytes 
subjected to 1 hour of hypoxia and 3 hours of reoxygenation. 2’-MeCCPA (10nM) was 
administered at 30 minutes post-reoxygenation in the presence and absence of unselective 
adenosine antagonist (1µM). Results were shown as Mean±SEM and were expressed as a 
percentage of 10 000 cells counted from 6 individual experiments. *** p<0.001 vs. 







4.3.2.5 Profiling effects of co-administration of 2’-MeCCPA (10nM) with A1 
adenosine antagonist, DPCPX (200nM) at the onset of reoxygenation, 15 
minutes post-reoxygenation and 30 minutes post-reoxygenation on cleaved 
caspase-3 activity within isolated rat cardiomyocytes when subjected to 1 
hour of hypoxia and 3 hours of reoxygenation 
 
4.3.2.5a Effects of administration of A1AR agonist 2’-MeCCPA (10nM) + 8-SPT 
(1µM) on cleaved capase-3 activity at the onset of reperfusion 
 
When 2’-MeCCPA (10nM) was administered in conjunction with unselective adenosine 
antagonist 8-SPT (1µM), there was an increase in cleaved caspase-3 activity compared to 
when 2’-MeCCPA (10nM) was administered alone (287 ± 22% 2’-MeCCPA + 8-SPT vs. 181 ± 
35% 2’-MeCCPA, p<0.01) (Figure 4.28). When 8-SPT (1µM) was administered alone at the 
onset of reoxygenation, there was no significant difference in comparison to the Hyp/Reox 







Figure 4. 28 Cleaved-caspase 3 activity in isolated rat cardiomyocytes subjected to 4 hours 
of reoxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of reoxygenation 
(Hyp/Reox). 2’-MeCCPA (10nM) was administered in the presence and absence of 
unselective adenosine receptor antagonist, 8-SPT (1µM) at the onset of reoxygenation. Data 
presented as percentage of Normoxia±SEM n=6. *** p<0.001 vs. Normoxia. ### p<0.001 vs. 
Hyp/Re. $$ p<0.01 vs. 2’-MeCCPA. 
 
4.3.2.5b Effects of administration of A1AR agonist 2’-MeCCPA (10nM) + 8-SPT 
(1µM) on cleaved capase-3 activity at 15 minutes post-reoxygenation 
 
When 2’-MeCCPA (10nM) was administered at 15 minutes post-reoxygenation, there was a 
significant decrease in cleaved caspase-3 activity when compared to the Hyp/Reox control 
group (232 ± 39% 2’-MeCCPA 15mins Post-R vs. 313 ± 35% Hyp/Reox, p<0.05) (Figure 4.29). 
When 2’-MeCCPA (10nM) and 8-SPT (1µM) were administered together at 15 minutes post-
reoxygenation, there was a significant increase in cleaved caspase-3 activity compared to 
when 2’-MeCCPA (10nM) was administered alone at 15 minutes post-reoxygenation (334 ± 
39% 2’-MeCCPA + 8-SPT 15mins Post-R vs. 232 ± 39% 2’-MeCCPA 15mins Post-R, p<0.05). 
(Figure 4.29).  
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No significant differences were detected when 8-SPT (1µM) was administered alone at 15 
minutes post-reoxygenation (p>0.05) (Figure 4.29).  
 
 
Figure 4. 29 Cleaved-caspase 3 activity in isolated rat cardiomyocytes subjected to 4 hours 
of reoxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of reoxygenation 
(Hyp/Reox). 2’-MeCCPA (10nM) was administered in the presence and absence of 
unselective adenosine receptor antagonist, 8-SPT (1µM) at 15 minutes post-reoxygenation. 
Data presented as percentage of Normoxia±SEM n=6. *** p<0.001 vs. Normoxia. # p<0.05 
vs. Hyp/Re. $ p<0.05 vs. 2’-MeCCPA.  
 
4.3.2.5c Effects of administration of A1AR agonist 2’-MeCCPA (10nM) + 8-SPT 
(1µM) on cleaved capase-3 activity at 30 minutes post-reoxygenation 
 
When 2’-MeCCPA (10nM) was administered at 30 minutes post-reoxygenation, there was a 
decrease in cleaved caspase-3 activity compared to the Hyp/Reox control group however this 
was not a significant decrease (p>0.05) (Figure 4.30).  
When 2’-MeCCPA (10nM) was administered in conjunction with 8-SPT (1µM) 30 minutes post-
reoxygenation, an increase in cleaved caspase-3 activity was observed compared to when 2’-
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MeCCPA (10nM) was administered alone at 30 minutes post-reoxygenation however this was 
no a significant increase (p>0.05) (Figure 4.30). 
No significant differences were observed when 8-SPT (1µM) was administered alone at 30 
minutes post-reoxygenation in comparison to the Hyp/Reox control group (p>0.05) (Figure 
4.30).  
 
Figure 4. 30 Cleaved-caspase 3 activity in isolated rat cardiomyocytes subjected to 4 hours 
of reoxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of reoxygenation 
(Hyp/Reox). 2’-MeCCPA (10nM) was administered in the presence and absence of 
unselective adenosine receptor antagonist, 8-SPT (1µM) at 30 minutes post-reoxygenation. 
Data presented as percentage of Normoxia±SEM n=6. *** p<0.001 vs. Normoxia. ### 










4.4 Discussion  
 
There have been numerous articles that have explored adenosine receptors as potential 
therapeutic targets (Jacobson and Gao 2006; Fredholm 2010; Chen et al. 2013; Covinhes et 
al. 2020; Gaundry et al. 2020). Research over the past 20 years has allowed for medicinal 
chemistry to generate various agonists and antagonists with affinity to selective adenosine 
receptor subtypes (Chen et al. 2013), however to date an effective adenosine related therapy 
has failed to translate to clinical settings.  
Our findings within this chapter have explored the A1 adenosine receptor subtype and its 
activation with A1AR agonist 2’-MeCCPA. This chapter has also explored the effects of A1AR 
antagonist DPCPX when administered alongside 2’-MeCCPA. The protection observed when 
2’-MeCCPA (10nM) was administered alone at the onset of reperfusion was abrogated when 
2’-MeCCPA (10nM) and DPCPX (200nM) were administered alongside each other at the onset 
of reperfusion. This can be supported by previous research conducted into the A1 adenosine 
receptor where DPCPX has been shown to reverse any protective effects, for example a study 
by Louttit et al. (1999) researched into a selective A1 adenosine agonist, GR79236 (10nM/kg) 
in an anaesthetised pig/porcine model of myocardial ischaemia-reperfusion injury. GR79236 
was seen to show cardioprotective effects by reducing infarct size and when DPCPX was 
administered alongside it, all cardioprotective effects were reversed (Louttit et al. 1999). This 
is also very similar to our findings where 2’-MeCCPA successfully limited infarct size in an 
isolated rat heart model of myocardial ischaemia-reperfusion injury however when DPCPX 
was administered alongside at the onset of reperfusion, there was a significant increase in 
infarct size which therefore reversed cardioprotective effects. The findings from this study 
were also supported in an isolated mouse heart models of ischaemia-reperfusion (Urmaliya 
et al. 2010). This therefore implies that the cardioprotection observed is due to specific 
activation of the A1 adenosine receptor as this protection is abrogated upon administration 
of A1 adenosine receptor antagonist. 
Our study further investigated into delayed post-reperfusion activation of the A1 adenosine 
receptor at 15 minutes and 30 minutes post-reperfusion. Currently there is limited research 
that explores post-reperfusion activation using an A1 adenosine receptor agonist however the 
study by Lubitz et al. (2001) successfully used the method of post-reperfusion activation of 
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the A3 adenosine receptor using A3 adenosine agonist IB-MECA which decrease infarct size 
following focal brain ischaemia. The methods of post-reperfusion activation of the A3 
adenosine receptor subtype draws direct links with our study in which post-reperfusion 
activation at 15 and 30 minutes of the A1 adenosine receptor also successfully limited infarct 
size. Furthermore this study also administered the A1 adenosine antagonist alongside 2’-
MeCCPA at the two different delayed activation time points of 15 minutes and 30 minutes 
post-reperfusion and when DPCPX was administered, there was a significant increase in 
infarct size and abrogation in 2’-MeCCPA mediated protection. This therefore implies that the 
A1 adenosine receptor subtype itself can provide cardioprotection. Later in the study the 
intracellular signalling pathways involved in the A1 adenosine receptor mediated 
cardioprotection is explored using western blot analysis and the assessment of cell death and 
cleaved caspase-3 activity.  
Alongside a decrease in infarct size in isolated rat hearts when 2’-MeCCPA (10nM) was 
administered alone at the onset of reperfusion, 15 minutes and 30 minutes post-reperfusion; 
and this protection abrogated in the presence of DPCPX (200nM). Cell death (apoptosis and 
necrosis) and cleaved caspase-3 activity was assessed. Overall when 2’-MeCCPA (10nM) was 
administered to isolated rat cardiomyocytes, there was a significant decrease in cellular 
apoptosis and necrosis however when DPCPX (200nM) was administered alongside, the level 
of cell death increased which in turn also increased the levels of cleaved caspase-3 at the 
points where 2’-MeCCPA and DPCPX was administered at the onset of reperfusion and also 
at 15 minutes post-reperfusion. When both 2’-MeCCPA and DPCPX were administered in 
conjunction at 30 minutes post-reperfusion, there was limited change in apoptosis and 
cleaved caspase-3 activity when compared to 2’-MeCCPA being administered alone at 30 
minutes post-reperfusion. This could have occurred due to the 30 minutes time-point being 
a long duration after the onset of reperfusion to have 2’-MeCCPA activating the A1 receptor. 
Hausenloy and Yellon (2003) stated that most protection occurs in the early stages of 
reperfusion and therefore this could support the findings of this current study in stating that 
the 30 minutes time point could just be too long after the commencement of reperfusion in 
order to ensure protection. Apoptosis could be occurring at such a high rate at this point 
which in turn increases caspase-3 activity. The activation of A1 adenosine receptors at 30 
minutes post-reperfusion could be too late in order to fully ensure protection. When 
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comparing infarct size of 2’-MeCCPA administration at the onset of reperfusion, 15 minutes 
post reperfusion and 30 minutes post reperfusion; the infarct size is the lowest at the point 
where 2’-MeCCPA is administered alone at reperfusion compared to when 2’-MeCCPA is 
administered alone at 30 minutes post-reperfusion. Although the decrease in infarct size at 
30 minutes post-reperfusion is still significant and ensures protective effects in terms of the 
isolated rat heart model, it is not as protective as when 2’-MeCCPA is administered at the 
onset of reperfusion and at 15 minutes post-reperfusion. Therefore this could support the 
little difference observed in apoptosis and cleaved caspase-3 levels when 2’-MeCCPA is 
administered at 30 minutes post-reperfusion.  
Interestingly the study conducted by Lubitz et al. (2001) administered A3AR agonist IB-MECA 
20 minutes after the onset of reperfusion. In order to understand if the defined timing of 
administration of the A1 adenosine receptor agonist has an impact on the extent of 
cardioprotection. It would be important to explore the differences between 15 minutes, 20 
minutes and 30 minutes post-reperfusion activation of A1 adenosine receptors. 
Our findings have been able to imply that the A1 adenosine receptor, when activated at the 
onset of reperfusion and at 15 minutes post-reperfusion, was able to successfully confer 
protection; however at 30 minutes protection was limited. This protection was reversed in 
the presence of the A1AR antagonist DPCPX which showed that the A1 adenosine receptor 
definitely played an important role when cardioprotection was observed to the isolate rat 
heart model as well as the isolated rat cardiomyocytes. It was therefore useful to assess if 
certain pro-survival signalling pathways played a role within this protective effect that was 
ensured. The western blot analysis carried out within this chapter was able to successfully 
determine if the PI3K-AKT and MEK1/2-ERK1/2 pro-survival signalling pathways were linked 
with the A1 adenosine receptor and if they played a role in the observed cardioprotection. 
From our findings, it can be implied that when 2’-MeCCPA (10nM) was administered at the 
onset of reperfusion, 15 minutes and 30 minutes post-reperfusion, there was a significant 
increase in p-AKT(Ser473) phosphorylation and this increase significantly decreased in the 
presence of DPCPX (200nM) at all three time points. This suggests that the protection 
observed throughout this chapter upon infarct size, cell death and cleaved caspase-3 activity 
occurred in a PI3K-AKT manner. This can be supported by a study conducted by Germack and 
Dickenson (2000) where the study of A1 adenosine receptor stimulation was carried out 
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where A1 adenosine agonist (1µM) increased PKB (AKT) phosphorylation and the 
administration of DPCPX antagonised the PKB (AKT) phosphorylation. This study was 
conducted upon DDT (1) MF-2 cells and although this is different to rat myocardium tissue, 
the trends in data still appear to be similar.  
Further study by Bibli and colleagues (2014) were also able to identify that AKT was 
significantly upregulated when A1AR agonist CCPA was administered to male rabbit hearts 
through a post-conditioning phenomenon. This shows that the RISK pathway was involved 
with A1AR activation specifically which can also support this current study that has shown that 
the RISK pathway does play a part in A1AR activation.  
With extensive investigation put into the effects of a selective A1 adenosine antagonist DPCPX 
being administered alongside an A1 adenosine agonist 2’-MeCCPA, a non-selective adenosine 
antagonist, 8-SPT was also studied when administered alongside selective A1 adenosine 
antagonist 2’-MeCCPA.  
 
4.5 Summary of Findings 
 
Within this chapter further evidence has implied that the A1 adenosine receptor plays a vital 
role in cardioprotection within the isolated rat heart model which was further supported by 
isolated rat cardiomyocyte model. The role of the A1 adenosine receptor was also explored 
when antagonised by selective A1 adenosine antagonist DPCPX as well as unselective 
adenosine antagonist 8-SPT. These effects were all explored at the onset of reperfusion, 15 
minutes and 30 minutes post-reperfusion. Our results showed that: 
- The administration of the A1AR agonist 2’-MeCCPA (10nM) implies that 
cardioprotection occurred. This was observed though the limited infarct effect, a 
decrease in cell death and a decrease in cleaved caspase-3 activity. These effects were 
observed when 2’-MeCCPA was administered at the onset of 
reperfusion/reoxygenation, 15 minutes and 30 minutes post-
reperfusion/reoxygenation.  
- The protective effects observed were significantly antagonised with the 
administration of selective A1 adenosine antagonist, DPCPX. When 2’-MeCCPA was 
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administered alongside 2’-MeCCPA at the onset of reperfusion, 15 minutes and 30 
minutes post-reperfusion; infarct limiting effects were antagonised and cell death 
increased. Showing the importance of the activation of the A1 adenosine receptor at 
the onset of reperfusion and 15 minutes into the onset of reperfusion. When 2’-
MeCCPA and DPCPX was co-administered at 30 minutes post-reperfusion, there was 
no effect upon caspase-3 activity. Summarising that delayed activation of A1 
adenosine receptors at 30 minutes post-reperfusion may be too late for activation. 
- Western blot analysis highlighted an increase of p-AKT (Ser473) when 2’-MeCCPA was 
administered at the onset of reperfusion, 15 minutes and 30 minutes post-reperfusion 
however the administration of DPCPX at these different time-points alongside 2’-
MeCCPA antagonised the phosphorylation of these proteins. This highlighted the 
importance of activation and delayed activation of A1 adenosine receptors and the 
recruitment of RISK pro-survival signalling pathway which includes the PI3K-AKT and 
MEK1/2-ERK1/2 cell signalling pathways.  
- Selective A1 adenosine agonist 2’-MeCCPA was administered alongside unselective 
adenosine antagonist 8-SPT and it was found that when both agonist and antagonist 
were administered together, there was an increase in infarct effect at the onset of 
reperfusion, 15 minutes and 30 minutes post-reperfusion.  
- An increase in cell death was observed when 2’-MeCCPA and 8-SPT were 
administered together in comparison to when 2’-MeCCPA was administered alone 
showing that 8-SPT blocked 2’-MeCCPA mediated cardioprotection. No difference in 
cell death was detected at 15 minutes and 30 minutes post-reperfusion. 
- An increase in cleaved caspase-3 activity was also observed when 2’-MeCCPA and 8-
SPT was administered together in comparison to when 2’-MeCCPA was administered 
alone at the onset of reperfusion and at 15 minutes post-reperfusion. No difference 
was detected when both agonist and antagonist was administered together at 30 




Chapter 5: Administration of A1 adenosine receptor agonist, 2’-
MeCCPA (10nM) at the onset of reperfusion compared to 15 minutes 
and 30 minutes post-reperfusion to protect the myocardium from 
ischaemia-reperfusion injury via the recruitment of the PI3K-AKT cell 
signalling pathway 
 
5.1 Introduction  
 
PI3K is a serine/threonine kinase and this plays a major role in regulating cell growth, 
differentiation and survival (Ban et al. 2008). PI3K is directly linked to the reperfusion injury 
salvage kinase (RISK) pathway and has been shown to be important in the intracellular 
signalling pathway required for cardioprotection. Studies conducted by Hausenloy et al. 
(2007) have undertaken detailed research into how activation of the PI3K-AKT cell signalling 
pathway can enhance cardioprotection; but until now there is limited research on the role of 
PI3K in the post-reperfusion A1 adenosine receptor mediated cardioprotection.  
The phosphorylation of PI3K can subsequently lead to phosphorylation of AKT (also known as 
protein kinase B). This cascade can therefore further lead to cardioprotective effects within a 
myocardial ischaemia-reperfusion setting (Jonassen et al. 2004; Mangi et al. 2003; Effendi et 
al. 2020). AKT, which is made up of serine and threonine b kinases, was discovered around 25 
years ago and has also been an important focus of many studies within the fields of biology 
and medicine since (Manning and Toker 2017). Studies conducted on mouse and human 
genetics have shown the physiological roles of the AKT network.  
AKT has been shown to play a key role when it comes to the induction of cardioprotection 
through ischaemic preconditioning (Lai et al. 2015; Singh et al. 2018). Links have been 
proposed to suggest that adenosine preconditioning also promotes AKT phosphorylation in 
order to trigger cardioprotection. A recent study conducted by Shao et al. (2017) reported 
that pre-treatment with A1 adenosine receptor agonist N6-cyclohexyladenosine had the 
ability to trigger cardioprotection against ischaemia-reperfusion injury via the increase in 
phosphorylation of AKT (Shao et al. 2017). The A1 and the A3 receptors play a major role in 
intracellular signalling in order to trigger cardioprotection (Cohen and Downey 2007).  
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The phenomenon of reperfusion is a prerequisite in order to salvage the viable myocardium 
following an acute myocardium infarction; however it is not without risk that the act of 
reperfusion can paradoxically result in myocyte death alongside (Hausenloy and Yellon 2004). 
This is termed lethal reperfusion-induced injury. Therapeutic strategies can be adhered to in 
order to target and attenuate reperfusion-induced cell death by providing pharmacological 
agents to limit myocardial infarction (Hausenloy and Yellon 2004). Recent evidence has 
implied that apoptotic cell death can be implicated during the phase of reperfusion to 
contribute to lethal reperfusion-induced injury and targeting the cellular anti-apoptotic 
mechanisms at the time of reperfusion is therefore a potential approach in being able to 
attenuate reperfusion-induced cell death (Hausenloy and Yellon 2004). It has been shown 
that the activation of anti-apoptotic cell survival kinase signalling cascades such as the PI3K-
AKT pathway has been implicated in conferring cardioprotection at the time of reperfusion 
and has limited infarct size (Hausenloy and Yellon 2004).  
With the pro-survival PI3K-AKT kinase cascade mediating cardioprotection at the time of 
reperfusion through the association of ischaemic preconditioning, evidence suggests the 
recruitment of this pro-survival pathway can occur at the time of reperfusion itself and cause 
cardioprotective qualities (Hausenloy and Yellon 2004).  
 
5.1.1 Aims and Objectives 
 
1. To determine the cardioprotective effects of the A1 adenosine receptor agonist, 2’-
MeCCPA (10nM) in association with the recruitment of the pro-survival PI3K-AKT cell 
signalling pathway. A1AR agonist 2’-MeCCPA (10nM) was administered at the onset 
of reperfusion in the presence and absence of PI3K inhibitor Wortmannin in order to 
assess infarct size (%), cell death (apoptosis and necrosis), p-AKT phosphorylation in 
Western blot and caspase-3 activity.  
2. To determine the cardioprotective effects of the A1 adenosine receptor agonist, 2’-
MeCCPA (10nM) in association with the post-reperfusion/reoxygenation recruitment 
of the pro-survival PI3K-AKT cell signalling pathway. A1AR agonist 2’-MeCCPA (10nM) 
was administered at 15 minutes post-reperfusion/reoxygenation in the presence and 
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absence of PI3K inhibitor Wortmannin in order to assess infarct size (%), cell death 
(apoptosis and necrosis), p-AKT phosphorylation and caspase-3 activity.  
3. To determine the effects of A1AR agonist 2’-MeCCPA (10nM) in the association of 
with the post-reperfusion/reoxygenation recruitment of the pro-survival PI3K-AKT 
cell signalling pathway. 2’-MeCCPA (10nM) was administered at 30 minutes post-
reperfusion/reoxygenation in the presence and absence of PI3K inhibitor 
Wortmannin in order to assess infarct size (%), cell death (apoptosis and necrosis), p-





2’-MeCCPA and Wortmannin were both supplied from Tocris Cookson (Bristol) and prepared 
in the same manner as described in Chapter 2, Section 2.2. 
5.2.2 Animals 
 
Adult male Sprague-Dawley rats (350 ± 50g) were supplied from Charles River (UK). Animals 
all received human care and assistance and were sacrificed by cervical dislocation as 
outlined in the Schedule 1 Home Office Procedure in accordance with the Scientific 
Procedure Act 1986. This process is described in Chapter 2, Section 2.1.  
5.2.3 Langendorff protocol – Isolated perfused rat heart preparation 
 
Briefly, experiments using the Langendorff technique were carried out for 175 minutes in 
total (full details in Chapter 2, Section 2.3.5). Hearts were allowed a 20 minutes stabilisation 
period where hearts were perfused with KH buffer, followed by 35 minutes of simulated 
regional ischaemia followed by 120 minutes of reperfusion. Hearts were randomly allocated 
to the following control and treatment groups: 
a) Normoxic control – Rat hearts perfused with KH buffer for 175 minutes (no 
simulated ischaemia induced). 
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b) Ischaemia-reperfusion (IR) control – Rats hearts were perfused with KH buffer for 20 
minutes followed by 35 minutes of simulated regional ischaemia and 120 minutes of 
reperfusion. 
c) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of PI3K 
inhibitor Wortmannin (100nM) at the onset of reperfusion – Rats were perfused with 
KH buffer for 20 minutes, 35 minutes of simulated regional ischaemia followed by 
120 minutes of reperfusion where drug administration occurred at the onset of 
reperfusion. 
d) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of PI3K 
inhibitor Wortmannin (100nM) at 15 minutes post-reperfusion - Rats were perfused 
with KH buffer for 20 minutes, 35 minutes of simulated regional ischaemia followed 
by 120 minutes of reperfusion where drug administration occurred at 15 minutes 
post-reperfusion. 
e) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of PI3K 
inhibitor Wortmannin (100nM) at 30 minutes post-reperfusion - Rats were perfused 
with KH buffer for 20 minutes, 35 minutes of simulated regional ischaemia followed 
by 120 minutes of reperfusion where drug administration occurred at 30 minutes 
post-reperfusion. 
Throughout the course of the Langendorff experiments, the stability of the hearts were 
consistently monitored by the heart rate (HR), left ventricular developed pressure (LVDP) 
and coronary flow (CF) haemodynamic parameters (as described in Chapter 2, Section 
2.3.2).  
After the reperfusion period, the infarct size to risk ratio was assessed with the use of Evans 
blue and triphenyltetrazolium chloride (TTC) staining procedures as described in Chapter 2, 
Section 2.3.6.  
 
5.2.4 Isolation of adult rat ventricular cardiomyocytes 
 
Isolation of adult rat ventricular cardiomyocytes was previously described in Chapter 2, 
Section 2.4.  
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5.2.5 Induction of hypoxia and reoxygenation conditions in adult rat 
cardiomyocytes 
 
Fully described in Chapter 2, Section 2.4.1. 
 
5.2.6 Experimental drug treatment protocol in adult rat ventricular 
cardiomyocytes 
 
The isolated rat cardiomyocytes were exposed to differing control and drug treatments. All 
experimental conditions are detailed as below: 
a) Normoxic control – Isolated myocytes were exposed to normoxic conditions for a total 
of 4 hours at 37oC, 5% CO2 and 95% O2.  
b) Hypoxia-Reoxygenation control – Isolated cardiomyocytes were exposed to 1 hour of 
hypoxia conditions followed by the onset of reoxygenation for 3 hours.  
c) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of PI3K 
inhibitor Wortmannin (100nM) at the onset of reoxygenation – Isolated 
cardiomyocytes were exposed to 1 hour hypoxia conditions followed by drug 
treatment at the onset of reoxygenation for 3 hours at 37oC, 5% CO2 and 95% O2.  
d) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of PI3K 
inhibitor Wortmannin (100nM) at 15 minutes post-reoxygenation – Isolated 
cardiomyocytes were exposed to 1 hour hypoxia conditions followed by drug 
treatment at 15 minutes post-reoxygenation for 3 hours at 37oC, 5% CO2 and 95% O2. 
e) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of PI3K 
inhibitor Wortmannin (100nM) at 30 minutes post-reoxygenation – Isolated 
cardiomyocytes were exposed to 1 hour hypoxia conditions followed by drug 






5.2.7 Quantitative Analysis of Cell Death using Dead Cell Apoptosis Kit with 
Annexin V FITC with Propidium Iodide (PI) in Adult Rat Cardiomyocytes 
 
Followed by the drug treatments described above, isolated rat ventricular cardiomyocytes 
were assess for their levels of apoptosis and necrosis using the Dead Cell Apoptosis Kit with 
Annexin V FITC and PI was purchased from ThermoFisher (UK) (previously detailed in Chapter 
2, Section 2.5.2). Data was normalised against the cell only control and the values obtained 
were calculated as a relative change in apoptosis and necrosis activity of the mean 
absorbance of the control group. 
5.2.8 Analysis of Cleaved Caspase-3 Activity in Adult Rat Cardiomyocytes 
 
Following the drug treatment protocol as described above, the rat cardiomyocytes were 
probed with cleaved caspase-3 antibody as described in Chapter 2, Section 2.5.1. Data 
obtained was normalised to the cell only control by subtracting the mean fluorescence 
background recorded in untreated samples. Data was presented as a relative change in 
fluorescence activity. 
 
5.2.9 Western blot analysis 
 
Western blot analysis was performed as described in Chapter 2, Section 2.6. Following the 
stages of separation and protein transfer procedure; membrane blots were probed for 
phosphorylated and total form of the monoclonal rabbit AKT (Ser473) protein (Cell Signalling, 
UK) as stated in Section 2.6.7. Protein detection was quantified with the use of Super Signal 
West Femto Maximum Substrate Solution (ThermoFisher Scientific, UK) to perform an 
enhanced chemi-luminescence assay (as detailed in Chapter 2, Section 2.6.8) and proteins 
bands were visualised with the use of Bio-Rad Quantity One programme. The relative 
variations of the levels of phosphorylated monoclonal rabbit AKT (Ser473) protein were 
normalised to the total form of the monoclonal rabbit AKT protein. GAPDH was also used as 





5.2.10 Data Analysis 
 
All data that was presented in this project is expressed at the mean ± standard error of the 
mean (SEM). IBM Statistical Package for Social Sciences (SPSS®) software was used to 
statistically analyse the data. The statistical tests currently used to analyse infarct sizes, band 
densities and cell population data was by one-way ANOVA accompanied by Fishers Protected 
Least Significant Difference (LSD) test for multiple comparisons. To assess the difference in 
the data sets, a p-value of p<0.05 was used to consider statistical significance.  
Microsoft Excel was also used to present all data graphically.  
 
5.3 Results  
 
5.3.1 Profiling the effects of the administration of 2’-MeCCPA (10nM) at the 
onset of reperfusion/reoxygenation in the presence and absence of PI3K-AKT 
inhibitor, Wortmannin (100nM) and its affects upon isolated rat myocardium 
model and isolated rat cardiomyocytes. 
 
5.3.1.1 Profiling the effects of 2’-MeCCPA in the presence and absence of 
PI3K-AKT inhibitor, Wortmannin (100nM) on haemodynamic parameters (left 
ventricular developed pressure, heart rate and coronary flow) at the onset of 
reperfusion. 
 
All hearts were subjected to 20 minutes stabilisation, 35 minutes ischaemia and a further 120 
minutes of reperfusion where 2’-MeCCPA (10nM) was administered in the presence and 
absence of Wortmannin (100nM) (PI3K-AKT inhibitor). Wortmannin (100nM) was also 
administered alone also. All treatments were administered at the onset of reperfusion to 
profile the effects of this inhibitor upon the A1 adenosine receptor agonist, 2’-MeCCPA 
(10nM). 
No significant difference between the groups at any of the time-points within the reperfusion 
period was observed (p>0.05) (Figure 5.1). Throughout the ischaemic period, all treatment 














Figure 5. 1 Effects of 2’-MeCCPA (10nM) in the presence and absence of Wortmannin 
(100nM) on the left ventricular developed pressure (LVDP) within isolated rat hearts when 
subjected to 20 minutes stabilisation, 35 minutes of ischaemia and 120 minutes of 
reperfusion. 2’-MeCCPA (10nM) was administered at the onset of reperfusion in the 
presence and absence of Wortmannin (100nM). Data was presented as Mean±SEM, n=6-8. * 
















There was no significant changes detected in the heart rate between all time-matched 
treatment groups (p>0.05) (Figure 5.2). 
 
Figure 5. 2 Effects of 2’-MeCCPA (10nM) in the presence and absence of Wortmannin 
(100nM) on the heart rate within isolated rat hearts when subjected to 20 minutes 
stabilisation, 35 minutes of ischaemia and 120 minutes of reperfusion. 2’-MeCCPA (10nM) 
was administered at the onset of reperfusion in the presence and absence of Wortmannin 
(100nM). Data was presented as Mean±SEM, n=6-8. 
 
No significant changes were observed between treatment groups at each time-matched 
points within the reperfusion period (p>0.05) (Figure 5.3). Although within the ischaemic 
period, all time-matched treatment groups had a significantly lower coronary flow in 




Figure 5. 3 Effects of 2’-MeCCPA (10nM) in the presence and absence of Wortmannin 
(100nM) on the coronary flow within isolated rat hearts when subjected to 20 minutes 
stabilisation, 35 minutes of ischaemia and 120 minutes of reperfusion. 2’-MeCCPA (10nM) 
was administered at the onset of reperfusion in the presence and absence of Wortmannin 
(100nM). Data was presented as Mean±SEM, n=6-8. * p<0.05 vs. Normoxia.  
 
 
5.3.1.2 Profiling the effects of 2’-MeCCPA (10nM) in the presence and 
absence of PI3K-AKT signalling pathway inhibitor, Wortmannin (100nM) on 
infarct size and risk ratio (%) in isolated hearts subjected to ischaemia 
reperfusion injury at the onset of reperfusion 
 
All hearts were subjected to 20 minutes of stabilisation, 35 minutes of ischaemia and 120 
minutes of reperfusion. A1 adenosine receptor agonist, 2’-MeCCPA (10nM), was firstly 
administered alone or in the presence of PI3K signalling pathway inhibitor, Wortmannin 
(100nM). All treatments were administered at the onset of reperfusion to profile their effects 
on infarct size to risk ratio (%).  
When 2’-MeCCPA (10nM) was administered alone, a significant decrease in infarct size to risk 
ratio (%) was observed compared to the IR control (28 ± 4% vs. 55 ± 6%, p<0.001) (Figure 5.4). 
A significant increase in infarct size to risk ratio was detected (%) when Wortmannin (100nM) 
+ 2’-MeCCPA (10nM) was administered in conjunction compared with when 2’-MeCCPA 
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(10nM) was administered alone at the onset of reperfusion (65 ± 7% vs. 28 ±  4%, p<0.001) 
(Figure 5.4). No significant effect was observed when Wortmannin (100nM) was administered 











Figure 5. 4 Infarct size to risk ratio (%) within isolated perfused hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion subjected to 2’-
MeCCPA (10nM) administered alone as well as Wortmannin (100nM) (PI3K-AKT signalling 
pathway inhibitor) administered alone and 2’-MeCCPA + Wortmannin co-administered 
together all at the onset of reperfusion. Data presented as Mean±SEM. n=6-8. *** p<0.001 
vs. normoxic, ## p<0.01 vs. IR, $$$ p<0.001 vs. 2’-MeCCPA.  
 
5.3.1.3 The role of PI3K-AKT cell signalling pathway in 2’-MeCCPA mediated 
cardioprotection when administered at the onset of reperfusion to isolated 
rat cardiomyocytes subjected to 1 hour of hypoxia and 3 hours of 
reoxygenation and its effect upon on apoptosis and necrosis. 
 
It has previously been elucidated within this chapter that when 2’-MeCCPA (10nM) is 
administered at the onset of reoxygenation there is significant protection of the rat cardiac 
myocytes from hypoxia-reoxygenation injury via anti-apoptotic and anti-necrotic manners.   
In order to identify the anti-apoptotic as well as the anti-necrotic mechanisms within this 
section, the role of the PI3K-AKT cell signalling pathway was explore using Wortmannin 
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(100nM) alongside 2’-MeCCPA (10nM). Isolated myocytes were subjected to 1 hour of 
hypoxia and 3 hours of reoxygenation where A1 adenosine receptor agonist, 2’-MeCCPA 
(10nM) was administered at the onset of reoxygenation in the presence and absence of PI3K-
AKT inhibitor Wortmannin (100nM).  
The administration of A1 agonist 2’-MeCCPA (10nM) in the presence of PI3K-AKT inhibitor 
Wortmannin (100nM) significantly abolished the anti-apoptotic characteristics detected 
when 2’-MeCCPA (10nM) when administered alone throughout reoxygenation (29±4% 2’-
MeCCPA + Wortmannin vs. 17±4% 2’-MeCCPA, p<0.001) (Figure 5.5).  
Administration of 2’-MeCCPA (10nM) in the presence of PI3K-AKT inhibitor Wortmannin also 
significantly abolished the anti-necrotic effects of when 2’-MeCCPA (10nM) was administered 
alone throughout reoxygenation (25±3% 2’-MeCCPA + Wortmannin vs. 13±2% 2’-MeCCPA, 
p<0.001).  
No significant effect was observed when Wortmannin (100nM) was administered alone 







Figure 5. 5 Assessment of apoptosis and necrosis within isolated rat cardiomyocytes 
subjected to 1 hour of hypoxia and 3 hours of reoxygenation. 2’-MeCCPA (10nM) was 
administered at the onset of reoxygenation in the presence and absence of PI3K-AKT 
inhibitor, Wortmannin (100nM). Results were shown as Mean±SEM and were expressed as 
a percentage of 10 000 cells counted from 6 individual experiments. ***p<0.001 vs. 















5.3.1.4 Profiling effects of 2’-MeCCPA (10nM) when administered at 
reperfusion on AKT phosphorylation at the onset of reperfusion 
 
It was shown that 2’-MeCCPA (10nM) was able to protect the myocardium from 
ischaemia/reperfusion injury within isolated perfused rat hearts where this same protection 
was abolished in the presence of PI3K inhibitor Wortmannin (100nM) (Figure 5.6). In order to 
understand the signalling pathways involved when 2’-MeCCPA (10nM) mediated 
cardioprotection when administered at the onset of reperfusion meant it was necessary to 
investigate the phosphorylation activity of the protein AKT (ser473) at the onset of reperfusion 
in the presence and absence of Wortmannin (100nM). 
It was found that phosphorylation of AKT (ser473) was observed within the non-treated control 
as well as within 2’-MeCCPA (10nM) treated hearts. At the onset of reperfusion, 2’-MeCCPA 
(10nM) was administered and continued to be administered throughout the 10 minutes of 
reperfusion of this protocol (as mentioned in the methodology section) in the presence of A1 
adenosine agonist 2’-MeCCPA (10 nM), there was a significant increase in phosphorylation of 
AKT(ser473) (p<0.01) compared to the time matched control hearts (Figure 5.6). 
The upregulation of AKT(ser473) phosphorylation observed by 2’-MeCCPA (10nM) after 10 
minutes of reperfusion was significantly reduced in the presence of the PI3K inhibitor, 
Wortmannin (100nM) (p<0.001) (Figure 3.37). When Wortmannin (100nM) was administered 
alone at the onset of reperfusion, there was no significant effect upon AKT (ser473) 






















Figure 5. 6 The assessment of AKT(ser473) phosphorylation within isolated hearts subjected to 
65 minutes perfusion (Normoxia) or 20 minutes stabilisation, 35 minutes ischaemia followed 
by 10 minutes of reperfusion for non-treated control (Control 10’Reperfusion). The A1 
adenosine agonist 2’-MeCCPA (10nM) was administered at the onset of reperfusion in the 
presence and absence of PI3K inhibitor Wortmannin (100nM) for the duration of 10 minutes 
of reperfusion. Results are shown as Mean±SEM of four individual experiments. *** p<0.001 
vs. Normoxia. ### p<0.001 vs. Control 10’Reperfusion. ## p<0.01 vs. Control 10’Reperfusion. 







5.3.1.5 Profiling the role of PI3K-AKT cell signalling pathway on cleaved-
caspase 3 activity upon the administration of 2’-MeCCPA (10nM) at the onset 
of reoxygenation 
 
The role of the PI3K-AKT cell signalling pathway on cleaved-caspase 3 was determined in 
terms of 2’-MeCCPA (10nM) mediated cardioprotection. Isolated adult rat myocytes 
underwent 1 hour of hypoxia and 3 hours of reoxygenation where the A1 adenosine receptor 
agonist 2’-MeCCPA (10nM) was administered in the presence and absence of PI3K-AKT 
inhibitor, Wortmannin (100nM) throughout the reoxygenation period.  
It was found that the administration of 2’-MeCCPA (10nM) throughout the reoxygenation 
period significantly decreased cleaved-caspase 3 activity; and in the presence of PI3K inhibitor 
Wortmannin (100nM), this decrease in cleaved-caspase 3 was abolished (181±35% 2’-
MeCCPA at onset of Reox vs. 258±18% 2’-MeCCPA + Wortmannin at onset of reoxygenation, 
p<0.01) (Figure 5.7). Administration of Wortmannin (100nM) alone throughout the duration 
of reoxygenation had no significant effect upon cleaved-caspase 3 activity compared with the 
Hyp/Reox control group (282±47% Wortmannin at onset of reoxygenation vs. 313±35% 





Figure 5. 7 Cleaved-caspase 3 activity within isolated rat cardiomyocytes subjected to 4 
hours of reoxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of 
reoxygenation (Hyp/Reox). 2’-MeCCPA (10nM) was administered at the onset of 
reoxygenation in the presence and absence of PI3K-AKT cell signalling inhibitor Wortmannin 
(100nM). Mean±SEM on 6 individual experiments. *** p<0.001 vs. Normoxia. ### p<0.001 












5.3.2 Profiling the effects of the administration of 2’-MeCCPA (10nM) at 15 
minutes or 30 minutes post-reperfusion/reoxygenation in the presence and 
absence of PI3K-AKT inhibitor, Wortmannin (100nM) and its affects upon 
isolated rat myocardium model and isolated rat cardiomyocytes. 
 
5.3.2.1a Effects of postponing the administration of 2’-MeCCPA (10nM) to 15 
minutes post-reperfusion in the presence and absence of PI3K-AKT inhibitor, 
Wortmannin (100nM) on haemodynamic parameters (left ventricular 
developed pressure (LVDP), heart rate and coronary flow). 
 
Throughout the Langendorff studies, the left ventricular developed pressure, heart rate and 
coronary flow was consistently monitored. Hearts were subjected to 20 minutes stabilisation, 
35 minutes of ischaemia followed by 120 minutes of reperfusion with the administration of 
2’-MeCCPA (10nM) in the presence and absence of Wortmannin (100nM) at 15 minutes post 
reperfusion.  
It was observed that throughout ischaemia, there was a significant decrease in LVDP of all 
treatment groups at time matched points in comparison to the normoxia control group 
(p<0.05) (Figure 5.8). Throughout the period of reperfusion, there was a general decline in 
LVDP after 15 minutes of reperfusion in all treatment groups, these changes were not 




Figure 5. 8 Assessing the effects of 2’-MeCCPA (10nM) in the presence and absence of 
Wortmannin (100nM) when administered at 15 minutes post reperfusion on left ventricular 
developed pressure (LVDP) within isolated rat hearts when subjected to 20 minutes 
stabilisation, 35 minutes of ischaemia and 120 minutes of reperfusion. Data was presented 















There was no significant effects detected on heart rate between all time-matched treatment 












Figure 5. 9 The effects of 2’-MeCCPA (10nM) in the presence and absence of Wortmannin 
(100nM) when administered at 15 minutes post reperfusion on heart rate within isolated rat 
hearts when subjected to 20 minutes stabilisation, 35 minutes of ischaemia and 120 












Within the ischaemic period of the Langendorff protocol, it was observed that the coronary 
flow for all treatment groups at all time-matched points significantly decreased in 
comparison to the normoxic control group (p<0.05) (Figure 5.3). No significant changes were 
observed between the treatment groups at each time matched points within the 
reperfusion period (p>0.05) (Figure 5.10). 
 
Figure 5. 10 The effects of 2’-MeCCPA (10nM) in the presence and absence of Wortmannin 
(100nM) when administered at 15 minutes post reperfusion on coronary flow within 
isolated rat hearts when subjected to 20 minutes stabilisation, 35 minutes of ischaemia and 
120 minutes of reperfusion. Data was presented as Mean±SEM, n=6-8. * p<0.05 vs. All 









5.3.2.1b Effects of postponing the administration of 2’-MeCCPA (10nM) to 30 
minutes post-reperfusion in the presence and absence of PI3K-AKT inhibitor, 
Wortmannin (100nM) on haemodynamic parameters (left ventricular 
developed pressure (LVDP), heart rate and coronary flow). 
 
Throughout the Langendorff studies, the left ventricular developed pressure, heart rate and 
coronary flow was consistently monitored. Hearts were subjected to 20 minutes stabilisation, 
35 minutes of ischaemia followed by 120 minutes of reperfusion with the administration of 
2’-MeCCPA (10nM) in the presence and absence of Wortmannin (100nM) at 30 minutes post 
reperfusion. 
During the ischaemic period, all treatment groups at time matched points significantly 
decreased the LVDP compared to the normoxic heart group (p<0.05) (Figure 5.11). 
Throughout the period of reperfusion, there was an overall decline in LVDP from all treatment 
groups however no significance was shown between different treatment groups at time 




























Figure 5. 11 Assessing the effects of 2’-MeCCPA (10nM) in the presence and absence of 
Wortmannin (100nM) when administered at 30 minutes post reperfusion on left ventricular 
developed pressure (LVDP) within isolated rat hearts when subjected to 20 minutes 
stabilisation, 35 minutes of ischaemia and 120 minutes of reperfusion. Data was presented 














There was no significant effects detected on heart rate between all time-matched treatment 












Figure 5. 12 Effects of 2’-MeCCPA (10nM) in the presence and absence of Wortmannin 
(100nM) when administered at 30 minutes post reperfusion on heart rate within isolated rat 
hearts when subjected to 20 minutes stabilisation, 35 minutes of ischaemia and 120 













A significant decrease in coronary flow was observed in all treatment groups within the 
ischaemic period compared to the normoxic group (p<0.05) (Figure 5.13). No significant 
changes were observed between the treatment groups at each time matched points within 




Figure 5. 13 Effects of 2’-MeCCPA (10nM) in the presence and absence of Wortmannin 
(100nM) when administered at 30 minutes post reperfusion on coronary flow within 
isolated rat hearts when subjected to 20 minutes stabilisation, 35 minutes of ischaemia and 
120 minutes of reperfusion. Data was presented as Mean±SEM, n=6-8. * p<0.05 All groups 








5.3.2.2a The Effects of postponing the administration of 2’-MeCCPA (10nM) 
to 15 minutes post-reperfusion in the presence and absence of PI3K-AKT 
inhibitor, Wortmannin (100nM) on infarct size to risk ratio (%) in isolated 
hearts subjected to ischaemia reperfusion injury 
 
Postponement of the administration of A1 agonist 2’-MeCCPA (10nM) to 15 minutes after the 
onset of reperfusion was also able to significantly protect the ischaemic-reperfused 
myocardium from injury. In order to elucidate the intracellular signalling pathway involved to 
cause this protection, hearts were perfused with 2’-MeCCPA (10nM) in the presence and 
absence of PI3K-AKT inhibitor Wortmannin (100nM) 15 minutes post reperfusion. 
It was found that the administration of the A1 agonist 2’-MeCCPA (10nM) in the presence of 
the PI3K-AKT inhibitor, Wortmannin (100nM), administered at 15 minutes into the onset of 
reperfusion significantly abolished the protection observed when 2’-MeCCPA (10nM) was 
administered alone at 15 minutes post reperfusion (472% 2’-MeCCPA+Wortmannin@ 
15mins Post-R vs. 3010% 2’-MeCCPA@15mins Post-R, p<0.05) (Figure 5.14).  
When Wortmannin (100nM) was administered alone at 15 minutes post reperfusion, there 
was no significant effect upon the infarct size to risk ratio when compared to the IR control 


























Figure 5. 14 The infarct size to risk ratio (%) in non-treated IR control and 2’-MeCCPA 
(10nM) treated ischaemic reperfused hearts in the presence and absence of Wortmannin 
(100nM). Isolated perfused rats’ hearts were subjected to 20 minutes of stabilisation, 35 
minutes of ischaemia and a further 120 minutes of reperfusion where A1 adenosine receptor 
agonist, 2’-MeCCPA (10nM) was administered at 15 minutes post reperfusion in the 
presence and absence of Wortmannin (100nM). n=6-8 Mean±SEM. *** p<0.001 vs. 
Normoxia. ### p<0.001 vs. IR control. $$$ p<0.001 vs. 2’-MeCCPA at 15mins Post-R.  
 
5.3.2.2b The Effects of postponing the administration of 2’-MeCCPA (10nM) 
to 30 minutes post-reperfusion in the presence and absence of PI3K-AKT 
inhibitor, Wortmannin (100nM) on infarct size to risk ratio (%) within isolated 
hearts subjected to ischaemia reperfusion injury. 
 
When administration of A1 adenosine agonist, 2’-MeCCPA (10nM) was postponed to 30 
minutes after the onset of reperfusion, significant protection to the myocardium was 
observed (Figure 3.10). In order to determine whether the PI3K-AKT cell survival pathway 
contributed towards this protection, hearts were perfused with 2’-MeCCPA (10nM) in the 




It was observed that the administration of 2’-MeCCPA (10nM) in the presence of PI3K-AKT 
inhibitor Wortmannin (100nM) at 30 minutes post reperfusion significantly abolished the 
protection compared to when 2’-MeCCPA (10nM) was administered alone at 30 minutes post 
reperfusion (54±3% 2’-MeCCPA+Wortmannin at 30mins Post-R vs. 35±6% 2’-MeCCPA at 
30mins Post-R, p<0.01) (Figure 5.15).  
When Wortmannin (100nM) was administered alone at 30 minutes post reperfusion, no 
significant effect was observed upon the infarct size to risk ratio in comparison to the IR 
control (58±7% Wortmannin at 30mins Post-R vs. 55±6% IR control, p>0.05) (Figure 5.15).  
 
Figure 5. 15 Infarct size to risk ratio (%) in non-treated IR control and 2’-MeCCPA (10nM) 
treated ischaemic reperfused hearts in the presence and absence of Wortmannin (100nM). 
Isolated perfused rats’ hearts were subjected to 20 minutes of stabilisation, 35 minutes of 
ischaemia and a further 120 minutes of reperfusion where A1 adenosine receptor agonist, 
2’-MeCCPA (10nM) was administered at 30 minutes post reperfusion in the presence and 
absence of Wortmannin (100nM). n=6-8 Mean±SEM. *** p<0.001 vs. Normoxia. ### 




5.3.2.3a Effects of postponing the administration of 2’-MeCCPA to 15 minutes 
post reoxygenation on isolated rat cardiomyocytes subjected to 1 hour of 
hypoxia and 3 hours of reoxygenation from reoxygenation injury via the 
recruitment of the PI3K-AKT cell signalling pathway and its effects on cellular 
necrosis and apoptosis. 
 
In order to further determine the cardioprotective role of A1 adenosine receptor agonist, 2’-
MeCCPA (10nM), it was administered 15 minutes post reperfusion to isolated adult rat 
cardiomyocytes that were subjected to 1 hour of hypoxia and a further 3 hours of 
reoxygenation. 2’-MeCCPA (10nM) was introduced to the cardiomyocytes 15 minutes after 
the initiation of reoxygenation in the presence and absence of PI3K inhibitor Wortmannin 
(100nM).  
When the administration of 2’-MeCCPA (10nM) was postponed to 15 minutes post 
reoxygenation, there was a decrease in the number of apoptotic cardiomyocytes compared 
to the Hyp/Reox control group (14±5% 2’-MeCCPA at 15mins Post-R vs. 34±6% Hyp/Reox, 
p<0.001) (Figure 5.16). 
Postponing the administration of 2’-MeCCPA (10nM) to 15 minutes post reoxygenation 
significantly decreased the number of necrotic cardiomyocytes when compared to the 
Hyp/Reox control group (16±4% 2’-MeCCPA at 15mins Post-R vs. 28±7% Hyp/Reox, p<0.001) 
(Figure 5.17).  
The administration of 2’-MeCCPA (10nM) at 15 minutes post reperfusion in the presence of 
PI3K inhibitor Wortmannin (100nM) was able to significantly abolish the anti-apoptotic 
effects that had been observed when 2’-MeCCPA (10nM) was administered alone at 15 
minutes post reperfusion (28±6% 2’-MeCCPA+Wortmannin at 15mins Post-R vs. 14±5% 2’-
MeCCPA at 15mins Post-R, p<0.001) (Figure 5.16). Moreover, the anti-necrotic effect 
observed when 2’-MeCCPA (10nM) was administered alone at 15 minutes post reoxygenation 
was abolished when in the presence of PI3K inhibitor, Wortmannin (100nM) (27±6% 2’-
MeCCPA+Wortmannin at 15mins Post-R vs. 2’-MeCCPA at 15mins Post-R, p<0.001) (Figure 
5.17).  
The administration of Wortmannin (100nM) alone at 15 minutes post reperfusion had no 
significant effect upon cellular apoptosis on cardiomyocytes when compared to the Hyp/Reox 
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group (27±5% Wortmannin at 15mins Post-R vs. 34±6% Hyp/Reox, p>0.05) (Figure 5.16). 
Administration of Wortmannin (100nM) alone at 15 minutes into reoxygenation had no 
significant effect on cardiomyocyte necrosis when compared to the Hyp/Reox group (25±6% 
Wortmannin at 15mins Post-R vs. 28±7% Hyp/Reox, p>0.05) (Figure 5.17).  
 
 
Figure 5. 16 Assessment of apoptosis in isolated rat cardiomyocytes subjected to 4 hours of 
oxygenation (Normoxia) or 1 hours of hypoxia and 3 hours of reoxygenation. A1AR agonist 
2’-MeCCPA (10nM) was administered in the presence and absence of PI3K inhibitor 
Wortmannin (100nM) at 15 minutes post reoxygenation in order to assess the involvement 
of the PI3K-AKT cell signalling pathway. Results are shown at Mean±SEM and expressed as a 
percentage of 10 000 cells counted from 6 individual experiments. *** p<0.001 vs. 







Figure 5. 17 Assessment of necrosis in isolated rat cardiomyocytes subjected to 4 hours of 
oxygenation (Normoxia) or 1 hours of hypoxia and 3 hours of reoxygenation. A1AR agonist 
2’-MeCCPA (10nM) was administered in the presence and absence of PI3K inhibitor 
Wortmannin (100nM) at 15 minutes post reoxygenation in order to assess the involvement 
of the PI3K-AKT cell signalling pathway. Results are shown at Mean±SEM and expressed as a 
percentage of 10 000 cells counted from 6 individual experiments. *** p<0.001 vs. 
Normoxia. ### p<0.001 vs. Hyp/Reox. $$$ p<0.001 vs. 2’-MeCCPA at 15mins Post-R.  
 
5.3.2.3b Effects of postponing the administration of 2’-MeCCPA to 30 minutes 
post reoxygenation on isolated rat cardiomyocytes subjected to 1 hour of 
hypoxia and 3 hours of reoxygenation from reoxygenation injury via the 
recruitment of the PI3K-AKT cell signalling pathway and its effects on cellular 
necrosis and apoptosis. 
 
It was observed that when postponing the administration of A1 adenosine receptor agonist 
2’-MeCCPA (10nM) to 30 minutes post reoxygenation, a significant decrease in cellular 
apoptosis was observed in comparison to the non-treated Hyp/Reox group (15±5% 2’-
MeCCPA at 30mins Post-R vs. 34±6% Hyp/Reox, p<0.001) (Figure 5.18). The postponement of 
2’-MeCCPA (10nM) to 30 minutes post reoxygenation was also able to significantly decrease 
cellular necrosis compared to the Hyp/Reox group (17±3% 2’-MeCCPA at 30mins Post-R vs. 
28±7% Hyp/Reox, p<0.001) (Figure 5.19).  
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The administration of 2’-MeCCPA (10nM) at 30 minutes post reperfusion was able to 
significantly decrease cellular apoptosis however when 2’-MeCCPA (10nM) and Wortmannin 
(100nM) were administered in conjunction, the decrease in cellular apoptosis was abolished 
(15±5% 2’-MeCCPA at 30mins Post-R vs. 27±4% 2’-MeCCPA+Wortmannin at 30mins Post-R, 
p<0.001) (Figure 5.18). Furthermore, it was observed that the anti-necrotic effects of when 
2’-MeCCPA (10nM) was administered alone at 30 minutes post reoxygenation were abolished 
in the presence of PI3K inhibitor Wortmannin (100nM) (17±3% 2’-MeCCPA at 30mins Post-R 
vs. 27±5% 2’-MeCCPA+Wortmannin 30mins Post-R, p<0.001) (Figure 5.19).  
Administration of Wortmannin (100nM) alone at 30 minutes post reoxygenation had no 
significant effect on cardiomyocyte apoptosis when compared to the Hyp/Reox control group 
(24±5% Wortmannin at 30mins Post-R vs. 35±6% Hyp/Reox, p>0.05) (Figure 5.18). The 
administration of Wortmannin (100nM) alone at 30 minutes post reperfusion had no 
significant effect on cardiomyocyte necrosis when compared to the Hyp/Reox control group 








Figure 5. 18 Assessment of apoptosis in isolated rat cardiomyocytes subjected to 4 hours of 
oxygenation (Normoxia) or 1 hours of hypoxia and 3 hours of reoxygenation. A1AR agonist 
2’-MeCCPA (10nM) was administered in the presence and absence of PI3K inhibitor 
Wortmannin (100nM) at 30 minutes post reoxygenation in order to assess the involvement 
of the PI3K-AKT cell signalling pathway. Results are shown at Mean±SEM and expressed as a 
percentage of 10 000 cells counted from 6 individual experiments. *** p<0.001 vs. 






Figure 5. 19 Assessment of necrosis in isolated rat cardiomyocytes subjected to 4 hours of 
oxygenation (Normoxia) or 1 hours of hypoxia and 3 hours of reoxygenation. A1AR agonist 
2’-MeCCPA (10nM) was administered in the presence and absence of PI3K inhibitor 
Wortmannin (100nM) at 30 minutes post reoxygenation in order to assess the involvement 
of the PI3K-AKT cell signalling pathway. Results are shown at Mean±SEM and expressed as a 
percentage of 10 000 cells counted from 6 individual experiments. *** p<0.001 vs. 
Normoxia. ### p<0.001 vs. Hyp/Reox. $$$ p<0.001 vs. 2’-MeCCPA at 30mins Post-R.  
 
5.3.2.4a The role of p-AKT (ser473) in 2’-MeCCPA mediated cardioprotection 
when administered at 15 minutes post reperfusion. 
 
Having been able to determine that 2’-MeCCPA (10nM) protects isolated perfused rat heart 
from ischaemia reperfusion injury when administered at 15 minutes post reperfusion via the 
PI3K-AKT cell signalling pathway This meant it was important to further examine the effects 
of the A1 adenosine agonist and the PI3K inhibitor Wortmannin (100nM) on AKT(ser473) 
phosphorylation. Hearts were harvested 25 and 35 minutes after reperfusion where A1 
adenosine agonist, 2’-MeCCPA (10nM) was administered at 15 minutes post reperfusion.  
Within the control hearts, AKT (ser473) phosphorylation was observed at 25 and 35 minutes of 
reperfusion (Figure 5.20). It was observed that the administration of 2’-MeCCPA (10nM) 
significantly upregulated the phosphorylation of AKT(ser473) with maximal phosphorylation of 
AKT(ser473) at 25 minutes of reperfusion compared with the time matched non-treated control 
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where the A1 agonist 2’-MeCCPA (10nM) was perfused at 15 minutes post reperfusion 
(p<0.001) (Figure 5.20 and Figure 5.21).  
The administration of 2’-MeCCPA (10nM) at 15 minutes post reperfusion significantly 
upregulated AKT (ser473) phosphorylation after 25 minutes of reperfusion; this was then 
abolished in the presence of PI3K inhibitor Wortmannin (100nM) (p<0.001) (Figure 5.21). The 
administration of the PI3K inhibitor Wortmannin (100nM) alone at 15 minutes post 
reperfusion until a total of 25 minutes of reperfusion caused a significant decrease in 
AKT(ser473) phosphorylation when compared to the time matched non-treated control group 
















Figure 5. 20 The assessment of AKT(ser473) phosphorylation in isolated hearts that were 
subjected to 60 minutes of perfusion (Normoxia) or 20 minutes of stabilisation, 35 minutes 
of ischaemia followed by 25 or 35 minutes of reperfusion in the presence and absence of A1 
adenosine receptor agonist, 2’-MeCCPA (10nM) administered at 15 minutes post-
reperfusion. 2’-MeCCPA (10nM) was administered in the presence and absence of PI3K 
inhibitor Wortmannin (100nM) at 15 minutes post-reperfusion. Results were shown as 
Mean ± SEM of four experiments. ### p<0.001 2’-MeCCPA 25’, 35’ vs. Control 25’, 35’ 
respectively. $$$ p<0.001 2’-MeCCPA+Wortmannin 25’, Wortmannin 25’ vs. 2’-MeCCPA 25’. 













Figure 5. 21 The comparison of AKT (ser473) phosphorylation in isolated hearts subjected to 20 
minutes stabilisation, 35 minutes of ischaemia followed by 25 minutes of reperfusion. A1 
adenosine receptor agonist, 2’-MeCCPA (10nM) was administered at 15 minutes post 
reperfusion in the presence and absence of PI3K inhibitor Wortmannin (100nM). Results are 
shown as Mean±SEM of 4 experiments. *** p<0.001 vs. Normoxia. ### p<0.001 vs. Control 





5.3.2.4b The role of AKT phosphorylation within the PI3K-AKT signalling 
pathway in 2’-MeCCPA mediated cardioprotection when administered at 30 
minutes post reperfusion. 
 
It was previously shown in Chapter 3 that when 2’-MeCCPA (10nM) was administered at 30 
minutes post reperfusion, development of infarction was limited within ischaemic reperfused 
hearts. This protection was then blocked in the presence of the PI3K inhibitor Wortmannin 
(100nM).  
In order to determine whether the protection afforded by 2’-MeCCPA (10nM) when 
administered at 30 minutes post reperfusion is via the recruitment of the PI3K-AKT cell 
survival pathway, heart tissues were treated with 2’-MeCCPA (10nM) in the presence and 
absence of the PI3K inhibitor Wortmannin (100nM) at 30 minutes post reperfusion and 
AKT(ser473) phosphorylation was assessed.  
Within the control heart groups, AKT (ser473) phosphorylation was observed at 40 and 50 
minutes of reperfusion. It was observed that the administration of 2’-MeCCPA (10nM) 
specifically at 30 minutes post reperfusion significantly upregulated the phosphorylation of 
AKT(ser473) after 40 minutes of reperfusion compared to its time matched control (p<0.001) 
(Figure 5.22). The administration of 2’-MeCCPA (10nM) and Wortmannin (100nM) together 
at 30 minutes post reperfusion significantly abolished the increase in AKT(ser473) 
phosphorylation incurred by 2’-MeCCPA (10nM) alone after 40 minutes of reperfusion 
(p<0.001) (Figure 5.22 and Figure 5.23). 
The administration of 2’-MeCCPA (10nM) at 30 minutes post reperfusion showed a significant 
down regulation of AKT(ser473) phosphorylation after 50 minutes of reperfusion compared to 














Figure 5. 22 The assessment of p-AKT phosphorylation in isolated hearts subjected to 60 
minutes of perfusion (Normoxia) or 20 minutes of stabilisation, 35 minutes of ischaemia 
followed by 40 or 50 minutes of reperfusion in the presence and absence of A1 adenosine 
receptor agonist 2’-MeCCPA (10nM). The PI3K inhibitor Wortmannin (100nM) was 
administered at reperfusion in the presence and absence of 2’-MeCCPA (10nM). Results are 
shown as Mean ± SEM of four experiments. *** p<0.001 Control 50’, 2’-MeCCPA 40’ and 
50’, Wortmannin 40’, 2’-MeCCPA+Wortmannin 40’ vs. Normoxia. * p<0.05 Control 40’ vs. 
Normoxia. ### p<0.001 2’-MeCCPA 40’ and 50’ vs. Control 40’ and 50’ respectively. $$$ 
p<0.001 Wortmannin 40’ vs. 2’-MeCCPA 40’. $$ 0.01 2’-MeCCPA+Wortmannin 40’ vs. 2’-





Figure 5. 23 A comparison of AKT phosphorylation within isolated rat hearts subjected to 60 
minutes of perfusion (Normoxia) or 20 minutes of stabilisation, 35 minutes of ischaemia 
followed by 40 minutes of reperfusion in the presence and absence of A1 adenosine 
receptor agonist (10nM). The PI3K inhibitor Wortmannin (100nM) was administered in the 
presence and absence of 2’-MeCCPA (10nM). Results are shown as Mean ± SEM of four 
experiments. * p<0.05 vs. Normoxia. *** p<0.001 vs. Normoxia. ### p<0.001 vs. Control 40’. 
# p<0.05 vs. Control 40’. $$$ p<0.001 vs. 2’-MeCCPA 40’.  
 
5.3.2.5a The effect of 2’-MeCCPA (10nM) when administered at 15 minutes 
post reoxygenation on cleaved-caspase 3 activity in isolated adult rat 
cardiomyocytes. 
 
In Chapter 3 the A1 adenosine receptor agonist 2’-MeCCPA (1nM, 10nM, 100nM and 1µM) 
significantly decreased cleaved-caspase 3 activity when administered at the onset of 
reoxygenation. Chapter 3 also stated that when 2’-MeCCPA (10nM) was administered at 15 
minutes post-reoxygenation, cardioprotection was conferred via decreasing the activity of 
cleaved-caspase 3 within isolated adult rat cardiomyocytes that were then subjected to 1 
hour of hypoxia and 3 hours of reoxygenation. Moreover, to determine whether the 
protection was caused via the recruitment of the PI3K-AKT cell signalling pathway, 2’-MeCCPA 
(10nM) was administered at 15 minutes post reoxygenation in the presence and absence of 
PI3K inhibitor Wortmannin (100nM).  
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The administration of 2’-MeCCPA (10nM) at 15 minutes post reoxygenation significantly 
decreased cleaved-caspase 3 activity compared to the non-treated Hyp/Reox group (232 ± 
16% 2’-MeCCPA 15mins Post-R vs. 313 ± 35% Hyp/Reox, p<0.01) (Figure 5.24).  
Administration of 2’-MeCCPA (10nM) significantly decreased cleaved-caspase 3 activity when 
administered 15 minutes post reperfusion however this was decrease was significantly 
abolished in the presence of PI3K inhibitor Wortmannin (100nM) (232 ± 16% 2’-MeCCPA 
15mins Post-R vs. 321 ± 22% 2’-MeCCPA+Wortmannin 15mins Post-R, p<0.001) (Figure 5.24).  
The administration of Wortmannin (100nM) alone at 15 minutes post reoxygenation resulted 
in a decrease in cleaved-caspase 3 activity when compared to the Hyp/Reox control group 
however this was not a significant change (285 ± 34% Wortmannin 15mins Post-R vs. 313 ± 
35% Hyp/Reox, p>0.05) (Figure 5.24).  
 
Figure 5. 24 Cleaved-caspase 3 activity within isolated adult rat cardiomyocytes subjected to 
4 hours of oxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of 
reoxygenation (Hyp/Reox). The A1 agonist 2’-MeCCPA (10nM) was administered 15 minutes 
post reoxygenation in the presence and absence of the PI3K inhibitor Wortmannin (100nM). 
Mean±SEM of 6 individual experiments. *** p<0.001 vs. Normoxia. ## p<0.01 vs. Hyp/Reox. 




5.3.2.5b The effect of 2’-MeCCPA (10nM) when administered at 30 minutes 
post reoxygenation on cleaved caspase-3 activity in isolated adult rat 
cardiomyocytes. 
 
The administration of 2’-MeCCPA (10nM) at 30 minutes post reoxygenation decreased 
cleaved-caspase 3 activity in isolated adult rat cardiomyocytes subjected to 1 hours of hypoxia 
and 3 hours of reoxygenation compared with the Hyp/Reox control group, however this was 
not a significant change (263±27% 2’-MeCCPA 30mins Post-R vs. 313±35% Hyp/Reox, p>0.05) 
(Figure 5.25).  
In order to determine whether the non-significant decrease in cleaved-caspase 3 by 2’-
MeCCPA (10nM) at 30 minutes post reoxygenation was via PI3K-AKT cell signalling pathway, 
the PI3K inhibitor Wortmannin (100nM) was used. The administration of 2’-MeCCPA (10nM) 
at 30 minutes post reoxygenation in the presence of PI3K inhibitor Wortmannin (100nM) 
significantly abolished the decrease observed in cleaved-caspase 3 when 2’-MeCCPA (10nM) 
was administered alone at 30 minutes post reoxygenation (371±22% 2’-
MeCCPA+Wortmannin 30mins Post-R vs. 263±27% 2’-MeCCPA 30mins Post R, p<0.05) (Figure 
5.25).   
The administration of Wortmannin (100nM) alone at 30 minutes post reoxygenation resulted 
in a decrease in cleaved-caspase 3 activity compared to the Hyp/Reox control group however 
this was not a significant decrease (301±40% Wortmannin 30mins Post-R vs. 313±35% 




Figure 5. 25 Cleaved-caspase 3 activity within isolated adult rat cardiomyocytes subjected to 
4 hours of oxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of 
reoxygenation (Hyp/Reox). The A1 agonist 2’-MeCCPA (10nM) was administered 30 minutes 
post reoxygenation in the presence and absence of the PI3K inhibitor Wortmannin (100nM). 
Mean±SEM of 6 individual experiments. *** p<0.001 vs. Normoxia. # p<0.05 vs. Hyp/Reox. $ 


















The PI3K-AKT cell signalling pathway has been a very well-studied pro-survival pathway in 
reference to its role in ischaemia reperfusion injury. AKT is the downstream target of PI3K and 
it can in turn activate a number of those downstream targets. These targets include eNOS, 
p70S6K, BAD and PKC (Cross et al. 2000; Park et al. 2006). The exact cellular mechanisms that 
are involved within the cardioprotection that is ensured via A1 adenosine receptors in the 
ischaemic reperfused myocardium still remains unclear as several studies have shown to 
activate different pathways in response to A1 adenosine receptor activation.  
Previous research conducted by Kudo et al. (2002) demonstrated that pharmacological 
preconditioning in male mice with A1AR agonist CCPA induced cardioprotection via the 
activation of Protein Kinase- δ (PKC-δ) in a way that it was able to reduce infarct size (Kudo et 
al. 2002). Taking this into consideration and research into literature so far, the activation of 
PKC-δ seems to have occurred through the phenomenon of pharmacological preconditioning. 
Our study applied the protocol of post-reperfusion activation of A1 adenosine receptors after 
the onset of reperfusion and found that the PI3K-AKT cell signalling pathway played a major 
role towards cardioprotection when 2’-MeCCPA was administered at the onset of 
reperfusion, 15 minutes and 30 minutes post-reperfusion. This cardioprotective effect was 
observed through a reduction in infarct size. Whereas when A1AR agonist 2’-MeCCPA (10nM) 
was administered alongside PI3K inhibitor Wortmannin (100nM) at the onset of reperfusion, 
15 minutes and 30 minutes post-reperfusion, there was an increase in infarct size, therefore 
implying that the PI3K-AKT cell signalling pathway played a major role in A1 adenosine 
mediated cardioprotection.  
Although protection, in the form of a reduction of infarct size was observed when 2’-MeCCPA 
(10nM) was administered at the onset of reperfusion, 15 minutes and 30 minutes post-
reperfusion, as the different time-points were studied, it was found that protection became 
less as time went on.  
This current study also showed that when the A1AR agonist 2’-MeCCPA was administered at 
the onset of reoxygenation, 15 minutes and 30 minutes post-reoxygenation, there was a 
decrease in cellular apoptosis and necrosis which also meant there was a decrease in caspase-
3 activity at all time-points and this decrease was reversed when 2’-MeCCPA (10nM) was 
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administered alongside PI3K inhibitor Wortmannin (100nM) implying that cardioprotection, 
in the form of reducing cell death and caspase-3 activity, was implicated through the PI3K-
AKT cell signalling pathway. Extensive amounts of research in this area have not been carried 
out, especially with the recruitment of the PI3K-AKT cell signalling pathway in delayed 
reperfusion activation of A1 adenosine receptor cardioprotection; however a previous study 
conducted by Regan et al. (2003) suggested that the cardioprotection observed in transgenic 
mice with an overexpression of A1 adenosine receptors attenuated ischaemia-reperfusion 
induced apoptosis and caspase-3 but this was independent of the acute PI3K signalling 
pathway. This confounding data is contradictory to the data observed within our study and 
could be due to the fact that there was no A1AR agonist specifically used to target the A1 
adenosine receptors within the study by Regan et al. (2003). Our study also used adult male 
rats whereas Regan et al. (2003) used transgenic mice which may be the reason for these 
confounding results. Although hearts had an overexpression of A1 adenosine receptors, they 
were not specifically activated by a specific A1AR agonist to detect the specific effects of the 
A1 adenosine receptor in accordance with the PI3K cell signalling pathway whereas our can 
imply study that the PI3K-AKT cell signalling pathway is activated upon A1 adenosine receptor 
activation to cause a decrease in infarct size as well as a reduction in apoptosis and necrosis 
followed by a decrease in caspase-3 activity. 
Further investigation into the links between the PI3K-AKT signalling pathway and targets such 
as eNOS, p70S6K, BAD and PKC can be made in future investigation to confer if they enhance 
the level of cardioprotection observed in our study. 
Previous research conducted by Wildmann et al. (1998) have shown that the upregulation of 
caspases can causes degradation of proteins such as AKT and ERK1 throughout cellular injury 
and when caspase inhibitors are administered they can lead to an overall increase in pro-
survival proteins which may be useful in future research and could provide a better 
understanding of the A1 adenosine receptor playing a role in the decrease in caspase-3 activity 
due to the activation of the PI3K-AKT cell signalling pathway.  
Our findings expressed that when A1AR agonist 2’-MeCCPA (10nM) was administered at the 
onset of reperfusion, there was a significant upregulation of AKT observed compared to when 
2’-MeCCPA (10nM) was administered alongside Wortmannin (100nM) and this was also 
observed when 2’-MeCCPA (10nM) was administered at 15 minutes and 30 minutes post-
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reperfusion. This implies that within the first 30 minute window of reperfusion, the A1 
adenosine receptor activation can cause protection to the myocardium after an ischaemic 
insult through the recruitment of the PI3K-AKT cell signalling pathway. This can be supported 
by research conducted by Hausenloy and Yellon (2004) who suggested that apoptotic cell 
death can be reduced during the early phase of reperfusion to reduce lethal reperfusion-
induced injury (Hausenloy and Yellon 2004).  
AKT has the ability to phosphorylate many downstream targets and previous literature has 
evidenced the infarct sparing effects of A3 adenosine receptor agonist IB-MECA in isolated rat 
heart. This cardioprotective effect through the A3 adenosine receptor also increased AKT 
phosphorylation and this protection was lost upon the PI3K inhibition with Wortmannin. With 
extensive research conducted into the A3 adenosine receptor, it was only appropriate to 
investigate these effects upon the activation of the A1 adenosine receptor. Our study found 
that AKT phosphorylation increased when A1AR agonist 2’-MeCCPA (10nM) was administered 
at the onset of reperfusion as well as being administered 15 minutes and 30 minutes post-
reperfusion. This could also imply that the A3 adenosine receptor activates the PI3K-AKT cell 
signalling pathway in order to ensure cardioprotection as well as the A1 adenosine receptor, 
when activated, recruiting the PI3K-AKT cell signalling pathway alongside to cause 
cardioprotective effects too.  
Our study can imply that when the A1 adenosine agonist 2’-MeCCPA was administered at 15 
minutes post reperfusion/reoxygenation, there was a significant limiting effect upon infarct 
development in the ischaemic reperfused myocardium and cell death (apoptosis and 
necrosis) within adult rat cardiomyocytes that were subjected to hypoxia-reoxygenation. This 
protection can implicate the recruitment of the PI3K-AKT cell signally pathway where 2’-
MeCCPA (10nM) also upregulated the phosphorylation of AKT when compared to the control 
hearts. The critical role of the PI3K-AKT cell signalling pathway for 2’-MeCCPA mediated 
cardioprotection when administered 15 minutes after reperfusion was determined using the 
PI3K inhibitor Wortmannin. Wortmannin abolished any cardioprotection previously 
observed. The A1 agonist was also seen to decrease the activity of cleaved caspase-3 which 
was also reversed by Wortmannin (PI3K inhibitor). Postponing the administration of 2’-
MeCCPA to 30 minutes post-reperfusion also attenuated myocardial infarction in isolated rat 
heart in a Wortmannin sensitive manner by the upregulation of AKT, decrease in cell death 
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(apoptosis and necrosis) and a decrease in cleaved caspase-3 activity. This post-
reperfusion/reoxygenation activation of A1 adenosine receptors has not currently been 
investigated which is where our findings can be rendered useful.  
Previously published literature has shown that when pharmacological agents are 
administered at the onset of reperfusion, cardioprotection can be ensured via the 
recruitment of the PI3K-AKT cell signalling pathway. A study by Jonassen et al. (2001) who 
administered Insulin at the onset of reperfusion to activate the PI3K-AKT cell signalling 
pathway was able to limit myocardial infarction. It can also be implied from this current study 
that when 2’-MeCCPA was administered at the onset of reperfusion to limit myocardial 
infarction via the infarct limiting effects, a decrease in cell death and cleaved caspase-3 
activity and an increase in AKT phosphorylation. Therefore, although it has already been 
published that administration of pharmacological agents at the onset of reperfusion can limit 
ischaemia-reperfusion injury, the exploration of the activation of the A1 adenosine receptor 
to limit ischaemia reperfusion injury at the onset of reperfusion as well as post-reperfusion 
activation was an area of further research which has been explored within this study. 
Bibli and colleagues also investigated that the activation of A1ARs via the administration of 
A1AR agonist CCPA throughout the phenomenon of post-conditioning significantly 
upregulated AKT levels to confer protection to male rabbit hearts which really consolidated 
how the PI3K branch of the RISK pathway plays a vital part in the cardioprotection observed 
within this current study. 
Further experiments could be carried out in order to determine the role of cellular crosstalk 
between the PI3K-AKT cell signalling pathways in accordance to the MEK1/2-ERK1/2 cell 









5.5 Summary of Findings 
 
In summary, this study implies that the A1 adenosine receptor agonist, 2’-MeCCPA can 
reduce myocardial ischaemia reperfusion injury in Sprague Dawley rat model via the 
recruitment of the PI3K-AKT cell survival pathway through the activation of A1 adenosine 
receptors at the onset of reperfusion, 15 minutes post reperfusion and 30 minutes post-
reperfusion. Our results show that: 
- The activation of the A1 adenosine receptor at the onset of reperfusion is suggested 
to offer cardioprotection via the recruitment of the PI3K-AKT cell signalling pathway. 
This can be observed through the limiting infarct effects, a decrease in cell death 
(apoptosis and necrosis), and a decrease in cleaved caspase-3 activity and an 
increase in p-AKT phosphorylation through western blots. These cardioprotective 
effects have been seen to be reversed with PI3K inhibitor Wortmannin. This implies 
that cardioprotection can potentially be ensured through a PI3K-AKT manner.  
- The activation of the A1 adenosine receptor at 15 minutes post-reperfusion is 
suggested to offer cardioprotection via the recruitment of the PI3K-AKT cell 
signalling pathway. This can be observed through the limiting infarct effects, a 
decrease in cell death (apoptosis and necrosis), and a decrease in cleaved caspase-3 
activity and an increase in AKT phosphorylation through western blots. These 
cardioprotective effects have been seen to be reversed with the PI3K inhibitor 
Wortmannin. 
- Activation of the A1 adenosine receptor at 30 minutes post-reperfusion is suggested 
to offer cardioprotection via the recruitment of the PI3K-AKT cell signalling pathway. 
This can be observed through the limiting infarct effects, a decrease in cell death 
(apoptosis and necrosis), and a decrease in cleaved caspase-3 activity and an 
increase in AKT phosphorylation through western blots. These cardioprotective 







Chapter 6: Administration of A1 adenosine receptor agonist, 2’-
MeCCPA (10nM) to protect the myocardium from ischaemia-
reperfusion injury via the recruitment of the MEK1/2-ERK1/2 cell 
signalling pathway at the onset of reperfusion compared to 15 




The ERK1/2 signalling cascade belong to the family of the mitogen-activated protein kinases 
(MAPKs); these are a family of serine-threonine kinases and can be implicated with the 
regulation of cell proliferation, differentiation and survival. They generally become activated 
in response to the occupation of the tyrosine kinase and G-protein-coupled receptors 
(Wildmann et al. 1999; Hausenloy and Yellon 2004). The ERK1/2 signalling cascade has the 
ability to be activated in an ischaemia-reperfusion setting and has been shown to mediate 
cellular protection by cardioprotective agents (Hausenloy and Yellon 2004). 
There are different members of the MAP kinase family and these include the extracellular 
signal-regulated kinases (ERK), p38 MAP kinases and JNKs (Singh et al. 2018). Studies have 
also shown that MAP kinases and MEK can play a major role within cardioprotection within 
the phenomenon of ischaemic pre-conditioning (da Silva et al. 2004; Singh et al. 2018).  
Previous literature has shown the activation of A1, A2 and A3 adenosine receptor activation 
can be associated with the phosphorylation of the ERK1/2 kinase cascade within Chinese 
Hamster ovary cell model (Schulte and Fredholm 2000). Further research by Baxter et al. 
(2000), using the in vivo rabbit heart model of ischaemia-reperfusion injury, found that A1/A2A 
receptor agonist AMP579 had the ability to induce cardioprotection when administered 
throughout reperfusion, this protection was abrogated in the presence of MEK1/2 inhibitor 
PD098059 (Baxter et al. 2000). This previously reported literature can further suggest that 
upon the activation of the A1 adenosine receptor, cardioprotection could be conferred via the 
recruitment of the MEK1/2-ERK1/2 cell signalling pathway. A study conducted by Zhao et al. 
(2001) demonstrated that preconditioning with A1 adenosine receptor agonist CCPA, reduced 
infarct size and increase phosphorylation of p38-MAP kinase which therefore suggests 
cardioprotective effects. Germack and Dickenson (2005) also reported that preconditioning 
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neonatal rat cardiomyocytes with A1 adenosine agonist CPA was also able to protect the 
myocardium from ischaemia-reperfusion injury via the recruitment of the MEK1/2-ERK1/2 
signalling pathway. When MEK1 inhibitor (PD98059) was administered, this reversed all 
cardioprotective effects which confirmed that the A1 adenosine receptor, upon activation, 
can ensure cardioprotection via the activation of the MEK1/2-ERK1/2 signalling pathway.  
Further research conducted by Maddock et al. (2002) examined the role of the A3 adenosine 
receptor in cardioprotection within the reperfusion phase in isolated rat cardiomyocyte 
models. It was found that the A3 adenosine receptor agonist 2-Cl-IB-MECA, when 
administered throughout reperfusion was able to limit infarct size and significantly decrease 
apoptosis and necrosis. Furthermore, Hussain et al. (2014) assessed the cardioprotective 
effects of 2-CI-IB-MECA via the recruitment of the MEK1/2-ERK1/2 cell signalling pathway and 
it was found that this pro-survival signalling pathway played a vital role in decreasing caspase-
3 levels and mediating cardioprotection. With such extensive research conducted into A3 
adenosine receptor mediated cardioprotection when activated throughout the reperfusion 
phase, this meant that more research needed to be conducted into the A1 adenosine receptor 
being activated at reperfusion and throughout reperfusion rather than through the 
preconditioning phenomenon.  
 
6.1.1 Aims and Objectives 
 
1. To determine the cardioprotective effects of the A1 adenosine receptor agonist, 2’-
MeCCPA (10nM) in association with the recruitment of the pro-survival MEK1/2-
ERK1/2 cell signalling pathway. A1AR agonist 2’-MeCCPA (10nM) was administered at 
the onset of reperfusion in the presence and absence of MEK1/2 inhibitor UO126 
(10µM) in order to assess infarct size (%), cell death (apoptosis and necrosis), p-ERK 
phosphorylation in Western blot and caspase-3 activity.  
2. To determine the cardioprotective effects of the A1 adenosine receptor agonist, 2’-
MeCCPA (10nM) in association with the post-reperfusion/reoxygenation recruitment 
of the pro-survival MEK1/2-ERK1/2 cell signalling pathway. A1AR agonist 2’-MeCCPA 
(10nM) was administered at 15 minutes post-reperfusion/reoxygenation in the 
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presence and absence of MEK1/2 inhibitor UO126 in order to assess infarct size (%), 
cell death (apoptosis and necrosis) and caspase-3 activity.  
3. To determine the effects of A1AR agonist 2’-MeCCPA (10nM) in the association of 
with the post-reperfusion/reoxygenation recruitment of the pro-survival MEK1/2-
ERK1/2 cell signalling pathway. 2’-MeCCPA (10nM) was administered at 30 minutes 
post-reperfusion/reoxygenation in the presence and absence of MEK1/2 inhibitor 
UO126 in order to assess infarct size (%), cell death (apoptosis and necrosis) and 






2’-MeCCPA and UO126 were both supplied from Tocris Cookson (Bristol) and prepared in 
the same manner as described in Chapter 2, Section 2.2. 
6.2.2 Animals 
 
Adult male Sprague-Dawley rats (350 ± 50g) were supplied from Charles River (UK). Animals 
all received human care and assistance and were sacrificed by cervical dislocation as 
outlined in the Schedule 1 Home Office Procedure in accordance with the Scientific 
Procedure Act 1986. This process is described in Chapter 2, Section 2.1.  
 
6.2.3 Langendorff protocol – Isolated perfused rat heart preparation 
 
Briefly, all experiments using the Langendorff technique were carried out for 175 minutes 
(full details in Chapter 2, Section 2.3.5). Hearts were given 20 minutes for stabilisation, 35 
minutes for simulated regional ischaemia followed by 120 minutes of reperfusion. Hearts 
were then randomly allocated into the following treatment groups: 
a) Normoxic control – Rat hearts were perfused with KH buffer for 175 minutes (no 
simulated ischaemia induced here). 
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b) Ischaemia-reperfusion (IR) control – Isolated rat hearts were perfused with KH buffer 
for 20 minutes followed by 35 minutes of simulated regional ischaemia and 120 
minutes of reperfusion.  
c) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of 
MEK1/2 inhibitor UO126 (10µM) at the onset of reperfusion – Rats were perfused 
with KH buffer for 20 minutes, 35 minutes of simulated regional ischaemia followed 
by 120 minutes of reperfusion where drug administration occurred at the onset of 
reperfusion. 
d) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of 
MEK1/2 inhibitor UO126 (10µM) at 15 minutes post-reperfusion - Rats were 
perfused with KH buffer for 20 minutes, 35 minutes of simulated regional ischaemia 
followed by 120 minutes of reperfusion where drug administration occurred at 15 
minutes post-reperfusion. 
e) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of 
MEK1/2 inhibitor UO126 (10µM) at 30 minutes post-reperfusion - Rats were 
perfused with KH buffer for 20 minutes, 35 minutes of simulated regional ischaemia 
followed by 120 minutes of reperfusion where drug administration occurred at 30 
minutes post-reperfusion. 
Throughout the Langendorff experiments, the stability of the hearts were consistently 
monitored via haemodynamic parameters of the heart rate (HR), left ventricular developed 
pressure (LVDP) and coronary flow (CF) (as described in Chapter 2, Section 2.3.2).  
Following the reperfusion period, the infarct size to risk ratio was assessed using Evans blue 
triphenyltetrazolium chloride (TTC) staining procedures as described in Chapter 2, Section 
2.3.6.  
6.2.4 Isolation of adult rat ventricular cardiomyocytes 
 
Isolation of adult rat ventricular cardiomyocytes was previously described in Chapter 2, 




6.2.5 Induction of hypoxia and reoxygenation conditions in adult rat 
cardiomyocytes 
 
Fully described in Chapter 2, Section 2.4.1. 
6.2.6 Experimental drug treatment protocol in adult rat ventricular 
cardiomyocytes 
 
Isolated rat cardiomyocytes were exposed to different control and drug treatments. All 
experimental conditions for this chapter are as detailed below: 
a) Normoxic control – Isolated myocytes were exposed to normoxic conditions for a total 
of 4 hours at 37oC, 5% CO2 and 95% O2.  
b) Hypoxia-Reoxygenation control – Isolated cardiomyocytes were exposed to 1 hour of 
hypoxia conditions followed by the onset of reoxygenation for 3 hours.  
c) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of MEK1/2 
inhibitor UO126 (10µM) at the onset of reoxygenation – Isolated cardiomyocytes were 
exposed to 1 hour hypoxia conditions followed by drug treatment at the onset of 
reoxygenation for 3 hours at 37oC, 5% CO2 and 95% O2.  
d) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of MEK1/2 
inhibitor UO126 (10µM) at 15 minutes post-reoxygenation – Isolated cardiomyocytes 
were exposed to 1 hour hypoxia conditions followed by drug treatment at 15 minutes 
post-reoxygenation for 3 hours at 37oC, 5% CO2 and 95% O2. 
e) A1AR agonist 2’-MeCCPA (10nM) administered in the presence and absence of MEK1/2 
inhibitor UO126 (10µM) at 30 minutes post-reoxygenation – Isolated cardiomyocytes 
were exposed to 1 hour hypoxia conditions followed by drug treatment at 30 minutes 







6.2.7 Quantitative Analysis of Cell Death using Dead Cell Apoptosis Kit with 
Annexin V FITC with Propidium Iodide (PI) in Adult Rat Cardiomyocytes 
 
Followed by the drug treatments described above, isolated rat ventricular cardiomyocytes 
were assess for their levels of apoptosis and necrosis using the Dead Cell Apoptosis Kit with 
Annexin V FITC and PI was purchased from ThermoFisher (UK) (previously detailed in Chapter 
2, Section 2.5.2). Data was normalised against the cell only control and the values obtained 
were calculated as a relative change in apoptosis and necrosis activity of the mean 
absorbance of the control group. 
 
6.2.8 Analysis of Cleaved Caspase-3 Activity in Adult Rat Cardiomyocytes 
 
Following the drug treatment protocol as described above, the rat cardiomyocytes were 
probed with cleaved caspase-3 antibody as described in Chapter 2, Section 2.5.1. Data 
obtained was normalised to the cell only control by subtracting the mean fluorescence 
background recorded in untreated samples. Data was presented as a relative change in 
fluorescence activity. 
 
6.2.9 Data Analysis 
 
All data that was presented in this project is expressed at the mean ± standard error of the 
mean (SEM). IBM Statistical Package for Social Sciences (SPSS®) software was used to 
statistically analyse the data. The statistical tests currently used to analyse infarct sizes, band 
densities and cell population data was by one-way ANOVA accompanied by Fishers Protected 
Least Significant Difference (LSD) test for multiple comparisons. To assess the difference in 
the data sets, a p-value of p<0.05 was used to consider statistical significance.  






6.3 Results  
 
6.3.1 Profiling the effects of the administration of 2’-MeCCPA (10nM) at the 
onset of reperfusion/reoxygenation in the presence and absence of MEK1/2-
ERK1/2 inhibitor, UO126 (10µM) and its effects upon isolated rat 
myocardium model and isolated rat cardiomyocytes 
 
6.3.1.1 Haemodynamic Data – Profiling the effects of 2’-MeCCPA in the 
presence and absence of MEK1/2-ERK1/2 inhibitor, U0126 (10µM) on 
haemodynamic parameters (left ventricular developed pressure, heart rate 
and coronary flow). 
 
Within this section, all hearts were subjected to 20 minutes stabilisation, 35 minutes 
ischaemia and a further 120 minutes of reperfusion where 2’-MeCCPA (10nM) was 
administered alone firstly and then further administered in conjunction with U0126 (10µM) 
(MEK1/2-ERK1/2 inhibitor). U0126 (10µM) was also administered alone also. All treatments 
were administered at the onset of reperfusion to profile the effects of this inhibitor upon the 
A1 adenosine receptor agonist, 2’-MeCCPA (10nM).  
Overall, it was found that there was no significant difference between the groups at any of 
the time-points within the reperfusion period (p>0.05) (Figure 6.1). 
Throughout the ischaemic period, all treatment groups had a significantly decreased LVDP in 




















Figure 6. 1 Effects of 2’-MeCCPA (10nM) in the presence and absence of U0126 (10µM) on 
the left ventricular developed pressure within isolated rat hearts when subjected to 20 
minutes stabilisation, 35 minutes of ischaemia and 120 minutes of reperfusion. 2’-MeCCPA 
(10nM) was administered at the onset of reperfusion in the presence and absence of U0126 













There was overall no significant difference detected on heart rate between treatment groups 
at all time-matched points (p<0.05) (Figure 6.2).  
 
Figure 6. 2 Effects of 2’-MeCCPA (10nM) in the presence and absence of U0126 (10µM) on 
the heart rate within isolated rat hearts when subjected to 20 minutes stabilisation, 35 
minutes of ischaemia and 120 minutes of reperfusion. 2’-MeCCPA (10nM) was administered 
at the onset of reperfusion in the presence and absence of U0126 (10µM). Data was 












No significant difference was detected between treatment groups at all time matched points 
within the reperfusion period (p<0.05) (Figure 6.3), however throughout the ischaemic 
period, all treatment groups had a significantly decreased coronary flow in comparison to the 
normoxic control (p<0.05) (Figure 6.3).  
 
 
Figure 6. 3 Effects of 2’-MeCCPA (10nM) in the presence and absence of U0126 (10µM) on 
the coronary flow within isolated rat hearts when subjected to 20 minutes stabilisation, 35 
minutes of ischaemia and 120 minutes of reperfusion. 2’-MeCCPA (10nM) was administered 
at the onset of reperfusion in the presence and absence of U0126 (10µM). Data was 
presented as Mean±SEM, n=6-8. * p<0.05 All groups vs. Normoxia (ischaemia).  
 
6.3.1.2 Profiling the effects of 2’-MeCCPA (10nM) with MEK1/2-ERK1/2 
signalling pathway inhibitor, U0126 (10µM) on infarct size to risk ratio within 
isolated hearts subjected to ischaemia reperfusion injury at the onset of 
reperfusion. 
 
All hearts were subjected to 20 minutes of stabilisation, 35 minutes of ischaemia and 120 
minutes of reperfusion. A1 adenosine receptor agonist, 2’-MeCCPA (10nM), was firstly 
administered alone and then co-administered in conjunction with MEK1/2-ERK1/2 signalling 
212 
 
pathway inhibitor, U0126 (10µM). U0126 was then further administered alone also. All 
treatments were administered at the onset of reperfusion to profile their effects upon infarct 
size to risk ratio (%).  
A significant decrease in infarct size to risk ratio was detected when 2’-MeCCPA (10nM) was 
administered alone to the heart when compared with the IR control (28 ± 4% vs. 55 ± 6%, 
p<0.001). A significant decrease in infarct size to risk ratio (%) was also detected when 2’-
MeCCPA (10nM) + U0126 (10M) was administered together when compared to the IR 
control (35  4% vs. 55 ± 6%, p<0.01). When 2’-MeCCPA + U0126 was administered together 
compared to 2’-MeCCPA being administered alone, a significant increase as shown here 













Figure 6. 4 Infarct size to risk ratio (%) within isolated perfused hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion subjected to 2’-
MeCCPA (10nM) administered alone as well as when U0126 (10M) (MAP1/2-ERK1/2 
signalling pathway inhibitor) administered alone and 2’-MeCCPA + U0126 co-administered 
together at the onset of reperfusion. Data presented as Mean±SEM. n=6-8. *** p<0.001 vs. 




6.3.1.3  The role of MEK-ERK1/2 cell signalling pathway in 2’-MeCCPA 
mediated cardioprotection when administered at the onset of reperfusion 
within rat cardiomyocytes subjected to 1 hours of hypoxia and 3 hours of 
reoxygenation on apoptosis and necrosis 
 
Administration of A1 adenosine receptor agonist 2’-MeCCPA (10nM) at reoxygenation was 
significantly able to decrease the number of apoptotic and necrotic cardiomyocytes when 
compared to the non-treated Hyp/Reox group (Figure 6.5). In order to determine the 
mechanisms involved within 2’-MeCCPA (10nM) mediated cardioprotection, the role of the 
MEK-ERK1/2 cell signalling pathway was carried out using the MEK-ERK1/2 inhibitor U0126 
(10µM). Isolated cardiomyocytes were subjected to 1 hour of hypoxia as well as a further 3 
hours of reoxygenation. Throughout the reoxygenation period, cardiomyocytes were 
incubated with 2’-MeCCPA (10nM) in the presence and absence of MEK-ERK1/2 inhibitor 
U0126 (10µM).  
The administration of A1 adenosine receptor agonist 2’-MeCCPA (10nM) in the presence of 
MEK-ERK1/2 inhibitor U0126 (10µM) attenuated the anti-apoptotic effect of 2’-MeCCPA 
(10nM) in comparison to when 2’-MeCCPA (10nM) was administered alone throughout 
reoxygenation, this was not a significant change (23±3% 2’-MeCCPA + U0126 at onset of 
reoxygenation vs. 16±4% 2’-MeCCPA at the onset of reoxygenation, p<0.05) (Figure 6.5). The 
administration of 2’-MeCCPA (10nM) throughout reoxygenation in the presence of U0126 
(10µM) did however significantly attenuate the anti-necrotic effects of 2’-MeCCPA (10nM) 
compared to when 2’-MeCCPA (10nM) was administered alone throughout reoxygenation 





Figure 6. 5 Assessment of apoptosis and necrosis within isolated rat cardiomyocytes 
subjected to 1 hour of hypoxia and 3 hours of reoxygenation. 2’-MeCCPA (10nM) was 
administered at the onset of reoxygenation in the presence and absence of MEK-ERK1/2 
inhibitor, U0126 (10µM). Results were shown as Mean±SEM and were expressed as a 
percentage of 10 000 cells counted from 6 individual experiments. *** p<0.001 vs. 
Normoxia. ** p<0.01 vs. Normoxia. ### p<0.001 vs. Hyp/Reox. $$$ p<0.001 vs. 2’-MeCCPA 
(10nM). 
 
6.3.1.4 The role of MEK/ERK1/2 cell signalling pathway on cleaved-caspase 3 
activity upon administration of 2’-MeCCPA (10nM) at reoxygenation in 
isolated adult rat cardiomyocytes subjected to 1 hour of hypoxia and 3 hours 
of reoxygenation 
 
The administration of 2’-MeCCPA (10nM) at reoxygenation significantly decreased cleaved-
caspase 3 activity when compared to cardiomyocytes undergoing 1 hour hypoxia and a 
further 3 hours of reoxygenation (Hyp/Reox) (retrospectively, 181±35% vs. 313±35%, 
p<0.001) (Figure 6.6). To further determine whether the decrease in cleaved-caspase 3 
activity by 2’-MeCCPA (10nM) involved the MEK-ERK1/2 cell signalling pathway, the MEK-
ERK1/2 inhibitor U0126 (10µM) was utilised. The isolated cardiomyocytes were subjected to 
1 hour of hypoxia and 3 hours of reoxygenation where 2’-MeCCPA (10nM) was administered 
at reoxygenation in the presence and absence of MEK-ERK1/2 inhibitor U0126 (10µM).  
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The administration of A1 adenosine receptor agonist 2’-MeCCPA (10nM) in the presence of 
MEK-ERK1/2 inhibitor U0126 (10µM) throughout reoxygenation significantly increased 
cleaved-caspase 3 activity compared to when 2’-MeCCPA (10nM) was administered alone at 











Figure 6. 6 Cleaved-caspase 3 activity within isolated rat cardiomyocytes subjected to 4 
hours of reoxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of 
reoxygenation (Hyp/Reox). 2’-MeCCPA (10nM) was administered at the onset of 
reoxygenation in the presence and absence of MEK-ERK1/2 cell signalling inhibitor U0126 
(10µM). Mean±SEM on 6 individual experiments. *** p<0.001 vs. Normoxia. ### p<0.001 vs. 









6.3.2  Effects of delayed administration of 2’-MeCCPA (10nM) at 15 minutes 
and 30 minutes post-reperfusion/reoxygenation in the presence and absence 
of MEK1/2-ERK1/2 inhibitor, UO126 (10µM) and its effects upon isolated rat 
myocardium model and isolated rat cardiomyocytes 
 
6.3.2.1a Effects of postponing the administration of 2’-MeCCPA (10nM) to 15 
minutes post-reperfusion in the presence and absence of MEK1/2-ERK1/2 
inhibitor, UO126 (10µM) on haemodynamic parameters (left ventricular 
developed pressure (LVDP), heart rate and coronary flow). 
 
Throughout Langendorff studies, the left ventricular developed pressure, heart rate and 
coronary flow was constantly monitored throughout all experiments. Perfused hearts were 
subjected to 20 minutes of stabilisation, 35 minutes of ischaemia and 120 minutes of 
reperfusion. A1 adenosine receptor agonist, 2’-MeCCPA (10nM) was administered in the 
presence and absence of MEK1/2-ERK1/2 inhibitor UO126 (10µM) at 15 minutes post 
reperfusion. 
Throughout the period of ischaemia, significant decrease in LVDP was detected in all 
treatment groups compared to the normoxia control group at time-matched points (p<0.05) 
(Figure 6.2); however throughout the period of reperfusion, an overall general decline in LVDP 
was detected after 15 minutes of reperfusion. These changes were not significant (p>0.05, 






















Figure 6. 7 Assessing the effects of 2’-MeCCPA (10nM) in the presence and absence of 
UO126 (10µM) when administered at 15 minutes post reperfusion on the left ventricular 
developed pressure (LVDP) in isolated rat  hearts when subjected to 20 minutes 
stabilisation, 35 minutes of ischaemia and 120 minutes of reperfusion. Data was presented 













Overall, no significant effects were observed on heart rate between all time matched points 
within all treatment groups when 2’-MeCCPA (10nM) was administered in the presence or 
absence of UO126 (10µM) at 15 minutes post reperfusion (p>0.05, Figure 6.8). 
 
Figure 6. 8 Effects of the heart rate when 2’-MeCCPA (10nM), in the presence and absence 
of UO126 (10µM), when administered at 15 minutes post within isolated rat hearts when 
subjected to 20 minutes stabilisation, 35 minutes of ischaemia and 120 minutes of 















Within the ischaemic period, the coronary flow for all treatment groups at each time matched 
points significantly decreased in comparison to the normoxic control (p<0.05, Figure 6.9). No 
significant changes were detected between treatments groups at all time matched points 














Figure 6. 9 Effects of coronary flow when 2’-MeCCPA (10nM, in the presence and absence of 
UO126 (10µM), when administered at 15 minutes post reperfusion within isolated rat hearts 
when subjected to 20 minutes stabilisation, 35 minutes of ischaemia and 120 minutes of 










6.3.2.1b Effects of postponing the administration of 2’-MeCCPA (10nM) to 30 
minutes post-reperfusion in the presence and absence of MEK1/2-ERK1/2 
inhibitor, UO126 (10µM) on haemodynamic parameters (left ventricular 
developed pressure (LVDP), heart rate and coronary flow). 
 
It was previously shown that the administration of A1 adenosine receptor agonist 2’-MeCCPA 
(10nM), when administered at the onset of reperfusion and 15 minutes post reperfusion can 
protect the ischaemic myocardium via the recruitment of the MEK1/2-ERK1/2 cell survival 
pathway. In order to further assess this cardioprotection, 2’-MeCCPA (10nM) was 
administered at 30 minutes post reperfusion in the presence and absence of MEK1/2 inhibitor 
UO126 (10µM) to determine if the MEK1/2-ERK1/2 cell survival pathway further enhanced 
cardioprotection at 30 minutes post reperfusion.  
The left ventricular developed pressure, heart rate and coronary flow was constantly 
monitored throughout all Langendorff studies; and hearts were subjected to 20 minutes of 
stabilisation, 35 minutes of ischaemia and 120 minutes of reperfusion. 2’-MeCCPA (10nM) 
was administered in the presence and absence of UO126 (10µM) at 30 minutes post 
reperfusion. 
It was observed that during the ischaemic period, all treatment groups at time matched points 
significantly decreased the LVDP in comparison to the normoxic heart group (p<0.05, Figure 
6.10). Throughout the period of reperfusion, there was an overall decline in LVDP however 
there was no significant difference between treatment groups at time matched points 























Figure 6. 10 Assessing the effects on left ventricular developed pressure when 2’-MeCCPA 
(10nM) was administered in the presence and absence of UO126 (10µM) at 30 minutes post 
reperfusion. Isolated rat hearts were subjected to 20 minutes of stabilisation, 35 minutes of 
ischaemia and a further 120 minutes of reperfusion. Data was presented as Mean±SEM, 















No significant effects were detected on heart rate between all time matched points between 















Figure 6. 11 The effects on heart rate when 2’-MeCCPA (10nM) was administered in the 
presence and absence of UO126 (10µM) at 30 minutes post reperfusion. Isolated rat hearts 
were subjected to 20 minutes of stabilisation, 35 minutes of ischaemia and a further 120 













Overall, a significant decrease in coronary flow was detected in all treatment groups at all 
time matched points within the ischaemic period of the protocol in comparison to the 
normoxic control groups (p<0.05, Figure 6.12). No significant changes were observed 














Figure 6. 12 Effects on coronary flow when 2’-MeCCPA (10nM) was administered in the 
presence and absence of UO126 (10µM) at 30 minutes post reperfusion. Isolated rat hearts 
were subjected to 20 minutes of stabilisation, 35 minutes of ischaemia and a further 120 
minutes of reperfusion. Data was presented as Mean±SEM, n=6-8. * p<0.05 All groups vs. 







6.3.2.2a The effects of postponing the administration of 2’-MeCCPA (10nM) 
to 15 minutes post-reperfusion in the presence and absence of MEK1/2-
ERK1/2 inhibitor, UO126 (10µM) on infarct size to risk ratio (%) within 
isolated hearts subjected to ischaemia reperfusion injury 
 
It was previously shown that the administration of A1 adenosine receptor agonist 2’-MeCCPA 
(10nM) at the onset of reperfusion was able to significantly protect the myocardium from 
ischaemia-reperfusion injury via the recruitment of the MEK1/2-ERK1/2 cell survival pathway. 
The involvement of the MEK1/2-ERK1/2 pathway was also assessed when 2’-MeCCPA (10nM) 
was administered at 15 minutes post reperfusion in the presence and absence of MEK1/2 
inhibitor UO126 (10µM). 
The administration of A1 adenosine receptor agonist 2’-MeCCPA (10nM) at 15 minutes post 
reperfusion in the presence of MEK1/2 inhibitor UO126 (10µM) significantly abolished the 
cardioprotection detected when 2’-MeCCPA (10nM) was administered alone at 15 minutes 
post reperfusion (46±3% 2’-MeCCPA+UO126 at 15mins Post-R vs. 30±10% 2’-MeCCPA at 
15mins Post-R, p<0.05) (Figure 6.13).  
When the MEK1/2 inhibitor UO126 (10µM) was administered alone, there was no significant 
effect detected upon infarct size to risk ratio (%) when compared to the IR control (48±4% 




























Figure 6. 13 The infarct size to risk ratio (%) within non-treated normoxic control, IR control 
and 2’-MeCCPA (10nM) treated ischaemic-reperfused hearts. All isolated perfused rat hearts 
were subjected to 20 minutes to stabilisation, 35 minutes of ischaemia and 120 minutes of 
reperfusion. A1 adenosine receptor agonist, 2’-MeCCPA (10nM) was administered in the 
presence and absence of MEK1/2 inhibitor, UO126 (10µM) at 15 minutes into the onset of 
reperfusion. *** p<0.001 vs. Normoxia. ### p<0.001 vs. IR control. $ p<0.05 vs. 2’-MeCCPA 
at 15mins Post-R.  
 
6.3.2.2b The effects of postponing the administration of 2’-MeCCPA (10nM) 
to 30 minutes post-reperfusion in the presence and absence of MEK1/2-
ERK1/2 inhibitor, UO126 (10µM) on infarct size to risk ratio (%) within 
isolated hearts subjected to ischaemia reperfusion injury. 
 
The administration of A1 adenosine receptor agonist 2’-MeCCPA (10nM) at 30 minutes post 
reperfusion, in the presence of MEK1/2 inhibitor UO126 (10µM) significantly abolished the 
2’-MeCCPA (10nM) mediated cardioprotection as shown in Figure 6.14 (48±5% 2’-
MeCCPA+UO126 at 30mins Post-R vs. 35±6% 2’-MeCCPA at 30mins Post-R, p<0.05) (Figure 
6.15). When MEK1/2 inhibitor UO126 (10µM) was administered alone at 30 minutes post 
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reperfusion, there was no significant effect on infarct size to risk ratio (%) in comparison to 













Figure 6. 14 The infarct size to risk ratio (%) within non-treated normoxic control, IR control 
and 2’-MeCCPA (10nM) treated ischaemic-reperfused hearts. All isolated perfused rat hearts 
were subjected to 20 minutes to stabilisation, 35 minutes of ischaemia and 120 minutes of 
reperfusion. A1 adenosine receptor agonist, 2’-MeCCPA (10nM) was administered in the 
presence and absence of MEK1/2 inhibitor, UO126 (10µM) at 30 minutes into the onset of 
reperfusion. *** p<0.001 vs. Normoxia. ### p<0.001 vs. IR control. $ p<0.05 vs. 2’-MeCCPA 
at 30mins Post-R.  
 
6.3.2.3a Effects of postponing the administration of 2’-MeCCPA to 15 minutes 
post reoxygenation on isolated rat cardiomyocytes subjected to 1 hour of 
hypoxia and 3 hours of reoxygenation from reoxygenation injury via the 
recruitment of the MEK1/2-ERK1/2 cell signalling pathway and its effects on 
cellular apoptosis and necrosis. 
 
In previous chapters, it has been studied that when A1 adenosine receptor agonist 2’-MeCCPA 
(10nM) is administered at 15 minutes into the onset of reoxygenation, a significant increase 
in cardioprotection of isolated perfused rat hearts was shown. This section studies whether 
the protection shown when 2’-MeCCPA (10nM) is administered at 15 minutes post 
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reoxygenation to cardiomyocytes that have undergone 1 hour of hypoxia and 3 hours of 
reoxygenation, is activated via the MEK1/2-ERK1/2 cell survival pathway. 
Postponing the administration of the A1 adenosine receptor agonist 2’-MeCCPA (10nM) to 15 
minutes after reoxygenation significantly decreased the number of apoptotic cells (14±5% 2’-
MeCCPA at 15mins Post-R vs. 34±6% Hyp/Reox, p<0.001) (Figure 6.15). Postponing the 
administration of 2’-MeCCPA (10nM) to 15 minutes post reoxygenation also significantly 
decreased the number of necrotic cells (16±4% 2’-MeCCPA at 15mins Post-R vs. 28±7% 
Hyp/Reox, p<0.001) (Figure 6.16).  
When 2’-MeCCPA (10nM) was administered at 15 minutes post reoxygenation in the presence 
of MEK1/2 inhibitor UO126 (10µM), anti-apoptotic effects that were studied when 2’-
MeCCPA (10nM) was administered alone at 15 minutes post reoxygenation were abolished 
(30±5% 2’-MeCCPA+UO126 at 15mins Post-R vs. 14±5% 2’-MeCCPA at 15mins Post-R, 
p<0.001) (Figure 6.15). The anti-necrotic effects observed when 2’-MeCCPA (10nM) was 
administered alone at 15 minutes post reoxygenation were significantly abolished when 2’-
MeCCPA (10nM) as administered alongside MEK1/2 inhibitor UO126 (10µM) (23±3% 2’-
MeCCPA+UO126 at 15mins Post-R vs. 16±4% 2’-MeCCPA at 15mins Post-R, p<0.05) (Figure 
6.16). 
When UO126 (10µM) was administered alone 15 minutes post reoxygenation, there was no 
significant effect observed upon apoptosis within cardiomyocytes compared to the Hyp/Reox 
group (30±4% UO126 at 15mins Post-R vs. 34±6% Hyp/Reox, p>0.05). (Figure 6.15). When 
UO126 (10µM) was administered alone at 15 minutes post reoxygenation, there was no 
significant effect observed upon necrosis within the cardiomyocytes in comparison to the 





Figure 6. 15 The assessment of apoptosis in isolated adult rat cardiac myocytes that were 
subjected to 4 hours of reoxygenation (Normoxia) or 1 hour of hypoxia and 3 hours of 
reoxygenation (Hyp/Reox). The role of the MEK1/2-ERK1/2 cell survival pathway in ensuing 
2’-MeCCPA mediated cardioprotection was assessed. The A1AR agonist 2’-MeCCPA (10nM) 
was administered at 15 minutes post reoxygenation in the presence and absence of MEK 
1/2 inhibitor UO126 (10µM). Results were shown as Mean±SEM and expressed as 
percentages of 10 000 total cells counted. *** p<0.001 vs. Normoxia. ### p<0.001 vs. 











Figure 6. 16 The assessment of necrosis in isolated adult rat cardiac myocytes that were 
subjected to 4 hours of reoxygenation (Normoxia) or 1 hour of hypoxia and 3 hours of 
reoxygenation (Hyp/Reox). The role of the MEK1/2-ERK1/2 cell survival pathway in ensuing 
2’-MeCCPA mediated cardioprotection was assessed. The A1AR agonist 2’-MeCCPA (10nM) 
was administered at 15 minutes post reoxygenation in the presence and absence of MEK 
1/2 inhibitor UO126 (10µM). Results were shown as Mean±SEM and expressed as 
percentages of 10 000 total cells counted. *** p<0.001 vs. Normoxia. ### p<0.001 vs. 
Hyp/Reox. $ p<0.05 vs. 2’-MeCCPA at 15mins Post-R. 
 
6.3.2.3b Effects of postponing the administration of 2’-MeCCPA to 30 minutes 
post reoxygenation on isolated rat cardiomyocytes subjected to 1 hour of 
hypoxia and 3 hours of reoxygenation from reoxygenation injury via the 
recruitment of the MEK1/2-ERK1/2 cell signalling pathway and its effects on 
cellular necrosis and apoptosis. 
 
It was observed that when the administration of A1 adenosine receptor agonist 2’-MeCCPA 
(10nM) was postponed to 30 minutes post reoxygenation, there was a significant decrease in 
cellular apoptosis when compared to the Hyp/Reox group (15±5% 2’-MeCCPA 30mins Post-R 
vs. 34±6% Hyp/Reox, p<0.001) (Figure 6.17). The postponement of the administration of A1 
adenosine receptor agonist 2’-MeCCPA (10nM) to 30 minutes post reoxygenation also 
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significantly decreased cellular necrosis when compared to the Hyp/Reox group (17±3% 2’-
MeCCPA 30mins Post-R vs. 28±7% Hyp/Reox, p<0.001) (Figure 6.18).  
The anti-apoptotic effect of the administration of 2’-MeCCPA alone at 30 minutes post 
reoxygenation were then significantly abolished when 2-MeCCPA was administered in the 
presence of MEK1/2 inhibitor UO126 (10µM) at 30 minutes post reoxygenation (35±3% 2’-
MeCCPA+UO126 30mins Post-R vs. 15±5% 2’-MeCCPA 30mins Post-R, p<0.001) (Figure 6.17). 
It was also found that when 2’-MeCCPA (10nM) and UO126 (10µM) were administered in 
conjunction at 30 minutes post reoxygenation, there as a significant increase in cellular 
necrosis compared to when 2’-MeCCPA (10nM) was administered alone at 30 minutes post 
reoxygenation, the anti-necrotic effects were reversed when UO126 (10µM) were 
administered in conjunction (25±4% 2’-MeCCPA+UO126 30mins Post-R vs. 17±3% 2’-MeCCPA 
30mins Post-R, p<0.05) (Figure 6.18). This was not a vast difference in necrosis however it was 
a significant difference. 
When MEK1/2 inhibitor UO126 (10µM) was administered alone at 30 minutes reoxygenation, 
there was no significant effects observed on cellular apoptosis when compared to the 
Hyp/Reox group (30±4% UO126 30mins Post-R vs. 34±6% Hyp/Reox, p>0.05) (Figure 6.17). 
When UO126 (10µM) was administered alone at 30 minutes post reoxygenation, there was 
no significant effect observed compared to the Hyp/Reox control group (28±4% UO126 




Figure 6. 17 The assessment of apoptosis in isolated adult rat cardiac myocytes that were 
subjected to 4 hours of reoxygenation (Normoxia) or 1 hour of hypoxia and 3 hours of 
reoxygenation (Hyp/Reox). The role of the MEK1/2-ERK1/2 cell survival pathway in ensuing 
2’-MeCCPA mediated cardioprotection was assessed. The A1AR agonist 2’-MeCCPA (10nM) 
was administered at 30 minutes post reoxygenation in the presence and absence of MEK 
1/2 inhibitor UO126 (10µM). Results were shown as Mean±SEM and expressed as 
percentages of 10 000 total cells counted. *** p<0.001 vs. Normoxia. ### p<0.001 vs. 
















Figure 6. 18 The assessment of necrosis in isolated adult rat cardiac myocytes that were 
subjected to 4 hours of reoxygenation (Normoxia) or 1 hour of hypoxia and 3 hours of 
reoxygenation (Hyp/Reox). The role of the MEK1/2-ERK1/2 cell survival pathway in ensuing 
2’-MeCCPA mediated cardioprotection was assessed. The A1AR agonist 2’-MeCCPA (10nM) 
was administered at 30 minutes post reoxygenation in the presence and absence of MEK 
1/2 inhibitor UO126 (10µM). Results were shown as Mean±SEM and expressed as 
percentages of 10 000 total cells counted. *** p<0.001 vs. Normoxia. ** p<0.01 vs. 
Normoxia. ### p<0.001 vs. Hyp/Reox. $ p<0.05 vs. 2’-MeCCPA at 30mins Post-R. 
 
6.3.2.4a The effect of 2’-MeCCPA (10nM) when administration at 15 minutes 
post reoxygenation on cleaved caspase-3 activity in isolated adult rat 
cardiomyocytes via the recruitment of the MEK1/2-ERK1/2 cell survival 
pathway 
 
It was previously found that when delaying the administration of 2’-MeCCPA (10nM) to 15 
minutes post reoxygenation, there was a significant decrease in cleaved-caspase 3 activity 
compared to the Hyp/Reox control group (232±39% 2’-MeCCPA 15mins Post-R vs. 313±35% 
Hyp/Reox, p<0.05) (Figure 6.19).  
In order to determine whether the decrease in cleaved-caspase 3 activity conferred by 2’-
MeCCPA (10nM) being administered at 15 minutes post reoxygenation was via the 
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recruitment of the MEK1/2-ERK1/2 cell survival pathway; isolated rat cardiomyocytes were 
subjected to 1 hour of hypoxia and 3 hours of reoxygenation where A1 adenosine receptor 
agonist 2’-MeCCPA (10nM) was administered at 15 minutes post reoxygenation in the 
presence and absence of MEK1/2 inhibitor UO126 (10µM).  
The administration of 2’-MeCCPA (10nM) at 15 minutes post reoxygenation in the presence 
of MEK1/2 inhibitor UO126 (10µM) failed to significantly abolish the decrease in cleaved-
caspase 3 that was observed when 2’-MeCCPA (10nM) was administered alone at 15 minutes 
post reoxygenation (293±32% 2’-MeCCPA+UO126 15mins Post-R vs. 232±39% 2’-MeCCPA 
15mins Post-R, p>0.05) (Figure 6.19).  
The administration of UO126 (10µM) alone at 15 minutes post reoxygenation had no 
significant effects upon cleaved-caspase 3 activity in comparison to the Hyp/Reox control 














Figure 6. 19 Cleaved-caspase 3 activity within isolated adult rat cardiomyocytes subjected to 
4 hours of oxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of 
reoxygenation (Hyp/Reox). The A1 agonist 2’-MeCCPA (10nM) was administered 15 minutes 
post reoxygenation in the presence and absence of the MEK1/2 inhibitor UO126 (10µM). 




6.3.2.4b The effect of 2’-MeCCPA (10nM) when administered at 30 minutes 
post reoxygenation on cleaved-caspase 3 activity in isolated adult rat 
cardiomyocytes via the recruitment of the MEK1/2-ERK1/2 cell survival 
pathway. 
 
It was previously observed that when 2’-MeCCPA (10nM) was administered alone at 30 
minutes post reoxygenation did not significantly reduce cleaved-caspase 3 activity when 
compared to the Hyp/Reox control group (263±43% 2’-MeCCPA 30mins Post-R vs. 313±35% 
Hyp/Reox, p>0.05) (Figure 6.20).  
The administration of 2’-MeCCPA (10nM) at 30 minutes post reoxygenation in the presence 
of MEK1/2 inhibitor UO126 (10µM) failed to abolish the slight decrease observed when 2’-
MeCCPA (10nM) was administered alone at 30 minutes post reoxygenation. There was no 
significant effect (300±16% 2’-MeCCPA+UO126 30mins Post-R vs. 263±43% 2’-MeCCPA 
30mins Post-R, p>0.05) (Figure 6.20).  
The administration of MEK1/2 inhibitor UO126 (10µM) alone at 30 minutes post 
reoxygenation had no significant effect upon cleaved-caspase 3 activity when compared to 
the control Hyp/Reox group (320±13% UO126 30mins Post-R vs. 313±35% Hyp/Reox, p>0.05) 







Figure 6. 20 Cleaved-caspase 3 activity within isolated adult rat cardiomyocytes subjected to 
4 hours of oxygenation (Normoxia) or 1 hour of hypoxia followed by 3 hours of 
reoxygenation (Hyp/Reox). The A1 agonist 2’-MeCCPA (10nM) was administered 30 minutes 
post reoxygenation in the presence and absence of the MEK1/2 inhibitor UO126 (10µM). 
















6.4 Discussion  
 
The MEK1/2-ERK1/2 cell signalling pathway has been shown to play a vital role in cell survival, 
growth and differentiation. In context of cell survival, the phosphorylation of ERK1/2 can 
further activate downstream targets to further induce cardioprotection (Mocanu et al. 2002; 
Bose et al. 2005; Germack and Dickenson 2004). Our study is able to support the idea of cell 
survival through the upregulation of the MEK1/2-ERK1/2 cell survival pathway. When A1 
adenosine receptor agonist 2’-MeCCPA is administered at the onset of 
reperfusion/reoxygenation, it was able to significantly cause infarct limiting effects, decrease 
cell death (apoptosis and necrosis) and decrease cleaved caspase-3 activity. This therefore 
supports previous literature in explicitly showing that the MEK1/2-ERK1 cell signalling 
pathway can be activated by A1 adenosine receptors and cause cardioprotection as seen in 
published literature by Germack and Dickenson (2004) who have shown that that stimulation 
of A1 adenosine receptors using CPA can further activate ERK1/2 within new born rat 
cardiomyocytes which can then cause myocardium protection (Germack and Dickenson 
2004). Our study can imply that the administration of A1AR agonist 2’-MeCCPA at 
reperfusion/reoxygenation was able to decrease infarction and cell death via the recruitment 
of the MEK1/2-ERK1/2 cell signalling pathway; inhibition of MEK1/2 with UO126 abolished all 
cardioprotective effects. Our data therefore supports Germack and Dickenson (2004) in being 
able to upregulate the MEK1/2-ERK1/2 cell signalling pathway in order to confer 
cardioprotection.  
Our study found that cleaved caspase-3 activity was seen to be reduced in response to A1AR 
activation at the onset of reoxygenation in adult rat cardiomyocytes that were subjected to 
hypoxia/reoxygenation injury. This positive effect was abolished in the presence of MEK1/2 
inhibitor UO126. This indicates that protection is dependent upon MEK1/2-ERK1/2 cell 
signalling pathway. Little research has been conducted into the A1 adenosine receptor 
activation in order to ensure cardioprotection by the decrease in apoptosis and necrosis 
which can lead to a decrease in caspase-3 activity at the onset of reperfusion; however a 
similar methodology was conducted by Hussain et al. (2014) where the A3 adenosine receptor 
was investigated. Similar results to our findings were observed when A3AR agonist 2-CL-IB-
MECA significantly reduced infarct size, upregulated p-ERK1/2 and reduced apoptosis, 
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necrosis and cleaved caspase-3 activity with manner that expressed the upregulation of the 
MEK1/2-ERK1/2 cell signalling pathway (Hussain et al. 2014). Although a different adenosine 
receptor subtype was investigated within the study, it drew similar conclusions to that of our 
study, implying that the activation of the A1 adenosine receptor subtype can confer 
cardioprotection via the upregulation of the MEK1/2 cell signalling pathway. These similar 
findings could be due to the fact that the A1 and A3 adenosine receptor subtypes are vital 
receptors to ensure cardioprotection and when activated, they stimulate the MEK1/2 cell 
signalling pathway in similar ways as both receptors involve Gi/o pertussis toxin proteins when 
activated (Germack and Dickenson 2004).  
It was then important to look into if the MEK1/2 cell survival pathway mediated protection in 
a time dependent manner within the isolated rat model. Our study showed that post-
reperfusion activation of the A1ARs at 15 minutes and 30 minutes after the onset of 
reperfusion was seen to limit infarct size and decrease apoptosis and necrosis. These 
techniques were measured in accordance with MEK1/2 inhibitor UO126 can imply that when 
A1 adenosine receptors were activated at 15 minutes and at 30 minutes post-reperfusion, a 
cardioprotective effect was observed. This is the first study to show that post-reperfusion 
activation of A1AR at 15 minutes and 30 minutes post-reperfusion can protect the isolated rat 
heart and adult rat cardiomyocytes from ischaemic injury via the MEK1/2 cell signalling 
pathway. This therefore implies that in addition to the PI3K-AKT cell signalling pathway 
playing a vital role in cardioprotection, the MEK1/2 also indicates an alternative pathway to 
ensure cardioprotection. 
From our study, post-reperfusion activation of the A1 adenosine receptor allowed for infarct 
limiting effects and decrease in apoptosis and necrosis at the 15 minutes and 30 minutes time-
point however a significant decrease in cleaved caspase-3 was not rendered significant during 
post-reperfusion activation of A1ARs. This therefore implies that post-reperfusion cleaved 
caspase-3 activity could be independent of the MEK1/2 cell signalling pathway. This could be 
due to the fact that research by Hausenloy and Yellon (2004) has stated that most 
cardioprotection is conferred at the early stage of reperfusion and therefore 15 minutes or 
30 minutes may be too late to administer A1AR agonist 2’-MeCCPA to confer cardioprotection 
through the upregulation of the MEK1/2 cell signalling pathway to decrease cleaved caspase-
3 activity.  
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Our findings within this study can be compared to those of Von Lubitz et al. (1994; 2001) as 
they looked into the administration of A3AR 2-CL-IB-MECA administration at the onset of 
reperfusion or 20 minutes post-reperfusion in order to protect cerebral ischaemia reperfusion 
injury. Although we did not look into the A3 adenosine receptor subtype, the delayed 
activation of the A1 adenosine receptor at 15 minutes and 30 minutes post reperfusion was 
able to provide the same time dependent protection however in myocardial ischaemia 
reperfusion injury. 
Hausenloy and Yellon (2004) stated that most protection occurs at early stages of reperfusion 
which is why administration of the A1AR agonist 2’-MeCCPA was explored. The 
cardioprotective effects were observed to be high in a MEK1/2 cell signalling manner as 
infarct size was the most reduced. When there was a delayed administration of 2’-MeCCPA 
at 15 minutes and 30 minutes post-reperfusion, MEK1/2 cell signalling was still expressed 
however infarct size did increase compared to when 2’-MeCCPA was administered at 
reperfusion meaning that MEK1/2-ERK1/2 signalling could have decreased as timing then 
goes beyond the ‘early phase of reperfusion’. 
Further study that could have taken place was to look into the phosphorylation of p-ERK to 
detect if p-ERK activity was upregulated at the onset of reperfusion, 15 minutes and 30 
minutes into the onset of reperfusion. This would have been useful and would have explored 
the ERK1/2 compartment to the MEK1/2-ERK1/2 cell signally pathway.  
In light of current published literature and the data from this study, we can hypothesise and 
imply that cardioprotection can be associated with delayed activation of A1ARs in the 











6.5 Summary of Findings 
 
To summarise this chapter, evidence can imply that the A1 adenosine receptor agonist. 2’-
MeCCPA has the ability to reduce myocardial ischaemia reperfusion injury in isolated 
perfused rat heart and adult rat cardiomyocyte models via the recruitment of the MEK1/2-
ERK1/2 cell survival pathway through the activation of the A1 adenosine receptor subtype at 
the onset of reperfusion but also through delayed activation at 15 minutes post-reperfusion 
and 30 minutes post-reperfusion. Our results show that: 
- When A1AR agonist 2’-MeCCPA was administered at the onset of reperfusion, this 
indicated that cardioprotection was conferred via the recruitment of the pro-survival 
MEK1/2-ERK1/2 cell signalling pathway. This was observed through the limiting infarct 
size effects, a decrease in apoptosis and necrosis, and a decrease in cleaved caspase-
3 activity which was all reversed in the presence of MEK1/2 inhibitor UO126.  
- When delayed activation of A1 adenosine receptors by the administration of A1AR 
agonist 2’-MeCCPA at 15 minutes post-reperfusion occurred, this conferred 
cardioprotection via the recruitment of the MEK1/2-ERK1/2 pro-survival pathway. 
This was observed through the limitation in infarct size, decreases in apoptosis and 
necrosis. An upregulation in p-ERK phosphorylation was also observed; all of which 
was reversed in the presence of MEK1/2 inhibitor UO126. There was no significant 
effect observed on cleaved caspase-3 activity. 
- Further delayed activation of A1 adenosine receptors occurred where A1AR agonist 2’-
MeCCPA was administration 30 minutes post-reperfusion which showed 
cardioprotective effects via the recruitment of the MEK1/2-ERK1/2 cell signalling 
pathway. A limiting effect in infarct size was observed as well as a decrease in 
apoptosis and necrosis. These effects were then reversed in the presence of MEK1/2 











Coronary heart disease is one of the leading causes of death within the UK and has the ability 
to affect individuals’ quality of life. With an increased risk of mortality due to coronary heart 
disease (CHD), an increase in research to reduce the prevalence of CHD is required 
(Department of Health 2018). In order to reduce the burden of coronary heart disease, 
policies have been put in place that identify high risk patients and treat them as early as 
possible (Skinner et al. 2007). Examples of these policies are patients over the age of 40 are 
required to attend regular checks by their GP (Skinner et al. 2007). The needs for novel 
therapies in order to reduce the damaging effects of a myocardial infarctions are still 
extensively being researched.  
Furthermore within a clinical setting, patients are often admitted following the development 
of angina or after having suffered from a myocardial infarction. Cardiac troponin and 
creatinine kinase levels are assessed to further determine the diagnosis of a myocardial 
infarction, an ECG is also conducted to confirm a diagnosis (Collinson and Gaze 2007). 
Following the diagnosis of myocardial infarction patients may undergo thrombolytic therapy, 
primary angioplasty or even coronary bypass grafting in order to restore blood flow back to 
the ischaemic region (Collinson and Gaze 2007). 
The restoration of coronary blood flow to the ischaemic myocardium is a phenomenon called 
reperfusion (Hausenloy and Yellon 2004). It remains to be one of the mechanisms of salvaging 
any reversible damage to cardiomyocytes after the injurious ischaemic event however 
reperfusion itself can also further the injury process too (Hausenloy and Yellon 2004); 
therefore due to this reason, it is essential to elucidate the mechanisms that contributes to 
the hastening of the injury process within this period but also imperative to research the 
potential targets within the reperfusion period in order to develop and research 
cardioprotective agents that could potentially limit ischaemia reperfusion injury when 
administered in a clinical setting. Many advances over time have led to better understanding 
in the signalling process to mediate myocardial ischaemia reperfusion injury (Hausenloy and 
Yellon 2004). A multitude of studies have also researched how endogenous and exogenous 
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agents can mediate ischaemia reperfusion injury, having detrimental effects; others can 
possess innate cardioprotective abilities (Hausenloy and Yellon 2004).  
When the myocardium becomes ischaemic there is insufficient availability of oxygen and 
nutrients in order to maintain oxidative phosphorylation and therefore intracellular 
adenosine levels increase following the breakdown of ATP and APD (Headrick et al. 2011). 
Adenosine has been described as a ‘retaliatory metabolite’ as it is a nucleoside that is released 
when in response to metabolically compromised cells (Headrick et al. 2011). Adenosine is 
known to exert its physiological effects via four know adenosine receptors which include; A1, 
A2A, A2B and A3 receptor subtypes. The A1 and A3 receptor subtypes are coupled with Gi/o 
proteins whereas the A2A and A2B receptor subtypes are coupled to the Gs/olf proteins (Sheth 
et al. 2014) which therefore could imply that the A1 and A3 receptors could function in similar 
ways.  
The A1 receptor subtype was the first adenosine receptor to be implicated in the 
cardioprotective effects of adenosine (McIntosh and Lasley 2011). The initial evidence of 
expression of A1 adenosine receptors was initiated by Lohse et al. (1987) where the 
investigation of the expression of A1 adenosine receptors in mammalian ventricular 
myocardium was conducted. This was then later investigated in 1988 and further confirmed 
that A1 adenosine receptors are expressed within isolated rat ventricular cardiomyocytes 
(Martens et al. 1988). The A1 adenosine receptor subtype was also known to be expressed on 
coronary vascular smooth muscle and cardiac fibroblasts in animal models (McIntosh and 
Lasley 2011). With this background information of the A1 adenosine receptor subtype being 
present in isolated rat myocardium, it became an area of interest within this study to look 
specifically at the effects of the A1 adenosine receptor activation at various time points post 
reperfusion and to determine their associated cell signalling pathways.  
Furthermore, research conducted in 1990 provided the first form of evidence for the 
stimulation of A1 adenosine receptors with the use of an A1 adenosine agonist named R-N6-
(phenyl-2R-isopropyl)-adenosine (PIA) whilst investigating the mechanism associated with 
pharmacological preconditioning. PIA was administered prior to ischaemia in isolated rat 
hearts and was associated with infarct sparing effects (Lasley et al. 1990). The study 
concluded the activation of A1 adenosine receptors having the ability to confer 
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cardioprotection. With this earlier information provided, the interest into A1 adenosine 
receptor agonists in causing cardioprotection became another area of interest.  
The findings from the current study further imply that the activation of the A1 adenosine 
receptors at the onset of reperfusion or delaying the activation to 15 or 30 minutes post-
reperfusion can also ameliorate the detrimental effects of ischaemia reperfusion. To further 
support that the A1 adenosine receptor played a major part in the protection observed, the 
A1AR antagonist DPCPX was co-administered with A1 adenosine receptor agonist 2’-MeCCPA 
at either reperfusion, 15 or 30 minutes post-reperfusion, DPCPX reversed all cardioprotection. 
The findings from this current study support the activation of A1 adenosine receptors in 
ameliorating myocardial ischaemia reperfusion injury.  
Our study implies that when the A1AR agonist 2’-MeCCPA was administered at the onset of 
reperfusion, 15 minutes and 30 minutes post-reperfusion, sufficient cardioprotection was 
observed via the significant decrease in infarct size, a reduction in apoptosis and necrosis as 
well as decreased cleaved caspase-3 activity and an upregulation in p-AKT phosphorylation 
(visually represented in Figure 7.1 below). These cardioprotective effects were reversed in 
the presence of PI3K inhibitor Wortmannin, indicating that 2’-MeCCPA mediated 
cardioprotection involved the recruitment of the PI3K-AKT pro-survival pathway. This cell 
survival signalling pathway has the ability to decrease pro-apoptotic proteins such as caspases 
and increase pro survival molecules such as AKT, endothelial nitric oxide synthase (eNOS) as 
well as p70S6K (Hausenloy and Yellon; Mocanu and Yellon 2004). Previous studies have not 
explicitly shown the administration of A1 adenosine receptors at the onset of reperfusion 
within the heart model however this has been investigated within the lung ischaemia-
reperfusion injury model and shown to cause protective effects (Gazoni et al. 2010). Previous 
studies have shown A1AR agonist to mediate cardioprotection via the PI3K-AKT signalling 
pathway however this is the first study to show cardioprotection conferred by an A1AR agonist 
being administered at the onset of reperfusion and post-reperfusion. Wortmannin, a well 
characterised PI3K inhibitor has previously shown to ameliorate cardioprotection in an 
ischaemia reperfusion setting and therefore used within this current study to evaluate the 
involvement of the PI3K-AKT signalling pathway (Hussain et al. 2014).  
Our study further observed the role of the MEK1/2 pro-survival pathway in A1 adenosine 
receptor mediated cardioprotection. As previously mentioned, when A1AR agonist 2’-
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MeCCPA (10nM) was administered at the onset of reperfusion, 15 minutes and 30 minutes 
post-reperfusion; this delayed activation of the A1 adenosine receptor subtype mediated 
cardioprotection via a limit in infarct size, reducing apoptosis and necrosis leading to a 
reduction in cleaved caspase-3 activity. These protective effects were reversed in the 
presence of MEK1/2 inhibitor UO126. Although, the decrease in cleaved caspase-3 activity 
seen when 2’-MeCCPA was administered at 15 or 30 minutes post reperfusion was not 
reversed by UO126 indicating that the anti-caspase 3 activity effects were more specifically 
associated with the PI3K cell signalling pathway. Germack and Dickenson (2004) have shown 
that ERK1/2 phosphorylation was upregulated with the activation of the A1 adenosine 
receptors via CPA administration in new born rat cardiomyocytes via the pre-conditioning 
phenomenon (Germack and Dickenson 2004) which could support that the MEK1/2 cell 
survival pathway may be upregulated throughout pre-conditioning but maybe not throughout 
post-reperfusion activation of A1ARs.  
These findings support the research conducted by Hausenloy and Yellon (2004) who stated 
that targeting anti-apoptotic mechanisms at the time of reperfusion and the early stages of 
reperfusion, was a potential approach in attenuating reperfusion-induced cell death. They 
further associate the ERK1/2 signalling pathway with cardioprotection.  
The A1 and A3 adenosine receptors activate in such a similar way that when activated they 
cause a decrease in cyclic AMP activation whereas A2A and A2B increase cyclic AMP production. 
Therefore similarities could be drawn upon between the A1 and A3 receptor subtypes in terms 
of the fact that the A3 adenosine receptor has a more extensive researched background rather 
than the A1 receptor subtype. A study conducted by Hussain et al (2014) investigated the 
effects of A3AR mediated cardioprotection. It was found that the A3ARs, when activated in 
adult rat cardiomyocytes, decreased caspase-3 activity however this implicated the 
upregulation of the PI3K-AKT and MEK1/2-ERK1/2 cell signalling pathways. Drawing these 
conclusions from the research conducted by Hussain and colleagues (2014), similar findings 
were detected within this current study when the A1 adenosine receptor was investigated 
implying that the upregulation of the PI3K-AKT and MEK1/2-ERK1/2 cell signalling pathways 
suggested cardioprotective effects in an A1AR activation manner.   
The PI3K-AKT and MEK1/2-ERK1/2 pro-survival pathways make up two branches of the 
Reperfusion Injury Salvage Kinase (RISK) pathway and pervious research has suggested that 
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both branches can be activated to protect following a lethal ischaemic insult (Hausenloy and 
Yellon 2004). Previous studies have shown how insulin , insulin-like growth factors (IGF-1), 
transforming growth factor-β1 (TGF- β1), urocortin, atorvastatin and bradykinin to protect 
the heart by the upregulation of both/or the PI3K-AKT and MEK1/2-ERK1/2 pathways 
(Hausenloy and Yellon 2004). Our findings therefore support that the A1AR agonist 2’-
MeCCPA, when administered at reperfusion causes both the PI3K and MEK1/2 pathways to 
upregulate to enhance protection after the ischaemic insult that has taken place. 
Our group has previously shown A3AR agonist 2-CI-IBMECA to limit reperfusion injury 
throughout anti-apoptotic and anti-necrotic mechanisms (Hussain et al. 2006). It was also 
shown that when activating A3 receptors at different time points throughout reperfusion (15 
or 30 minutes), this resulted in reduced myocardial injury and was dependent on AKT and 
ERK1/2 activation. Rat hearts were subjected to 35 minutes of coronary artery occlusion 
followed by 120 minutes of reperfusion where 2-CI-IBMECA was administered at reperfusion, 
15 or 30 minutes post reperfusion. This protocol is similar to the current project due to when 
the A1AR agonist 2’-MeCCPA was administered at reperfusion, 15 minutes or 30 minutes post 
reperfusion, there was a significant decrease upon infarct size and this was then reversed in 
the presence of UO126 (MEK1/2 inhibitor) which further suggests that the MEK1/2 signalling 
pathway does play a part to the cardioprotection observed. The PI3K-AKT signalling pathway 
was also depended on in a time point manner to ensure cardioprotection.  
A study by Lubitz et al (2001) also investigated that when A3AR agonist IB-MECA was 
administrated 20 minutes into the onset of reperfusion, a significant decrease in infarct 
volume within the brain was detected which also proved that the concept of post-reperfusion 
activation of adenosine receptors confers cytoprotective effects.   
7.2 Evaluation of pharmacological adenosine preconditioning and post 
conditioning in comparison to delayed reperfusion A1 adenosine receptor 
activation 
 
Endogenous and exogenous agents, especially adenosine, has been investigated within 
mechanical mechanisms; such as the phenomenon of pre-conditioning and post-conditioning 
to ensure that ischaemia reperfusion injury is salvaged. Pre-conditioning is an intrinsic process 
in which repeated short episodes of ischaemia are induced to prevent the long term damage 
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caused by prolonged episodes of ischaemia (Iliodromitis et al. 2007; Singh et al. 2018). With 
ischaemic preconditioning being such a powerful tool, researchers have demonstrated that 
adenosine plays an important role within protection of the myocardium in remote 
preconditioning (McCully et al. 2001; Singh et al. 2018). Therefore in order to elucidate the 
mechanisms that were involved in adenosine mediated cardioprotection in a preconditioning 
setting, scientists further administered adenosine exogenously which is known as adenosine 
pharmacological preconditioning (Singh et al. 2018). It was furthermore shown that 
preconditioning studies involving adenosine induced cardioprotection by various mechanisms 
that included the activation of the KATP channels in rat and rabbit species (Baxter and Yellon 
1999; Takano et l. 2001; Singh et al. 2018). Interaction with various kinases were also 
investigated for example PKC, MAP Kinase, MEK 1, ERK1/2 and tyrosine kinases within rat and 
rabbit species (Kudo et al. 2002; Dana et al. 2000; Germack and Dickenson 2005; Zhao et al. 
2001; Ballard-Croft et al. 2005; Williams-Pritchard et al. 2011). With the phenomenon of 
pharmacological preconditioning with adenosine being able to activate various mechanisms 
to promote myocardial salvage, it was important to investigate the various mechanisms that 
become activated throughout delayed reperfusion A1 adenosine receptor activation to 
explore if similar pathways were able to ensure cardioprotection. For this reason, the PI3K 
and MEK1/2 signalling pathways were investigated within this current study.  
With adenosine having the ability to induce cardioprotection, the A1 adenosine receptor is an 
important receptor and area of research within this project and previous research by Germack 
and Dickenson (2005) showed that A1 mediated adenosine receptor activation through the 
phenomenon of preconditioning ensured cardioprotection in neonatal rat cardiomyocytes. 
The A1 agonist of choice within this study was CPA. Therefore with proven research showing 
the effects of the A1 receptor ensuring cardioprotection through pharmacological 
preconditioning, it was interesting to investigate the effects of the delayed reperfusion 
activation of the A1 adenosine receptor to ensure cardioprotection through the PI3K and 
MEK1/2 signalling pathways.  
Preconditioning with adenosine comes with its own share of disadvantages and an important 
one is that the clinical application is limited due to ethical and practical reasons (Andreadou 
et al. 2008). Although this phenomenon has an ability to limit infarct size, we can’t apply it to 
patients as we do not know if they are or are not going to encounter a cardiac event 
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(Andreadou et al. 2008). Therefore our current project is useful in bringing forward research 
that involves post-reperfusion activation of A1 adenosine receptors in order to salvage the 
myocardium from ischaemia reperfusion injury. The clinical relevance of this study suggests 
that if patients have already endured a myocardial infarction then administering a therapeutic 
agent that targets the A1 adenosine receptors and ensuring cardioprotection up to 30 minutes 
after a patient has had an ischaemic insult, could prove beneficial and an area for further 
research beyond the scope of this current project.  
With preconditioning being such an extensively researched phenomenon within an 
experimental setting, post conditioning is also a very interesting concept that has been 
extensively researched. This is when brief periods of coronary occlusions are performed just 
at the beginning of reperfusion (Pagliaro and Penna. 2011). Adenosine has been said to play 
a part in the post conditioning phenomenon however a study by Kin et al (2005) have shown 
that the A2 adenosine receptor plays an important role in the protective effects within mouse 
hearts rather than the A1 adenosine receptor (Kin et al. 2005). Previous researchers have 
shown that pharmacological post conditioning with adenosine can activate the RISK (PI3K-
AKT and MEK1/2-ERK1/2 signalling pathways) and SAFE pathways in order to ensure 
cardioprotection (Shi and Vinten-Johansen 2012; Procopio et al. 2020). So therefore it could 
mean that endogenous adenosine can ensure cardioprotection but through the A2 adenosine 
receptor subtype (Kin et al. 2005). However researchers such as Xi et al (2008) researched 
that distinctive strains of gene knockout mice, post conditioning induced infarct-limiting 
cardioprotection was conferred and this was triggered by the activation of the A1 adenosine 
receptor (Xi et al. 2008). This suggests that there is confounding research when it comes to 
post conditioning and the activation of the A1 adenosine receptor. So having this current 
project highlighting the importance of post-reperfusion activation of the A1ARs is another 









7.3 Haemodynamic Studies (Coronary Flow, Left Ventricular Developed 
Pressure and Heart Rate) 
 
Within this study, minimal significance was shown within haemodynamic data which included 
coronary flow, left ventricular developed pressure and heart rate when 2’-MeCCPA (10nM) 
was administered. This could have been due to the fact that such a low concentration of the 
A1 adenosine agonist 2’-MeCCPA was used. It was shown that the concentration of 10nM 
made a significant effect upon infarct size, cell death and caspase-3 activity however there 
was little/no effect upon haemodynamic data. This could mean that for haemodynamic 
parameters to efficiently be investigated, higher concentrations of the A1 adenosine receptor 
agonist 2’-MeCCPA could have been investigated in order to detect significance in 
parameters. This could support the fact that in Chapter 2, the higher concentration of 100nM 
of 2’-MeCCPA caused a decrease in HR only. 
Using the Langendorff technique itself can be unreliable and it comes with its own set of 
disadvantages. The longer the hanging process of the heart takes, the more damage the rat 
hearts could have incurred and therefore can lead to further ischaemic damage to the heart. 
Additionally, the exposure of the heart to our natural environment without any sort of 
protective element to it could contribute to tissue temperature changes and ischaemic 
damage which could therefore cause inconsistencies within results (Motayagheni 2017). 
Therefore due to the fact that the Langendorff may not be the most reliable technique to 
measure haemodynamic parameters, further damage may have been caused and this could 
have led to the insignificant results detected within the haemodynamic parameter results 
within this project.  
Within this current study, Figure 3.2. has shown that when the concentration of 100nM of 2’-
MeCCPA was administered at the onset of reperfusion, there was a consistent decrease in 
heart rate, which was not detected when the 10nM concentration of 2’-MeCCPA was 
administered. This effect of the slowing of heart rate can be compared to a study conducted 
by Koeppen et al. in 2009 where they showed that ex vivo studies implicated the A1 adenosine 
receptor in the slowing down of the heart rate (Koeppen et al. 2009). More importantly, 
studies conducted by Albrecht-Küpper et al. in 2011 found that when administering A1 
adenosine agonist CCPA to male Wistar rats at increasing concentrations of 1nm – 1µM, the 
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higher concentrations resulted in a reduced heart rate within isolated rat Langendorff hearts. 
Higher concentrations even caused complete AV block (Albrecht-Küpper et al. 2011). This 
could therefore support why at the concentration of 100nM of 2’-MeCCPA, there was a 
reduced heart rate within the reperfusion period when 2’-MeCCPA (100nM) had been 
administered. With this being said, presumably the effects of 2’-MeCCPA at the 
concentrations of 1µM had also been explored and no significant difference in heart rate was 
detected when compared to the IR control; which leads to believe that potentially 2’-MeCCPA 
may not have been a fully selective A1 adenosine agonist when compared to A1AR agonist 
such as CCPA (Albrecht-Küpper et al. 2011). This also leads to believe that more experimental 
research could have been conducted to look into why the heart rate didn’t cause a significant 
change at the highest concentration of 2’-MeCCPA (1µM). 
Furthermore, this current study showed no significant effect upon heart rate was detected 
when A1 adenosine antagonist DPCPX was administered alongside A1AR agonist 2’-MeCCPA 
throughout the project and this can be supported by published literature by Koeppen et al. in 
2009 which showed that when DPCPX was administered to A1ARs, there was no effect upon 
heart rate (Koeppen et al. 2009).  
This current project showed that there was no significant differences in left ventricular 
developed pressure (LVDP) and coronary flow (CF) when A1AR agonist was administered to 
the isolate perfused rat hearts throughout the period of reperfusion. After ischaemia was 
induced a general decrease in LVDP and CF was observed and this can be supported by a study 
by Lozza et al. (1997) where they showed that when perfused hearts underwent ischaemia, 
there was a general decrease in LVDP and CF by around 50-75% compared to the control 
group. Lozza et al. (1997) also went on to find that when reperfusion commenced, the 
perfused hearts administered with CCPA (3nM) allowed for immediate LVDP recovery 
immediately after coronary flow was restored. This supports our findings as it shows that A1 
adenosine agonists have the ability to restore LVDP and CR after an ischaemic event and 






7.4 Study Limitations and Further Investigations 
 
Although cross talk between the two branches of the RISK pathway was not something that 
was investigated within this study; previous research has touched on the fact that there is 
cross-talk interaction between the PI3K-AKT and MEK1/2-ERK1/2 pro-survival pathways. A 
study conducted by Hausenloy et al. (2004) showed that cross-talk between the two branches 
of the RISK pathway did occur at the early reperfusion in an ischaemic preconditioning setting 
within isolated perfused rat hearts. Therefore it would be useful to investigate if cross-talk 
occurred within our study in the phenomenon of delayed reperfusion activation of A1 
adenosine receptors. When UO126 (10µM) and 2’-MeCCPA (10nM) was administered 
together at 15 minutes and 30 minutes post-reoxygenation, it was unable to block the 
protective effects shown on cleaved-caspase-3 activity suggesting that there was little effect 
seen from the MEK1/2-ERK1/2 cell signalling pathway. This could also suggest that potentially 
cross-talk was occurring as similar experiments to explore the PI3K-AKT cell signalling 
pathway at the 15 minutes and 30 minute time-points were carried out in this study and the 
PI3K-AKT sell signalling branch of the RISK pathway was upregulated at these time-points in a 
caspase-3 manner whereas the MEK1/2-ERK1/2 cell signalling pathway was not. Further 
investigation into cross-talk between the two branches of the RISK pathway could be 
explored. 
With ample research being conducted into the RISK pathway, our findings imply that A1 
adenosine activation recruits the PI3K-AKT pathway in a delayed reperfusion activation 
manner however the MEK1/2-ERK1/2 pathway is also implicated alongside. Further 
investigations can be conducted beyond the RISK pathway to explore the activation of the 
novel protective pathway named Survivor Activating Factor Enhancement (SAFE) pathway 
(Lecour 2009).  
Other cell survival pathways have been involved in mediating cell survival and further studies 
are required in order to determine if they have a part to play towards cardioprotection. These 
cell signalling cascades can include; p38 and PKC. The survivor activating factor enhancement 
(SAFE) pathway is an alternative intrinsic pro-survival signalling pathway to the RISK pathway 
for cardioprotection. Therefore further studies can be conducted in order to investigate the 
above cell signalling pathways with the activation of A1 agonist 2’-MeCCPA mediating 
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cardioprotection. Another A1 agonist, CCPA can also be investigated with the above cell 
signalling pathways to determine if cardioprotection is enhanced. Recent has shown that the 
Wnt/β-catenin pathway could be considered as a therapeutic target when activated by 
adenosine however more research needs to be conducted (Procopio et al. 2020). 
When the assessment of various concentrations of A1 adenosine receptor (A1AR) agonist, 2’-
MeCCPA was conducted, the concentrations of 100nM and 1µM also displayed effective 
cardioprotective effects by reducing infarct size to risk ratio (%) within an isolated rat’s heart. 
It would have been useful to further examine the effects of this higher concentrations (100nM 
and 1µM) rather than 10nM to investigate their effects upon the PI3K-AKT and MEK1/2-
ERK1/2 cell signalling pathways. 
When the activation of A1ARs was delayed with 2’-MeCCPA (10nM) to 60 minutes post-
reperfusion, there was a failure in protecting the Langendorff rat heart from ischaemia 
reperfusion injury. Further studies could be carried out in order to determine if higher 
concentrations of 2’-MeCCPA administered at 60 minutes post-reperfusion make a difference 
in protecting the ischaemic-reperfused myocardium from injury. 
There are a variety of different potent A1 adenosine agonists that have been reported in 
literature, therefore it was would useful in determining the different effects of the different 
A1 agonists to ensure that they all contribute towards cardioprotection and if there are other 
agonists that ensue more cardioprotective that 2’-MeCCPA. 
There are previous studies that report A3AR agonist 2-CL-IB-MECA to activate AKT and ERK1/2 
in a concentration/time dependent manner and also to be pro- and anti-apoptotic (Mocanu 
et al. 2002). In this current study, it has been established that the A1AR agonist 2’-MeCCPA 
can activate PI3K and MEK1/2 in a time and concentration dependent manner but also further 
studies may be required to determine the threshold that is required for AKT and MAPK1/2 
activation by 2’-MeCCPA to observe cardioprotection instead of just using one concentration 
of 10nM.  
Phosphorylation of p-ERK1/2 could have been fully explored within this study to detect if 




In order to determine the activity of caspase 3 in this current study, the activity of 
active/cleaved caspase 3 was assessed. The activation of caspase-3 requires the proteolytic 
processing of the inactive zymogen into cleaved/activated p16 and p12 fragments. In our 
study we used the cleaved-caspase 3 antibody to detect the endogenous levels of cleaved-
caspase 3. This antibody is not able to fully recognise the full length of caspase 3 or other 
caspases therefore the data needs to be interpreted with caution as it is not a direct measure 
upon caspase 3 itself. Further study needs to be conducted.  
This overall project hightlights the importance of the delayed activation of A1ARs within the 
reperfusion period in a rat model and how this can could be taken further for future research 
and extrapolating into a clinical setting. The specific signalling pathways, for example the PI3K 
and MAPK1/2 cell signalling pathways were implicated within A1AR activation 
cardioprotection and further research and study would need to be conducted to fully evaluate 




The work carried out in this thesis has successfully implied the cardioprotective effects of the 
activation of A1 adenosine receptors in an ischaemia/reperfusion injury model. This is the first 
study to imply the delayed activation of A1 adenosine receptors with A1AR agonist 2’-MeCCPA 
to confer cardioprotection in isolated perfused rat hearts. This cardioprotective effect is 
associated with decreased infarct size (%) and decreased apoptosis and necrosis via the 
recruitment of the PI3K and MEK1/2 cell survival pathways, this has been visually represented 
in the graphical abstract, Figure 7.1 below. The findings from this study indicate clinically 
important developments in the field of managing myocardial infarction. Urgent studies are 
required to investigate the potential role of A1 adenosine receptor agonists in ameliorating 

































Figure 7. 1 Graphical abstract to summarise the key findings and the cell signalling pathways 
that were implicated in ensuring cardioprotection. When A1AR agonist 2’-MeCCPA (10nM) 
was administered at the onset of reperfusion, it can be implied that cardioprotection has 
occurred through the activation of the PI3K and MAPK1/2 cell signalling pathways. This was 
represented by a decrease in infarct size (%) as well as a decrease in apoptosis and necrosis 
leading to a decrease in cleaved caspase-3 activity. When 2’-MeCCPA (10nM) was 
administered at 15 minutes and 30 minutes post-reperfusion, the same effects can be 






The first results chapter (Chapter 3) successfully implied that the concentration of 10nM of 
A1AR agonist 2’-MeCCPA, when administered at the onset of reperfusion, 15 minutes and 30 
minutes post-reperfusion, protected an isolated perfused rat heart undergoing simulated 
ischaemia/reperfusion as well as in rat cardiomyocytes that underwent 
hypoxia/reoxygenation. There was a decrease in infarct size, a decrease in cell death and 
cleaved caspase-3 activity.  
Chapter 4 determines that the A1 receptor in particular plays a vital role in the conferred 
cardioprotection that is shown in this study. A1AR agonist is administered alongside A1AR 
antagonist DPCPX and this antagonist blocks all protective effects seen when the A1 adenosine 
receptor is activated implying that the A1 adenosine receptor is vital for cardioprotection. This 
is apparent at the onset of reperfusion, 15 minutes and 30 minutes post-reperfusion. DPCPX 
abrogates the limit in infarct size, decrease in cell death and cleaved caspase-3 activity, which 
has been visually represented in Figure 7.1. Chapter 4 also investigates the upregulation of 
AKT phosphorylation which in turn implies the PI3K-AKT cell signalling pathway is playing a 
vital role to ensure cardioprotection via the A1 adenosine receptor.  
Furthermore, Chapter 5 investigates how the PI3K cell survival pathway is upregulated by the 
activation of the A1AR by 2’-MeCCPA and the protection conferred in reversed with the PI3K 
inhibitor Wortmannin. This shows the direct link between the upregulation of the PI3K cell 
survival pathway and the activation of the A1 adenosine receptors at the onset of reperfusion, 
15 minutes and 30 minutes post-reperfusion/reoxygenation as seen in Figure 7.1.  
Lastly, Chapter 6 investigated the role of the MEK1/2 cell survival pathway when the A1ARs 
are activated. It was found that when 2’-MeCCPA was administered at the onset of 
reperfusion, 15 minutes and 30 minutes post-reperfusion/reoxygenation; there was a 
decrease in infarct size and cell death and this was abrogated in the presence of MEK1/2 
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inhibitor UO126. However this reverse was not observed when UO126 was administered 
alongside 2’-MeCCPA on cleaved caspase-3 activity at 15 minutes and 30 minutes post-
reoxygenation. Therefore this could imply that the PI3K branch of the RISK pathway plays 
more of a role in cardioprotection conferred by the activation of the A1 adenosine receptors 
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